Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
1  
  
MSK  PROTOCOL  COVER  SHEET  
TALAZOPARIB AND AVELUMAB IN GENOMICALLY  DEFINED METASTATIC  
RENAL  CELL  CARCINOMA  
 
Principal  Investigator/Department:  Ritesh  Kotecha,  MD/Medicine  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
2  
 1.0 PROTOCOL  SUMMARY  AND/OR  SCHEMA ...................................................................  6 
2.0 OBJECTIVES AND SCIENTIFIC AIMS  ............................................................................ 7 
3.0 BACKGROUND  AND  RATIONALE  ................................................................................. 7 
3.1 Renal  Cell Carcinoma  Epidemiology ............................................................................. 7 
3.2 Renal  Cell Carcinoma  Subtypes  .................................................................................... 7 
3.3 Renal  Cell Carcinoma  Genomics ................................................................................... 8 
3.4 DNA -damage  Response (DDR)  Pathways ..................................................................... 9 
3.5 VHL-deficiency  and Genomic  Maintenance .................................................................. 9 
3.6 PARPi  and RCC ............................................................................................................. 10 
3.7 Treatment  Paradigms  for Metastatic  RCC ...................................................................  12 
3.8 Combination PARPi  and ICB Rationale ....................................................................... 14 
3.9 Talazoparib Pre-Clinical and Clinical Experience ....................................................... 14 
3.10 Avelumab  Pre-Clinical  and Clinical  Experience .......................................................... 15 
4.0 OVERVIEW  OF STUDY  DESIGN/INTERVENTION ........................................................ 18 
4.1 Design  ........................................................................................................................ 18 
4.2 Intervention  ................................................................................................................. 18 
5.0 THERAPEUTIC/DIAGNOSTIC  AGENTS  .......................................................................  18 
5.1 Talazoparib Drug  Information and Storage  .................................................................  18 
6.1 Avelumab Drug  Information and Storage  .................................................................... 19 
6.1 Avelumab Premedication ............................................................................................. 20 
6.1 Treatment  Interruptions  / Delays ................................................................................. 21 
6.1 Drug  Accountability  ..................................................................................................... 22 
6.0 CRITERIA  FOR  SUBJECT  ELIGIBILITY  ....................................................................... 22 
6.1 Subject  Inclusion Criteria  ............................................................................................. 22 
6.2 Subject  Exclusion  Criteria ............................................................................................  23 
6.3 Lifestyle Requirements  ................................................................................................ 25 
7.0 RECRUITMENT  PLAN .................................................................................................. 26 
8.0 PRETREATMENT  EVALUATION .................................................................................. 27 
9.0 TREATMENT/INTERVENTION PLAN ........................................................................... 28 
9.1 Talazoparib Administration ..........................................................................................  28 
9.2 Avelumab Administration............................................................................................. 28 
9.3 Talazoparib and Avelumab Combination Administration  ..........................................  29 
9.4 Medication  Compliance  ................................................................................................ 29 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
3  
 9.5 Talazoparib Dose Modifications .................................................................................. 30 
9.6 Avelumab  Dose Modifications ..................................................................................... 31 
9.7 Concomitant  Medications ............................................................................................  31 
9.8 Concomitant  Surgery ................................................................................................... 32 
9.9 Concomitant  Radiation .................................................................................................  32 
9.10 Hypercalcemia Management  ........................................................................................ 33 
10.0 EVALUATION DURING  TREATMENT/INTERVENTION  ................................................ 33 
10.1 Screening  ...................................................................................................................... 33 
10.2 Treatment  Period  .......................................................................................................... 33 
10.3 Safety  Assessments ..................................................................................................... 34 
10.4 Pregnancy/Contraception Safety Monitoring for Female  Patients of Childbearing 
Potential  ................................................................................................................................... 35 
10.5 Disease Response Evaluation  During  Treatment  ....................................................... 36 
10.6 Treatment  Beyond  Progression ................................................................................... 36 
10.7 Schedule of Activities .................................................................................................. 38 
11.0 TOXICITIES/SIDE  EFFECTS ......................................................................................... 42 
11.1 Severity  Assessments .................................................................................................  42 
11.2 Adverse  Events .............................................................................................................. 42 
11.7 Talazoparib Toxicity  ..................................................................................................... 44 
11.7.1 Hematologic  Toxicity  Related to Talazoparib  ............................................................. 44 
11.7.2 Talazoparib Related  Non-Hematologic Toxicity  .......................................................... 46 
11.7.3 Talazoparib Related Gastrointestinal  Toxicity  ............................................................. 47 
11.8 Avelumab Toxicity ........................................................................................................... 47 
11.8.1 Avelumab Related  Pulmonary  Toxicity  ....................................................................... 47 
11.8.2 Avelumab Related Gastrointestinal  Toxicity ............................................................... 48 
11.8.3 Avelumab Relate d Endocrine  Toxicity  ........................................................................ 48 
11.8.4 Avelumab  Related  Skin Toxicity  .................................................................................. 49 
11.8.5 Avelumab  Related  Renal  Toxicity  ................................................................................ 49 
11.8.6 Avelumab Related Neurologic  Toxicity  ...................................................................... 49 
11.9 Combination Talazoparib / Avelumab  – Dose Modifications for Treatment - 
Emergent,  Unrelated Adverse Events .................................................................................... 49 
12.0 CRITERIA FOR  THERAPEUTIC RESPONSE/OUTCOME  ASSESSMENT  ................... 49 
12.1 Calculated  Study  Endpoints ........................................................................................ 52 
12.2 Short -Term  and Long -Term  Follow  Up ........................................................................ 53 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
4  
 12.3 Study Research  Plan .................................................................................................. 53 
13.0 CRITERIA FOR  REMOVAL  FROM  STUDY ...................................................................  57 
13.1 Study Treatment  Discontinuation ................................................................................ 57 
13.2 Voluntary  Withdrawal  of Consent  ................................................................................ 58 
13.3 Lost  to Follow -Up ......................................................................................................... 58 
14.0 BIOSTATISTICS  ............................................................................................................ 58 
14.1 Cohort  1 Enrollment  and Statistical  Plan .................................................................... 59 
14.2 Cohort  2 Enrollment  and Statistical  Plan .................................................................... 60 
14.3 Sample  Size/Accrual  Rate ............................................................................................  60 
14.4 Exploratory Analyses ................................................................................................... 61 
15.0 RESEARCH PARTICIPANT  REGISTRATION  AND RANDOMIZATION PROCEDURES  
61 
15.1 Research Participant  Registration  ............................................................................... 61 
15.2 Randomization  ............................................................................................................ 61 
16.0 DAT A M ANAGEMENT  ISSUES  .................................................................................... 61 
16.1 Quality  Assurance ....................................................................................................... 62 
16.2 Data  and Safety Monitoring ......................................................................................... 62 
16.3 Study Treatment  Accountability  .................................................................................. 62 
16.4 Conditions  for Protocol  Modification  .......................................................................... 63 
16.5 Conditions  for Termination of Study  ........................................................................... 63 
17.0 PROTECTION  OF HUMAN  SUBJECTS  ........................................................................ 63 
17.1 Privacy  ........................................................................................................................ 64 
17.2 Serious Adverse  Event  (SAE)  Reporting  ..................................................................... 65 
17.2.1  SAE Reporting to Pfizer  ............................................................................................... 66 
18.0 INFORMED CONSENT  PROCEDURES  ........................................................................ 68 
19.0 REFERENCES  ............................................................................................................... 68 
20.0 APPENDICES  ................................................................................................................ 73 
Appendix 1: Eastern  Cooperative Oncology Group (ECOG)  Performance Status Chart  .... 74 
Appendix 2: iRECIST  and RECIST  v1.1 Guidelines ............................................................... 75 
Appendix  3: Avelumab  Infusion Related Events and Management  ..................................... 78 
Appendix  4: Avelumab  Immune Related Adverse Events  and Management  ....................... 79 
Appendix  5: Prohibited  Potent  P-gp Inhibitors  ..................................................................... 87 
Appendix 6: Correlative  Laboratory Manual  .......................................................................... 88 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
5  
  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
6  
 1.0 PROTOCOL  SUMMARY  AND/OR SCHEMA  
This is a phase II, open- label, single- institution trial  to study  the combination of talazoparib 
and avelumab in patients with advanced or metastatic renal cell carcinoma (RCC). This 
protocol leverages underlying genomic instability in three genomically defined RCC 
variants and pairs targeted immunotherapy with PARP inhibition.  
RCC represents a heterogenous set  of tumors  distinguished by histology, molecular  and 
genomic features. A hallmark of clear cell RCC, the most common histologic RCC 
subtype, is von Hippel Lindau (VHL)  inactivation occurring  in >90% of tumors.  VHL acts 
as a hypoxic sense regulator and, amongst other functions, supports DNA repair and genomic integrity; consequently, VHL  loss promotes  genomic instability. Similar in  effect, 
in two rare RCC subtypes characterized by loss -of-function mutations in fumarate 
hydratase ( FH) and succinate dehydrogenase ( SDH), downstream oncometabolite 
accumulation leads  to DNA  repair  inhibition,  resulting  in genomic  instability.  Further,  renal 
medullary carcinoma  (RMC) also has been associated with high DNA replication stress. 
All of these sett ings ( VHL, FH/SDH  loss, and RMC) have been shown  to render cancer 
cells vulnerable to PARP inhibitors. As DNA damage is thought to increase neo- antigen 
repertoires  and innate immune effectors,  paired PARP inhibition  with immune  checkpoint 
blockade may achieve additive and/or synergistic effects in both clear  and non- clear  cell 
cohorts with separate rationales.  
This protocol investigates the use of talazoparib, a potent selective PARP inhibitor, and avelumab, an anti -PD-L1 monoclonal antibody blocker, in patients with advanced RCC. 
The protocol will enroll patients in two independent, non- randomized cohorts in parallel 
(Table 1). Cohort 1 will enroll patients with previously treated VHL -deficient RCC in a 
Simon two -stage design: if  ≥1/10 patients achieve an objective response in Stage I, the 
trial will then continue to accrue  a total of 29 patients for efficacy analysis. Cohort 2 will 
enroll 15 patients with advanced RCC and FH - or SDH- loss or medullary RCC, and 
analysis will be de scriptive given disease rarity.  
 
Cohort  Population  Target  Enrollment  Talazoparib  Avelumab  
1 VHL-deficient  RCC Stage  I: 10 patients 
Stage II: 19 patients  1 mg daily 
PO 800 mg IV 
2 FH-, SDH - deficient  RCC, 
RMC  Total  = 15 patients  1 mg daily 
PO 800 mg IV 
Table 1. Cohort Design. VHL: von Hippel Lindau; FH: fumarate hydratase, SDH: succinate 
dehydrogenase,  PO: oral, IV: intravenous  
All patients  will receive  combination treatment  at the previously  established  recommended 
phase II dose, 800 mg avelumab every 2 weeks with 1 mg talazoparib daily, in 28 -day 
cycles. The primary endpoint will be objective response rate (ORR) measured by 
iRECIST. Secondary endpoints include progression- free survival (PFS), overall sur vival 
(OS),  and safety and tolerability  of combination therapy.  Exploratory endpoints  for both 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
7  
 cohorts include analysis of expression- based biomarkers for tissue response, 
characterization of inflammatory recruitment responses,  and oncometabolite analysis in 
cohort 2 patients.  
2.0 OBJECTIVES  AND SCIENTIFIC  AIMS  
Primary  Aim: To determine the objective response rate (ORR)  of combination talazoparib 
and avelumab in all treatment cohorts by iRECIST.  
 
Secondary aims  will include:  
1. To determine the progression- free survival (PFS)  in all treatment cohorts by  RECIST 
v1.1.  
2. To determine the overall  survival  (OS) in all treatment  cohorts  by RECIST  v1.1.  
3. To evaluate the safety  and tolerability,  and compliance of combination talazoparib and 
avelumab in all treatment cohorts.  
 
Exploratory aims will include:  
1. Cohorts 1 & 2: 
a. To characterize DNA damage response pathways including homolgous 
recombination deficiency (HRD), large scale transition (LST) scores, inflammatory and microenvironment changes.  
2. Cohort  2: 
a. To assess metabolomic changes and oncometabolite generation for 
Cohor t 2. 
 
3. 0 BACKGROUND AND RATIONALE  
3.1 Renal  Cell Carcinoma  Epidemiology  
Renal cell carcinoma (RCC) is the most common and lethal form of kidney cancer, 
affecting over 65,000 each year in the United States with a rising incidence ( 1). The 
growing incidence of RC Cs stems from modifiable risk factors including tobacco use, 
hypertension, and obesity, as well as a shift in incidental radiographic diagnoses in asymptomatic patients ( 2). As one- third of patients with RCC present with metastatic 
disease at diagnosis, and one- fourth of patients experience disease relapse following 
nephrectomy,  there continues to  remain a high unmet  need for systemic  therapy options 
for patients with advanced disease.  
3.2 Renal  Cell Carcinoma  Subtypes  
The World Health Organization (WHO)  classifies  sixteen distinct  kidney cancer  subtypes 
based on genomic,  molecular,  histologic and syndromic features  (3). The most  common 
RCC variant  in the metastatic  setting is clear  cell RCC,  accounting for ~75%  of diagnoses, 
followed by  other non- clear cell histologies  like papillary, chromophobe, and unclassified 
tumors. Although these subtypes occur most  commonly  as sporadic cancers,  many  also 
occur in the  syndromic  setting with  several familial syndromes characterized  in terms of  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
8  
 germline alterations and ensuing pathobiology. Von Hippel Lindau (VHL) syndrome is 
characterized by bi -allelic VHL loss and the development of bilateral and multifocal  clear 
cell RCCs with additional tumor developments including hemangioblastomas, 
pheochromocytomas,  and neuroendocrine  tumors.  Hereditary  Leiomyomatosis  and Renal 
Cell Carcinoma (HLRCC) syndrome usually manifests with papillary RCC tumors 
developing in the context  of germline loss of fumarate  hydratase  (FH), and is characterized 
by the development of cutaneous leiomyomas, leiomyosarcomas and paragangliomas  . 
Hereditary  paragangliomas  and paragangliomas (HPGL/PCC),  characterized by germline 
loss of succinate dehydrogenase ( SDH) is characterized by RCC as well as 
pheochromocytomas,  paragangliomas, and gastrointestinal stromal tumor development. 
Renal medullary ca rcinoma  (RMC) is a rare, lethal form of kidney cancer most  notably 
associated with hemoglobinopathies  and occurs  mainly  in young individuals  and is highly 
refractory to systemic therapies that are successfully  applied in other RCC  variants  . 
3.3 Renal  Cell Carcinoma  Genomics  
The genomic  landscape for clear  and non -clear  RCC  variants  have been  outlined through 
large- scale efforts with The Cancer Genome Atlas (TCGA) and the TRACERx study, 
helping uncover  patterns  within  the context  of clinical and tumor  evolution (4-6). A hallmark 
event  that characterizes  >90%  of clear  cell RCCs  is chromotripsis  of chromo some 3p, with 
then subsequent  gains in chromosome 5q and loss  of 15q (4). Haploinsufficiency of VHL 
is insufficient  for tumor  growth and may precede  RCC development by  even decades  (7), 
and secondary genomic or epigenetic events affecting VHL and other chromosome  3p 
genes are central to disease pathogenesis. Complete loss of pVHL, the encoded protein, 
leads to downstream accumulation of hypoxia inducible factor (HIF) proteins and trans criptional upregulation of HIF- dependent  pathways that affect cell  proliferation, cell 
migration, cell metabolism, and angiogenesis. Functional loss of VHL may be due to 
acquired point  or frame  mutations,  as well as mutations  in partnering  proteins  (i.e. TCEB1) 
and promotor methylation silencing ( 8-10). 
While  chromosome 3p loss remains  the linchpin in characterizing clear cell RCC biology, 
other RCC  variants (non -clear cell) harbor distinct  genomic alterations that contribute to 
disease pathogenesis. This includes loss -of-function (LOF)  mutations in FH, a gene that 
encodes for a Krebs cycle  enzyme  catalyzing the  hydration of fumarate  to malate, which 
can be lost in sporadic and syndromic papi llary variants of RCC ( 11). FH- loss radically 
shifts metabolism to aerobic glycolysis obliging cells to become  dependent on  glycolysis 
for subsequent ATP production ( 12). Similarly, LOF mutations in SDH, a mitochondrial 
enzyme responsible for the oxidation of succinate to fumarate, also leads to metabolic 
dysregulation in other non- clear cell RCC entities. In addition, RMC tumors are almost 
uniformly characterized by SMARCB1 (INI1)  (13), which functions as a subunit of the 
SWItch/Sucrose Non-Fermentable (S WI/SNF) complex  and has been  characterized with 
increased DNA replication stress ( 14). 
Beyond these well understood mechanisms  for clear  cell ( VHL-deficient)  and other tumor 
subtypes ( FH / SDH- deficient or SMARCB1 -loss medullary),  several recent  reports have  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
9  
 highlighted each of these genes are integral to genomic maintenance described below, 
providing molecular  rationale for the present study.  
3.4 DNA- damage  Response (DDR)  Pathways  
DNA repair is an essential mechanism  for genomic integrity  maintenance as unrepaired 
DNA damage  ultimately leads to cell  death or senescence.  Minor alterations in DNA are 
corrected using base or nucleotide excision repair mechanisms,  and more lethal DNA 
damage events like strand breaks (single or  double) or complex events like interstrand 
cross- linking are usually repaired using two complex pathways: homologous 
recombination (HR)  and non-homologous  end joining (NHEJ)  (15). HR retains  the highest 
fidelity, as this process requires a template DNA strand for repair and ligation, whereas 
NHEJ relies on processing terminal end strands only for subsequent DNA ligation. Because of the template requirement, HR can only occur in certain cell cycle phases compared to NHEJ. DNA double strand breaks (DSBs)  are particularly challenging as 
repair relies on  the coordination of multiple pathways as  detailed below.  
Consequences of ineffective DNA repair have been highlighted through analysis of 
specific  DNA  damage response (DDR)  pathway  alterations found in several  malignancies 
as well effects from cytotoxic DNA damaging chemotherapies. Multiple DDR pathways 
have been characterized  with specific components ( 16) including:  
1. Nucleotide Excision Repair  (NER) : ERCC1/2/34/5/6/8,  DDB1/2,  RPA1/2/3,  XPC, 
RAD23B, CETN2, GTF  
2. M ismatch Repair (MMR) : MLH1,  MSH2,  MSH6,  PMS1/PMS2  
3. HR: BRCA1/2,  PARP1,  ATM,  ATR,  RAD51C, BAP1,  PALB2,  MRE11A/NBN, 
BARD1/BRIP1,  RAD50/51/51B/51D  
4. NHE J:  PRKDC,  XRCC5/6,  LIG4,  XRCC4, NHEJ1  
5. Others:  FANCC, FANCA, BLM, CHEK1/2, POLE, ATRX, ATR, RAD1, HUS1, TP53, 
RIF1, CLK2, TOPB1, PER1  
Loss of one or more DDR pathways may lead to increased cancer predisposition (i.e. 
BRCA  or ATM mutant  malignancies),  as well as enhanced susceptibility  to DNA da mage 
therapies  through  “synthetic  lethality”  (17). This has been exploited  recently  through PARP 
inhibition in patients with underlying BRCA  germline mutations in multiple tissue models 
(18-22). Additionally,  other DDR losses like MMR deficiency have been shown to have 
higher  mutational  load correlating with improved  response to immune checkpoint  blockade 
therapy ( 23). 
3.5 VHL-deficiency and Genomic Maintenance  
Besides promotion of the adaptive pseudohypoxia response through HIF- dependent 
pathways, VHL plays an integral role in other cellular processes including extracellular 
matrix regulation, microtubule stabilization, and cell cycle regulation through DNA repair 
and regulation of apoptosis and senescence (24, 25 ). Interestingly, pre -clinical work 
highlights that VHL  loss increases  DNA damage and replication stress,  with increases  in 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
10  
 ATR (ATM  and RAD-3 related), CHK1 , and replication fork  stalling, all of which  contribute 
to increased genomic  instability,  replication mechanism  collapse,  and cell cycle arrest  
(26). In addition,  VHL-deficient  RCC cells also show  impaired  NER capacities  as well ( 27). 
BRCAness,  the notion that DDR  associated genes other  than BRCA1  and BRCA2  confer 
similar  defects in DNA repair, has increasingly been applied in many tumor models and 
genes ( 28). Interestingly,  an analysis of RCC tumors with associated tumor  thrombus,  a 
common  and poor prognostic feature, has also highlighted that many RCC tumor s have 
conferred BRCAness.  Based upon identification of BRCAness mutational signatures in 
this select population with associated tumor thrombus, investigators re- analyzed 400 
patients in the  TCGA  clear cell  RCC cohort irrespective of  tumor  thrombus and identified 
high predominance of a BRCAness mutational signature, accounting for 74.25% of 
patients (297/400 samples) ( 29). 
VHL-deficient clear cell RCCs have shown to have lower expression of HR and MMR 
genes,  with 30 -60% reductions of  mRNA  levels of BRCA1,  RAD51,  MLH1, and FANCD2 
compared  with VHL-wildtype  tumor  cells ( 30). Expression  changes were  confirmed  upon 
TCGA interrogation, and VHL-loss specifically was associated with impaired DNA DS 
break repair, conferring a BRCAness  phenotype  (31). Based on the above studies, this 
BRCAness phenotype is associated with a majority of clear  cell RCCs.  
3.6 PARPi  and RCC 
Poly(ADP -ribose) polymerase (PARP) are enzymes that activate upon damaged DNA 
binding, with further functions including: detection of single- stran ded and DS breaks, 
recruitment  of DNA repair  machinery  and replication formation at the injured site. PARP 
is usually  upregulated  during replication  stress, with DDR pathway  signal  transduction and 
protein complex modification through PARylation  (32). 
The concept of exploiting synthetic lethal interactions between inherently impaired DNA 
repair and PARP inhibitors (PARPi) has proven successful  in human malignancies. For 
instance, as functional BRCA1/2 proteins are integral for DSB  repair,  BRCA1/2  mutants 
are increasingly  vulnerable to  PARPi with significant  clinical responses  in this genomically 
defined population. Interestingly, treatment with niraparib has shown clinical benefit in patients irrespective of BRCA status ( BRCA  wild-type or mutant), and significant clinical 
effects were seen in patients  with HR deficient  tumors also irrespective of BRCA  status  
(21). In total,  the FDA has approved  multiple  agents  across  tumors  in mostly  BRCA  mutant 
populations (Table 2), and further exploration of other DDR  pathway mutants including 
those tumors with BRCAness remains underway.  
 
PARPi  FDA Approved  Indications  
Rucaparib  1. Treatment of advanced  stage, BRCA1/2 mutant ovarian  cancer 
refractory to ≥2 prior lines of therapy  
2. Maintenance for advanced stage,  recurrent  ovarian cancer  in CR 
or PR after platinum -based chemotherapy  
Niraparib  1. Maintenance  for patients  with advanced  stage  ovarian  cancer  who 
are in CR or PR after platinum -based  chemotherapy  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
11  
  
Olaparib  1. Maintenance  therapy  for advanced  stage,  recurrent  ovarian 
cancer in CR or PR after  platinum -based chemotherapy  
2. Treatment of advanced stage, BRCA1/2 mutant ovarian cancers 
refractory to ≥3 prior lines of therapy.  
3. Treatment  for metastatic  HER2  negative, BRCA1/2 mutant  breast 
cancer refractory to chemotherapy  
Talazoparib  1. Treatment  of BRCA  mutated,  HER2 negative locally advanced or 
metastatic breast cancer  
Table 2:  FDA Approved  PARPi  in 2018:  PARPi=PARP inhibitor;  CR=complete response; 
PR=partial response 
Interestingly, tumor hypoxia leads to repression of DNA repair through both HIF - 
dependent  and independent  mechanisms  with suppression  of multiple  repair  mechanisms 
including BRCA1/2  (33), and cells without intrinsic DNA repair defects are increasingly 
sensitive to PARPi in hypoxic microenvironments ( 34). In RCC, where tumors have 
hypoxic  pathway  upregulation through HIF dependent  pathways,  pre-clinical evidence has 
also shown that clear  cell RCCs  are sensitive  to the PARP inhibitor  olaparib,  with evidence 
of subsequent  increase in replication stress,  suppression  of DNA  synthesis,  and event ual 
cell cycle arrest. RCC cells that also harbor BAP1 mutations, a known secondary 
chromatin modifying gene mutation with aggressive clinical courses, have also shown 
increased sensitivity to the PARP inhibitor olaparib ( 35). In line with  supportive evidence 
of PARPi in  BRCAness  tumors,  VHL-deficient cells  were  sensitive to  PARPi  olaparib and 
talazoparib when compared with VHL-wild type cells ( 30). 
Interestingly, germline and somatic loss of FH and SDH also contribute to genomic 
instability  through accumulation of oncometabolites and HR suppression.  Recently,  these 
specific mutations have been shown to lead to accumulation of fumarate and succinate 
respectively,  resulting  in inhibition of  α-ketoglutarate  (αKG) -dependent  dioxygenases and 
eventual accumulation of DNA DSBs through HR impairment and activation of DDR pathways ( 36). Taken a step further,  FH- and SDH - deficient tumors were also found to 
be sensitive  to the  PARP inhibitors olaparib and talazopar ib in vitro  and in vivo . Selected 
results  regarding tumor  xenograft models of FH - and SDH-  knockdown in nude mice are 
displayed below ( 36). 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
12  
 
 
 
 
SDH -deficient  
 
  
 
FH-deficient  
 
 
 
 
 
 
Figure  1: FH - and SDH - Sensitivity to Talazoparib: Nude mice  tumor  xenografts were implanted with FH- 
and SDH-deficient  cell lines by shRNA  knockdown versus vehicle control. Treatment  with talazoparib (BMN  - 
673) resulted in significantly  delays in growth after tumor implantation. Adapted from ( 36). 
RMC tumors  which  are characterized for SMARCB1 -loss have also  been proposed to be 
sensitive to PARPi therapeutic  strategy.  Firstly, in vitro growth of SMARCB1 -loss cell  lines 
have been shown to be inhibited to olaparib and this drug sensitivity appeared more 
profound when compared to BRCA1 -mutant cell lines (HCC1395 and HCC1937) ( 14). 
Moreover,  RMC cell lines shown  sensitivity to both olaparib and niraparib, and a patient 
derived xenograft (PDX) RMC model demonstrated that niraparib treatment led to a significant reduction in tumor volume in vivo  (Figure 2). ( 14) 
 
Figure  2: RMC Sensitivity  to PARPi.  A RMC PDX model  was generated using  banked implanted  tumor 
tissue implanted into subcutaneous tissue of immunodeficient mouse. Treatment with niraparib (PARPi) led 
to regression in tumor  volume compared to vehicle control. Adapted from  (14). 
3.7 Treatment  Paradigms  for Metastatic  RCC  

Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
13  
 Current systemic therapies used for patients with metastatic RCC include vascular 
endothelial growth factor (VEGF) targeted agents, immune checkpoint blockade (ICB), and targeted agents against the mTOR  pathway. Currently, no predictive biomarker has 
been identified to aid in therapy selection, and treatment is clinically determined based upon disease risk  assessed by nomograms  like the MSKCC and International Database 
of Metastatic RCC (IMDC) ( 37, 38 ). Both risk models include clinical and laboratory 
markers which correlate with disease progn osis and ultimately stratify patients into 
favorable,  intermediate or poor -risk disease.  
Based on results from  CheckMate- 214, a randomized phase III study  of ipilimumab  (anti- 
CTLA -4) and nivolumab (anti -PD-1) versus sunitinib in patients with  metastatic clear  cell 
RCC,  combination  ICB is superior  in patients with  intermediate and poor-risk disease with 
improved overall survival (HR=0.53) and objective response rates (42%  ICB versus 27% 
sunitinib) ( 39). In the s econd- line setting, nivolumab monotherapy is also superior to 
everolimus ( 40), and subsequent lines of therapy often employ VEGFR TKI therapies in 
sequential manner. With use of ICB in the first -line setting, focus has shifted towards 
overcoming primary and adaptive mechanisms of treatment resistance.  
For patients with non -clear cell histologies, no sub- type specific large -scale trial has 
defined therapy standards, and VEGFR TKI treatment with sunitinib remains the most frequently chosen agent given combined efficacy results in phase II trials conducted across  all non-clear  cell histologies  (41, 42). Despite  advancements in tumor  subtyping at 
the molecular  and genomic  levels,  treatment  strategies  that incorporate this data continue 
to lag. In patients with  major  papillary component  or HLRCC (sporadic or  syndromic),  two 
treatment programs have been specifically developed. Combination bevacizumab and 
erlotinib have preliminarily shown an ORR 60% compared to 29% in HLRCC patients 
versus sp oradic papillary tumors, respectively, with a significantly prolonged PFS ( 43), 
however  final results  regarding the  efficacy  of this regimen  are pending. In a phase  II trial, 
combination bevacizumab and everolimus also showed robust  response rates  in patie nts 
with major papillary component (ORR 43% versus 29% for all non -clear cell tumors), 
however does not identify genomic features of responding tumors ( 44). Retrospective 
analyses have shown that treatment naïve and refractory  patients also  have response  to 
monotherapy immune  checkpoint blockade (anti -PD-1/PD -L1) with varied ORR 10 -20%, 
without any specific subtype / genomic alteration  associated  with response ( 45, 46 ). 
Outcomes  for patients  with RMC are uniformly  poor,  with <5% of patients surviving greater 
than 36 months,  and treatment  guidelines  have been proposed for patients based upon 
expert consensus ( 47, 48). Based upon a retrospective multi -center review, cytotoxic 
chemotherapy was shown to have an ORR of 29%, generally of s hort duration. The 
reported regimens  in the report  reflect  commonly  used  therapeutic strategies  for RMC and 
included carboplatin / paclitaxel, carboplatin / paclitaxel / bevacizumab, carboplatin / 
gemcitabine, and gemcitabine / doxorubicin. In the same multicenter study, over half of 
the patients were subsequently treated with a targeted agent (sunitinib, bevacizumab, 
pazopanib,  sorafenib,  everolimus,  imatinib),  and treatment  had a median duration  of 8 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
14  
 weeks  with an ORR of 0% (49). This highlights  a desperate need  to develop new regimens 
for this unfortunate group of young RMC patients.  
3.8 Combination PARPi and  ICB Rationale  
Combination PARPi with immune checkpoint blockade therapy may provide additive or 
synergistic  effects  based  upon sever al rationales  (50). PARPi  induced DNA  damage  may 
increase overall tumor mutational burden (TMB) thereby increasing overall neoantigen 
repertoires  for increased cytotoxic T-cell exposure  through  epitope diversity  and enhanced 
immune stimulation. RCC has onl y modest TMB compared  with other tumors which  are 
traditionally immune sensitive ( 51), and mutational burden has been shown to lead to 
enhanced clinical benefits irrespective of PD -L1 status in other tumor models ( 52, 53). 
Moreover,  PARPi induced DNA DS breaks inherently lead to accumulation of cytosolic 
DNA which in turn activates the ST ING (stimulator of interferon genes)/cGAS innate 
immune pathway for stimulation ( 54), and therefore PARPi achieves anti -tumor immune 
effects  outside  of synthetical  lethal  mechanisms.  Interestingly,  pre-clinical work  has shown 
that PARPi  increases  PD-L1 expression,  and blockade of PD -1/PD -L1 axis through PD -1 
blockade may resensitize  tumors  to ICB therapy ( 55), leading to  prolonged model  survival 
compared  with PARPi alone in vivo  (54). PARPi treatment  also leads to release of  many 
pro-inflammatory  cytokines like IFN- γ and TNF- α, thereby priming the microenvironment 
for enhanced immune effector responses in combination strategies.  
Importantly, early trials have employed combination PARPi and ICB therapy without 
significant  overlapping toxicities seen  thus far  in early signals.  The proposed combination 
of talazoparib  and avelumab is being  investigated in other tumor  models  (NCT033304 05), 
and other PARP + ICB combinations  are being tested in many HR deficient (i.e. BRCA 
mutant) populations ([STUDY_ID_REMOVED], [STUDY_ID_REMOVED], [STUDY_ID_REMOVED]). Interestingly, 
preliminary responses have been seen in unselected tumor models ( BRCA mutant and 
wild-type) with combination approaches. A phase I trial of pamiparib (BGB -290), a 
selective PARP inhibitor with tisleizumab (anti -PD-1) has shown preliminary efficacy 
across multiple tumor types ([STUDY_ID_REMOVED]), and in both BRCA -mutant and wild- type 
patients ( 56). 
3.9 Talazoparib  Pre-Clinical and Clinical Experience 
Talazoparib / BMN -673 is a bioavailable, oral PARP1 and PARP2 inhibitor that blocks 
PARP enzyme activity and allows for persistent PARP trapping onto DNA, all of which 
lead to enhanced  cytotoxicity  via inadequate repair  of DNA  damage.  Talazoparib was FDA 
approved in October  2018 for the treatment  of adult  patients  with deleterious  or suspected 
deleterious germline BRCA mutated, HER2 negative, locally advanced or metastatic breast cancers,  tested with an FDA  approved  companion diagnostic designation.  
Early phase data has shown that talazoparib pharmacokinetics remain linear with doses 
increased from 0.25 – 2 mg, and median time to maximum plasma  concentration is 1- 2 
hours after each dose with a steady -state within 2 -3 weeks. Talazoparib undergoes 
minimal hepatic  metabolism  and is mainly  renally  excreted.  Pre-clinical work  has also 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
15  
 shown that when compared to other PARP inhibitors including olaparib and rucaparib, 
talazoparib has a stronger potency  for PARP inhibition  and resultant cytotoxicity ( 57). 
FDA approval was  based on the EMBRACA study, a phase III,  open -label, multi -center 
study ([STUDY_ID_REMOVED]) which evaluated talazoparib 1 mg daily and physician’s choice 
chemotherapy in patients with treatment refractory BRCA -mutant, locally advanced or 
metastatic  breast  cancer  (20). Enrolled patients were treated until disease  progression or 
unacceptable toxicity, and  the median duration of  study  treatment  was 6.1 months  versus  
3.9 months  for talazoparib and physician’s  choice chemotherapy, respectively.  The major 
efficacy outcome measure was PFS evaluated by RECIST v1.1 assessed by blinded independent central  review. When compared to chemotherapy, talazoparib monotherapy 
showed a PFS of 7.6 months  versus  5.6 months  (HR 0.54,  p<0.0001),  ORR  50.2%  versus 
18.4%, and median duration of response of 6.5 months versus 3.9 months.  
Dosing interruptions due to adverse reactions of any grade occurred in 65% of patients 
who received talazoparib, and dose reductions due any causes occurred in 53% of 
patients who received talazoparib versus 40% of patients on chemotherapy. Permanent 
discontinuation due to adverse  reactions of  talazoparib was  only seen  in 5.9% of  patients 
with talazoparib. In <20% of patients treated with talazoparib on trial, following adverse reactions  were  seen  including abdominal  pain (19%),  dizziness  (17%),  leukopenia (17%), 
dysgeusia (10%), dyspepsia (10%), stomatitis (8%), and lymphopenia (7%). Adverse reactions are outlined (Table 3).  
 
Adverse Reactions (in >20% of 
Patients Receiving Talaz oparib) 
in EMBRACA Adverse Reactions Talazoparib  N=286  (%) Chemotherapy  N=126  (%) 
Grades  
1-4 Grade  
3 Grade  
4 Grades  
1-4 Grade  
3 Grade  
4 
       
Blood  and lymphatic  system  disorders  
Anemia  53 38 1 18 4 1 
Neutropenia  35 18 3 43 20 16 
Thrombocytopenia  27 11 4 7 2 0 
Metabolism  and nutrition  disorders  
Decreased  appetite  21 <1 0 22 1 0 
Nervous  system  disorders  
Headache  33 2 0 22 1 0 
Gastrointestinal  disorders  
Nausea  49 <1 0 47 2 0 
Vomiting  25 2 0 23 2 0 
Diarrhea  22 1 0 26 6 0 
       
Skin  and subcutaneous  tissue  disorders  
Alopecia  25 0 0 28 0 0 
General  disorders  and administration  site conditions  
Fatigue  62 3 0 50 5 0 
Table 3:  Summary of  >20% Adverse Reactions on EMBRACA  Phase III Trial. The  majority  of 
non-hematologic  events  in talazoparib group were  grade I in severity  (Adapted from (20)). 
3.10 Avelumab  Pre-Clinical and Clinical Experience 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
16  
 Avelumab / MSB0010718C is a human IgG1 monoclonal antibody that blocks PD -L1 
thereby competitively disr upting the immune checkpoint in T- cell regulation. Amongst 
other immune checkpoint blockers, avelumab is uniquely human IgG1 and therefore 
additionally is capable of antibody dependent cell mediated cytotoxicity due to its  native 
Fc region ( 58). 
In the ear ly phase trial (JAVELIN,  [STUDY_ID_REMOVED] ( 59)) pharmacokinetic analyses have 
shown that there remains a dose proportional exposure of avelumab from 3 mg/kg –  20 
mg/kg,  and population studies  have shown no significant  effects  on clearance of avelumab 
from preme dications or concomitant therapies like opiates or corticosteroids.  Avelumab 
has a drug half -life of 95 -99 hours at the 10 mg/kg and 20 mg/kg dose. Receptor target 
occupancy  was >90% at 3- 10 mg/kg doses.  Anti-drug antibodies have been detected in 
minority of patients (4% in early phase trial). Primary excretion of avelumab remains 
intracellular lysosomal proteolytic degradation, with a terminal half -life of 65.1 days in 
patients receiving 10 mg/kg. Avelumab is not expected to interfere with small molecular 
drugs through p450 enzyme modulators or through absorption or elimination.  
Avelumab gained FDA regulatory accelerated approval based on clinical response for patients with metastatic Merkel cell carcinoma (MCC) in March 2017. In the JAVELIN 
Merkel 200 trial ([STUDY_ID_REMOVED]), an open -label single- arm multicenter study  in patients 
with metastatic  treatment refractory MCC, patients received avelumab 10 mg/kg every 2 
weeks  with an ORR  of 32%,  complete response  (CR)  of 11.4% and  partial response (PR) 
of 21.6%.  The duration of response  was 2.8-23.3+  months,  with 45% of patients  sustaining 
a clinical response  ≥12 months ( 60). Updated results from JAVELIN  Merkel  200a Part  B 
testing monotherapy  avelumab in the first-line setting continue  to show  robust  and durable 
responses ( 61). Multidisplinary review of avelumab for accelerated regulatory approval 
showed that simulated AUC for 10 mg/kg Q2 week dosing had similar overall drug 
variability  for both body weight  based and flat dosing schemes,  and a flat dosing regimen 
should be acceptable.  As such,  the FDA-label for  avelumab was updated in October  2018 
for a recommended flat -dose schedule instead of traditional weight -based dosing. 
Recently launched clinical investigations have also incorporated this approach, notably the JAVELIN -PARP phase II clinical trial in BRCA/ATM mutant tumors 
([STUDY_ID_REMOVED])( 62), and other phase II combination treatments  (i.e. [STUDY_ID_REMOVED]).  
In May 2017,  avelumab received FDA accelerated  approval  for the use in locally  advanced 
or metastatic urothelial carcinoma who have had disease progression during or  following 
platinum -containing chemotherapy, and in patients with disease progression within 12 
months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy. 
Results from the urothelial carcinoma  cohort of the JAVELIN  solid tumor trial showed a 
confirmed  ORR of  16.1%, with a CR rate of 5.6% and PR rate of 10.6% with ≥6 months 
follow- up (63). 
Recent  early  phase  data from the JAVELIN  phase  I solid tumor  renal  cell carcinoma cohort 
of avelumab 10 mg/kg monotherapy every 2 weeks has shown monotherapy clinical 
activity  in both the first-line and second -line settings  (Table  4) (64). In JAVELIN  Renal  101, 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
17  
 a phase III study  combining avelumab and axitinib, a VEGFR TKI, compared to sunitinib, 
superior  results  were  seen  with combination therapy, including: ORR  51% versus  26% by 
IRC, improved PFS  13.8 months  versus 8.4 months  (HR 0.69, p=0.0001)  (65, 66).  
 
Treatment 
Line Patient  # Follow - 
Up TRAE  
(grade  
>3) ORR  Duration of 
Response  mPFS  mOS  
IL 62 14.2 12.9%  16.1%  10.4 8.3 NE 
 patients  months   (8- (2.8-10.4)    
  (6-17)  27.7%)     
2L 20 22.1 5% 10% NE 5.6 16.9 
 patients  months   (1.2- (6.9-NE) (2.3- (8.3- 
  (16-23)  31.7%)   8.2) NE) 
Table 4: Avelumab Monotherapy  in ccRCC. 1L: first -line 2L: second- line TRAE: treatment -related 
adverse events  ORR:  objective  response  rate mPFS: median  progression- free survival  mOS: 
median overall  survival  
Pooled safety data regarding monotherapy avelumab from the phase I JAVELIN  solid 
tumor and phase II JAVELIN  Merkel 200 clinical trial (1650 patients + 88 patients, 
respectively) has been reported ( 67). Grade ≥3 treatment related adverse events were 
seen in 177 patients (10.2%), with  the most  common  being fatigue 1%, increased  lipase 
1%), infusion related reactions (0.6%), and nausea (0.6%). Immune related adverse 
events occurred at any grade in 14.2% of patients (247/1738), with the most common 
including endocrinopathies (6.1%) of which thyroid (5.6%) remained the most 
predominant, as well as rash (5.2%) of any grade. Grade ≥3 immune related adverse events occurred in 1.8% of patients only. Other clinical significantly, immune related adverse reactions  occur ring at an incidence  of <1% of patients  treated with avelumab  have 
also included immune -mediated myositis, arthritis, pemphigoid, hypopituaritism, Guillan - 
Barre syndrome, and systemic inflammatory response. 
3.11 Combination Talazoparib  and Avelumab  Combination Therapy  
As avelumab is  eliminated by  proteolytic degradation, it is  not expected to be affected by 
small m olecule drugs, the cytochrome p450 enzyme system, or the absorption or 
elimination  of other  small  molecule drugs.  Therefore,  expected drug-drug interactions  with 
combination talazoparib and avelumab are low. Furthermore,  there does  not appear to be 
overlapping toxicities  anticipated with this combination given with known individual safety 
profiles.  Avelumab has been previously  combined with axitinib for  patients with advanced 
RCC with no unexpected safety  signals in  a large-scale randomized study  (65). Reported 
treatment  emergent  events ≥3  in the combination were  71.2% versus  71.5%  with sunitinib 
monotherapy.  
Based on the above rationales, this clinical  trial is testing the combination of talazoparib 
and avelumab in patients  with metastatic  renal cell  carcinoma  in two genomically defined 
populations. Based on the phase Ib portion of the JAVELIN PARP Medley 
([STUDY_ID_REMOVED]), in which patients were treated with 0.5 mg, 0.75 mg, and 1 mg daily talazoparib and 800 mg avelumab the recommen ded phase II dose  (RP2D)  was 1 mg 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
18  
 talazoparib for combination therapy. This RP2D was considered based upon a lower 
observed DLT rate than pre- specified  rate per protocol  (<0.33).  No unexpected AEs  were 
also seen with combination avelumab and talazoparib compared to the expected profiles 
of each  individual  agent, and the incidence and severity of  AEs was  generally consistent 
with previously observed rates  for each  individual  agent and  were generally manageable 
(Summary  of Phase Ib Safety Data, Pfizer  Internal  Communication).  
4.0 OVERVIEW  OF STUDY  DESIGN/INTERVENTION  
4.1 Design  
This is a phase  II, open- label, single institution clinical trial of combination talazoparib and 
avelumab in patients  with metastatic  RCC.  This clinical trial will enroll  two separate  cohorts 
in parallel.  The first cohort  of patients will include VHL-deficiency  and will enroll  in a Simon 
two-stage manner (first  stage=10 patients, second stage=19 patients, total=29 patients) 
to allow for  early futility analysis and final efficacy  analysis. The second cohort  will enroll 
15 patients with either FH - or SDH- deficiency  or renal medullary carcinoma (RMC), and 
will enroll a total of 15 patients c ontinually given disease rarity for each of these three 
entities. Given the uniformly aggressive nature of RMC, typically with rapidly progressive 
clinical picture without standard treatment options following failure of first -line 
chemotherapy,  and considering  the fact that SMARCB1  (INI1)  is lost in nearly  all patients, 
we will not require IHC/NGS  testing for RMC patients as part  of study eligibility.  
4.2 Intervention  
Combination talazoparib  and avelumab will be administered in 28-day cycles until disease 
progression or unacceptable toxicity. All treatments will be given in the outpatient clinic. 
Avelumab will be administered  as a 1-hour intravenous  infusion  every 2  weeks  on days 1, 
15 of each 28-day cycle,  at a flat dose of 800 mg. Premedicat ion with acetaminophen and 
diphenhydramine will be included for  all patients to minimize risk for infusion- reactions as 
specified in Section 5.3. Talazoparib will be self -administered orally at 1 mg  daily on a 
continuous schedule. All study medications will be supplied by Pfizer.  
 
5.0 THERAPEUTIC/DIAGNOSTIC AGENTS  
5.1 Talazoparib  Drug  Information and Storage  
Commercial  supply  of Talazoparib / BMN -673 will be acceptable  for this protocol,  and drug 
will be supplied by trial sponsor  Pfizer.  Drug  will be supplied in a dosing container which 
will contain sufficient drug for each treatment period including overage. T alazoparib will 
be stored  at room temperatures (15 -30ºC, 59 -86ºF) or per  the approved label. Research 
staff will inform patients on the proper storage requirements for the take home 
investigational drug. Further information regarding talazoparib handling i s listed in the 
investigational brochure.  Any excursions from  the product  label storage  conditions will be 
reported upon discovery. Deviations from the storage requirements should be 
documented  and reported.  Once an excursion  is identified,  the investigational  product  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
19  
 must be quarantined and not used until Pfizer provides permission to use the 
investigational product.  
Talazoparib is self -administered orally once daily on a continuous schedule during days 
1-28 of the treatment cycle. Talazoparib should be at the same tim e, and if a dose is 
missed,  it may be taken up to 12 hours after scheduled time. Patients should not take 
more than one dose within a 24- hour period, and if any doses are missed in the cycle, 
they will not be made up and should be recorded as missing in the patient’s diary.  The 
reason for the missed  dose  should be recorded in the diary for  study  personnel to review. 
The patient is then instructed to resume subsequent doses the next day as prescribed.  
Patients are to self -administer  talazoparib orally with or without food.  Capsules should be 
swallowed whole with a glass of water without chewing, dissolving or opening prior to 
swallowing. Talazoparib can be taken with a light meal/snack, and then should be 
swallowed  whole and not chewed,  crushed,  dissolved or  divided.  If vomiting occurs  after 
talazoparib is swallowed,  the dose  itself should only be replaced  if intact tablets are seen 
and counted.  
Patients are not to exceed the prescribed  dose  at any time.  The use of study  medication 
in doses exceeding that specified in this protocol will be considered an overdose. There 
are no known antidotes for talazoparib in the event of an overdose, and treatment for 
adverse events should be aimed at underlying adverse symptoms.  
6.1 Avelumab  Drug  Information and Storage 
Commercial  supply Avelumab / MSB0010718C  will be acceptable for this protocol, and 
drug will be supplied by Pfizer.  Drug will be  supplied as a clear,  colorless,  non-pyrogenic 
solution, packaged in a type I glass vial containi ng 10 ml  of solution with  a rubber  stopper 
and aluminum overseal and flip off cap. Each single use vial of avelumab contains a 
sufficient amount of product to ensure an extractable volume of 10 ml (200 mg) at 
concentration of 20 mg/Ml, formulated with a pr eservative -free acetate buffered solution 
at pH 5.2 in the presence of polysorbate 20 and mannitol. Avelumab solutions must  be 
prepared in 0.9% sodium  chloride (normal  saline), with  final concentration of avelumab in 
the infusion solutions between 0.15 mg/mL to 8 mg/mL. Total volume of final prepared solution must  be 250 mL. The parenteral investigational  drug products  must  be inspected 
visually for particulate matter.  
Avelumab must  be stored in a refrigera tor, at 2-8ºC, 36-46ºF. It  is not frozen and must  be 
protected from light. It cannot  be shaken  vigorously. The solution itself must  be allowed  to 
reach room temperature for a minimum of 30 minutes prior to dose preparation. The 
immediate administration of a prepared solution kept at room temperature is preferred. 
Further information regarding avelumab storage and preparation is provided in the 
investigational brochure.  
Avelumab will be  provided to each  patient in the outpatient chemotherapy  administration 
suite  and will be provided  on cycle  day 1 and day 15 (every  2 weeks).  Doses  may be given  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
20  
 within a 72- hour period per visit window (Schedule of Activities), and if any doses are 
missed in the cycle, they will not be made up and should be recorded as missing. 
Avelumab will be administered with a pre -medication as per below (Section 5.3).  
6.1 Avelumab Premedication 
Avelumab must be infused with premedication to mitigate the rate of infusion- related 
reactions. Premedication will include antihistamine and acetaminophen 30- 60 minutes 
prior to the first 4 infusions. Premedication should be then administered for subsequent 
avelumab infusion based upon clinical  judgement and presence/severity  of prior infusion 
reactions. Availability for immediate access to intensive care unit or equivalent 
environment for treatment of anaphylaxis is required. This should include access to steroids  (i.e. dexamethasone), epinephrine (i.e. 1:1000 dilution), allergy medications (IV 
histamines), bronchodilators or equivalents, as well as oxygen. Following the first four infusions of avelumab, patients should be observed for at least 60 minutes for potential 
infusion related complications  and reactions.  Provided no infusion reactions  are seen this 
observation period is not required beyond dose  #4. If a hypersensitivity reaction occurs, 
the patient should be treated according to the best available medical practice with 
consideration for treatment modification (Table 5).  
Symptoms  of hypersensitivity reactions may  include, but are not limited to, fevers, chills, 
hypotension, flushing, dyspnea, wheezing, back  pain, abdominal pain, urticaria. Patients 
should be instructed  to immediately report to the Investigator  any delayed reactions that 
occur after clinic. Management of infusion related reactions are listed below, and in Appendix 3.  
 
NCI CTCAE  Severity  Grade  Treatment  Modification  
Grade  1 – mild 
• Mild transient  reaction; infusion 
interruption not indicated; intervention 
not indicated.  • Decrease the avelumab infusion rate by  
50% and monitor  closely for any  worsening.  
• Next scheduled  infusion can be re- 
attempted at original  rate, per treating 
investigator’s  discretion.  
Grade  2 – moderate  
• Therapy  or infusion interruption indicated 
but responds  promptly  to symptomatic 
treatment (for  example, antihistamines, 
NSAIDs, narcotics, IV fluids; prophylactic 
medications indicated for ≤24 hours.  • Temporarily  discontinue avelumab infusion. 
• Resume avelumab infusion  at 50%  of 
previous  rate once infusion- related reaction 
has resolved  or decreased to at least 
Grade 1 in severity  and monitor closely for 
any worsening 
• Next scheduled  infusion should be initiated 
at 50% of original  rate. Added 
premedication should be considered. 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
21  
  
Grade 3 or Grade 4 – severe or 
life-threatening  
• Grade 3: Prolonged (for example, not 
rapidly  responsive  to symptomatic 
medication and/or  brief interruption of 
infusion);  recurrence of symptoms 
following initial improvement; 
hospitalization indicated for  clinical 
sequelae.  
• Grade 4: Life- threatening consequences; 
urgent  intervention indicated.  • Stop the avelumab infusion immediately 
and disconnect infusion tubing from the 
patient.  
 
• Patients must be withdrawn immediately 
from avelumab treatment and should not 
receive  any further  avelumab  treatment.  
Table 5: Avelumab Infusion Reaction Algorithm. For each NCI CTCAE  grade, a treatment 
modification instruction should be followed.  
If the infusion rate of avelumab has been decreased by 50% due to  an infusion reaction, 
it should remain at the decreased infusion for the next scheduled dose. If no infusion 
reactions were observed during that next scheduled infusion, the infusion rate may be 
returned to baseline at subsequent infusions.  
If, in the event of a Grade 2 infusion related reaction that does not improve or worsens 
after implementation of  the modifications  indicated above (including reducing the infusion 
rate by 50%), systemic corticost eroids should be considered, per treating physician’s 
discretion and with  discussion  with the PI. At  the next dose,  the treating physician should 
consider  addition of H2 blocker antihistamines  (i.e. famotidine or  ranitidine),  meperidine, 
or ibuprofen to the mandatory premedication. Prophylactic corticosteroids up to the 
equivalent of 10 mg prednisone could be considered for recurrent grade 1- 2 reactions 
despite premedication with above medications.  
6.1 Treatment Interruptions / Delays  
Talazoparib may be maximal ly interrupted for 28 consecutive days. Avelumab may be 
maximally  interrupted for 42 consecutive days.  Should treatment  toxicities warrant  longer 
treatment interruptions than these, the respective agent should be discontinued 
permanently.  
If a treatment -related adverse event is clearly attributable to one, not both, of the two 
investigational agents and triggers a treatment interruption per protocol guidelines, the 
other agent may be continued at the treating investigator’s discretion. In the case of permanent discontinuation of either agent despite the absence of disease progression, 
the other drug may be continued as monotherapy, if tolerable.  
For the therapy cycle, it will be acceptable to have therapy delivered within a 72- hour 
window  before and after  the protocol  related date. The exception for this 72- hour window 
rule will be if regularly scheduled treatment dates occur  on Fridays, as the window will 
include Tuesday (day -3), and Tuesday (D+4).  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
22  
 For each 28- day treatment cycle, the patient may be permitted to have a new cycle 
delayed for up to +7 days without being considered a protocol deviation.  
6.1 Drug  Accountability  
The study  team  will maintain adequate documentation regarding the receipt,  use, loss and 
other dispositions of all investigational drug supplies. All the investigational products 
should be accounted  for using a drug accountability  form/record.  Unused talazoparib must 
be returned to the investigator or  study  team personnel  by each patient on Day 1 of every 
cycle and at the end of the clinical trial participation.  
6.0 CRITERIA FOR  SUBJECT  ELIGIBILITY  
6.1 Subject  Inclusion  Criteria  
1. Biopsy proven, histological confirmed renal cell carcinoma  (RCC)  or renal medullary 
carcinoma (RMC). Patients with surgery and biopsy at outside institutions will be 
eligible for this protocol once archival material is reviewed and the above diagnosis 
confirmed by genitourinary pathology review at Memorial Sloan Kettering Cancer 
Center (MSKCC).  
 
2. Cohort  1: 
a. Presence of VHL alteration by next -generation sequencing (NGS) with a 
state - approved assay  
b. Patients must have radiographic evidence of disease progression after 
treatment with at least one prior PD -1 or PD -L1 agent and one prior VEGF 
inhibitor  
c. Maximum 3 prior lines of therapy  
 
3. Cohort  2: 
a. For FH/SDH patients:  FH- or SDH-  expression- loss by immunohistochemistry 
(IHC) or alteration (somatic  or germline)  in FH or SDH per NGS with  a state - 
approved assay  
b. For Renal Medullary Carcinoma (RMC) patients: histologic confirmation of 
RMC (no IHC/NGS  criteria required)  
c. At least  one prior line of therapy:  
i. For FH/SDH  patients:  Patients  must  have  radiographic  evidence of disease 
progression after treatment  with at least one prior  line of  therapy (one prior 
PD-1/PD -L1 and/or VEGF inhibitor).  
ii. For Renal Medullary Carcinoma (RMC) patients: prior radiographic 
evidence of disease progression on/after  at least  one line of chemotherapy 
(e.g. carboplatin / paclitaxel, carboplatin / paclitaxel / bevacizumab, 
carboplatin / gemcitabine, and gemcitabine / doxorubicin).  
d. No maximum lines of therapy  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
23  
 Both  Cohorts  1 & 2: 
4. Adequate Hematologic  Function  
(1) Absolute Neutrophil  Count  ≥ 1.5 x 109 / L 
(2) Platelet  Count  ≥ 100 x 109 / L 
(3) Hemoglobin ≥ 9 g/dL 
(4) No transfusion  of packed  red blood cells  or platelets  within  21 days of  Cycle  1 Day 
1 
5. Adequate Renal  Function ≥ 30 ml/min  according  to Cockcroft -Gault  Equation 
(1) Patients  with moderate renal  impairment  (creatinine clearance 30-59 by Cockcroft - 
Gault Equation) will start with a reduced dose of talazoparib.  
6. Adequate Hepatic  Function including:  
(1) Total  bilirubin  ≤ 1.5 x upper  limit of normal  (ULN)  
(2) AST ≤ 3 x upper  limit of normal  (ULN)  without  liver metastasis  
(3) ALT ≤ 3 x upper  limit of normal  (ULN)  without  liver metastasis  
(4) AST or ALT ≤ 5 x upper  limit of normal  (ULN)  for patients with  liver metastasis  
(5) Patients  with known Gilbert’s  syndrome  may be included if total bilirubin  ≤ x 3 ULN 
7. Eastern Cooperative  Group  (ECOG)  Performance  Status  0-2. 
8. Patients must  have measurable disease by RECIST v1.1. At least one measurable 
lesion should not have been previously irradiated.  
9. Women of childbearing potential must have negative serum pregnancy testing at 
screening. All women will be considered childbearing potential unless meeting criteria 
including:  
(1) Achieved post -menopausal status as defined by cessation  of regular menses  for 
at least 12 consec utive months with no alternative pathological or physiological 
cause and have follicular stimulation hormone showing postmenopausal state. 
Women  who have  been amenorrhoeic for  ≥12 months  are still considered to be  of 
childbearing potential if the amenorrhea is possibly due to prior chemotherapy, 
anorexia, low body weight, ovarian suppression, anti -estrogen therapy or other 
medically inducible reasons.  
(2) Documented  hysterectomy  or bilateral  oophorectomy  surgery  
(3) Medically  confirmed ovarian failure  
(4) Sexually active participants and their partners must agree to use medically accepted methods of contraception (i.e. barrier methods including condoms, 
female condom, or diaphragm with spermicidal gel) during the study an d for 7 
months after the last dose of the study treatment for females, and 4 months for 
males.  
10. Recovery  of baseline CTCAE  v5.0 grade  ≤1 toxicities related to  prior study  treatments 
unless adverse  events are clinically non -significant and/or stable on supportive therapy if 
needed.  
11. Patients  must  be willing and able to comply  with trial protocol.  This includes adhering 
to the treatment plan, scheduled visits,  laboratory  and other study procedures.  
6.2 Subject  Exclusion  Criteria  
1. Patients <  18 years  old 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
24  
 2. Patients who are pregnant or breast -feeding. Fertile patients who are unwilling or 
unable to use two methods  of contraception  (at least  one of which  considered highly 
effective)  for duration of  study  and after 7 months  after last dose of study  treatment 
for female, and 4 months for males.  
3. Patients  who had prior immune checkpoint  blockade therapy  (either  anti-PD-1, anti- 
PD-L1 and/or  anti-CTLA -4) discontinued due to development of  an immune  related 
adverse event.  
4. Prior diagnosis of myelodys plastic syndrome (MDS) or diagnosis of other 
malignancy that requires anti -cancer directed therapy within the last 24 months. 
Exclusions include those cancers that are considered cured by local therapy (i.e. 
Basal cell carcinoma, squamous  cell carcinoma, d ucal carcinoma in situ of breast, 
bladder of cervix) or other cancers that have low malignant potential and do not require systemic therapy (i.e. Gleason- grade <6 prostate adenocarcinoma, 
borderline ovarian malignancy / low malignant potential).  
5. Prior  treatment  with talazoparib or other  agents  that target  PARP  
6. Treatment with anti -cancer therapies within 21 days or five half -lives, whichever 
shorter,  of start date, including monoclonal antibody, cytotoxic therapy, or another 
investigational agent. There is no specific time window between last PD -1/PD -L1 
therapy and start  date of new therapy on protocol.  
7. Significant vascular disease (i.e. aortic aneurysm requiri ng surgical repair, recent 
arterial thrombosis)  within 6 months prior to first dose of therapy.  
8. Evidence of bleeding diathesis  or significant  unexplained coagulopathy  (i.e. absent 
of anticoagulation)  
9. Clinical signs  or symptoms  of gastrointestinal  obstructi on requirement  parenteral  
hydration,  parenteral  nutrition,  or feeding tube.  
10. Uncontrolled effusion management (pleural effusion, pericardial effusion, or 
ascites) which requires recurrent drainage procedures.  
11. Patients  treated  with systemic  immunosuppressants;  except  for 
a) chronic physiologic replacement of ≤ 10mg prednisone (or equiv alent) for 
treatment of adrenal insufficiency; Steroids required for pre- medication 
reactions  
b) Local steroid use  is permitted (e.g. intranasal, topical, inhaled, or local steroid 
injection, i.e. intra- articular)  
12. Patients  with autoimmune disease that may worsen during immune  checkpoint  
blockade therapy are excluded. Patients with diabetes type I, vitiligo, psoriasis, 
hypo-  or hyperthyroid disease not requirement immunosuppressive  treatment as 
above are eligible.  
13. Prior  organ  transplantation including allogenei c stem  cell transplant.  
14. No active  infection  requiring parenteral  antibiotic  therapy.  
15. Prior  diagnosis  of HIV/AIDS  
16. History of either positive HCV RNA viral load or anti -HCV antibody screening 
detectable;  HBV infection with  HBV surface  antigen detection and/or positive HBV 
DNA viral load.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
25  
 17. Known hypersensitivity to talazoparib or avelumab, or any component in 
formulations.  Patients  with known hypersensitivity  to monoclonal  antibodies  (Grade  
≥3 by CTCAE  v5.0)  
18. Live vaccination within 4 weeks of first dose of therapy. All vaccines except 
inactivated are prohibited while on study.  
19. Severe acute  or chronic  medical  conditions  which  may significantly  increase the 
risk of study  participants,  per treating investigator’s  discretion 
20. Radiation therapy to any site (including bone) <2 weeks prior to the first dose of 
therapy. Patients with  clinically  relevant ongoing  complications  from prior radiation 
therapy, per investigators’ assessment, are not eligible.  
21. Symptomatic brain metastasis or leptomeningeal disease requiring steroid use. 
Patients are eligible  if they neurologically stable for 4 weeks,  and have completed 
radiation therapy or surgery, and recovered from side effects.  Patients must  have 
discontinued steroid therapy for at least 2 weeks prior to first dose of study 
treatment.  
22. Current or anticipated use of potent P -gp inhibitors within 7 days prior to 
randomization or anticipated use during the study. Please see Appendix  5 for a list 
of potent P -gp inhibitors.  
23. Inability to swallow capsules, known intolerance to talazoparib or its excipients, 
known malabsorption syndrome, or other conditions which impair intestinal 
absorption.  
24. Investigator  site staff members  directly  involved in study co nduct,  including but not 
limited  to their family  members,  or patients who  are Pfizer  members,  including their 
family members,  who are directly involved in study conduct.  
6.3 Lifestyle Requirements  
The teratogenic risk of combination talazoparib and avelumab remains unknown. 
Talazoparib has been associated with teratogenic risk. Therefore, all fertile male 
patients and female patients who are of childbearing potential, and who remain sexually  active during this study and who are at risk for  pregnancy  must  agree for 
2 methods  of contraception (one which  is considered highly  effective), for at least 7 
months  after last dose  of study  treatment  for women,  and for at least  4 months  after 
last dose of study  treatment for men.  
Study team personnel including investigators and clinical nursing staff should 
confirm that the patient and their partner have selected 2 appropriate methods of 
contraception from the list of contraceptive methods (as listed below). The study 
team will confirm that the patient has received informed consent regarding proper 
use. Continued confirmation of contraceptive use will be obtained during the study 
protocol at time  points outlined, with documentation of affirmation.  
Highly  effective  contraceptive methods  include, but  not limited  to: 
1. Established hormonal methods  of contraception  associated with  ovulation 
inhibition (i.e. oral, inserted, injected  or implanted), provided that  the patient  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
26  
 or male patient’s partner remains on same  treatment throughout the entire 
study period.  
2. Intrauterine device 
3. Male  sterilization  with absence of sperm  in post vasectomy  ejaculate 
4. Bilateral tubal ligation, bilateral salpingectomy or bilateral tubal occlusive 
procedure.  
5. Female partner of male patient who meets criteria for non- childbearing 
potential as defined above, including:  
a. Medically  confirmed ovarian failure  
b. Hysterectomy  and/or  bilateral  oophorectomy  
c. Post-menopausal  state  as defined as a cessation  of regular  menses  >12 
months with no alternative pathologic or physiologic cause,  with serum 
follicular  stimulating  hormone  within  reference  range for postmenopausal 
women by laboratory.  
6. All sexually active male patients must  agree to prevent potential  transfer  or 
exposure of  study agents through ejaculate by using a condom consistently 
and correctly. Condom use must begin at the first dose of investigational 
product, and for at least 30 days after avelumab or after at least 4 months 
after last dose of talazoparib, whichever is later.  
7.0 RECRUITMENT  PLAN 
Patients will be recruited in the outpatient  genitourinary medical oncology service clinics 
at Memorial  Sloan Kettering Cancer  Center  (MSKCC).  Investigators  listed  on this protocol 
will screen patients  for eligibility  for trial participation. Men and women  of all ethnic  groups 
are eligible for participation. Alternative treatment options, particularly FDA approved  
regimens will be discussed with each patients, and questions will be answered by the 
treating investigator before written consent is obtained.  
Potential  research  subjects  will be identified by a member  of the patient’s  treatment  team, 
the protocol investi gator, or research team at Memorial Sloan- Kettering Cancer Center 
(MSKCC). If the investigator is a member of the treatment team, s/he will screen their 
patient’s medical records for suitable research study participants and discuss the study and their potential for enrolling in the research study.  Potential subjects  contacted by their 
treating physician will be referred to the investigator/research staff  of the study.  
 
During  the initial conversation between the investigator/research staff  and the patient, the 
patient  may be asked  to provide certain  health  information  that is necessary  to the 
recruitment  and enrollment  process.  The investigator/research  staff may also review 
portions of their medical  records  at MSKCC in  order to further  assess  eligibility.  They will 
use the information  provided by the patient  and/or  medical  record  to confirm  that the 
patient is eligible and to contact the patient regarding study  enrollment. If  the patient 
turns  out to be ineligible  for the research study,  the research  staff will destroy  all 
information collected on the patient  during  the initial conversation and medical records 
review, except for any information that must  be maintained for screening log purposes.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
27  
  
In most  cases,  the initial contact  with the prospective subject  will be conducted either by 
the treatment team, investigator or the research staff working in consultation with the 
treatment team.  The recruitment  process  outlined presents no more  than minimal risk  to 
the privacy of the patients who  are screened and minimal  PHI will be maintained as part 
of a screening  log. Fo r these reasons,  we seek a (partial) limited waiver of authorization 
for the purposes of (1) reviewing medical records to identify potential research subjects and obtain information relevant to the enrollment process;  (2) conversing with patients 
regarding possible enrollment; (3) handling of PHI contained within those records and 
provided by the potential subjects;  and (4) maintaining information in a screening log of 
patients approached (if applicable).  
8.0 PRETREATMENT  EVALUATION  
Pre-treatment  evaluation to be completed ≤30 days prior  to study  treatment  day 1. 
1. History  and Physical  Examination  
2. Vital Signs  
3. Eastern Cooperative  Group  (ECOG)  Performance Score  
4. Toxicity  Assessment  via CTCAE  v5.0 
5. Assessment  of concomitant medications  and treatment  
6. 12-lead electrocardiogram  
7. Optional  pre-treatment  biopsy  
8. Radiographic  tumor  assessment  of chest,  abdomen,  or pelvis  
9. Radiographic  brain imaging 
10. Bone scan  if clinically  indicated  
11. Verification of  tumor  alteration status  by state -approved NGS assay  (MSK IMPACT 
or other)  
12. Confirmation  of tissue  availability:  
(1) Availability  of archival tissue must  be confirmed prior to study  initiation,  but 
specimens  do not have to be physically  received  or processed  for determination 
of eligibility;  20 unstained slides should be requested, but there is  no minimum 
slide requirement.  
13. Peripheral  Blood Tests  including:  
(1) Complete blood count with differential  (including at minimum neutrophils, 
basophils,  eosinophils, lymphocytes,  monocytes,  hematocrit,  platelet  count, 
hemoglobin, RBC count)  
(2) Comprehensive Metabolic  Profile  (including alkaline phosphatase,  AST,  ALT, 
Total bilirubin, total protein, albumin, sodium,  potassium,  chloride, carbon 
dioxide,  bicarbonate, calcium,  BUN,  creatinine, amylase, lipase, glucose)  
(3) Lactate  Dehydrogenase 
(4) Serum  Pregnancy  Testing for women  of childbearing potential  
(5) Thyroid Function Testing:  TSH,  free T4, free T3 
(6) Urinalysis;  urine protein / creatinine ratio 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
28  
 (7) Screening for hepatitis  B: HBV surface  antigen,  HBV core antibody, with HBV 
PCR performed reflexively  if abnormal results  
(8) Screening for hepatitis  C: anti-HCV  antibody  and HCV  RNA  PCR  performed 
reflexively if abnormal results  
9.0 TREATMENT/ INTERVENTION  PLAN 
Talazoparib and avelumab will be initiated concurrently on Cycle 1 Day 1 and both will 
be continued until confirmed disease progression (except where treatment is allowed 
beyond progression; refer to section 10.6 for further information), patient refusal, 
unacceptable toxicity, or until the study is terminated by the Sponsor,  whichever occurs 
first. 
If talazoparib is  held for  > 28 consecutive  days,  it should  be permanently discontinued.  If 
avelumab is held for > 42 consecutive days, it should be permanently discontinued. 
Should the treating investigator  determine that  exceptional circumstances  apply  and that 
it would  be clinically  beneficial  for the patient  to re-initiate therapy  after a longer  treatment 
break, re- initiation must  be discussed with and approved by the study PI. In the event 
that treatment -related toxicity  is clearly  attributable to only one of drugs,  the other can be 
continued while the first  is being held.  
9.1 Talazoparib Administration  
Talazoparib / BMN -673 will be provided to study participants in capsules for oral self - 
administration.  The 0.25 mg (opaque, white) and  1 mg (opaque, pale pink) capsules  are 
supplied in separate bottles and labeled according to r egulatory requirements. 
Talazoparib will be packaged in induction sealed, high density polyethylene bottles with 
child resistant caps with 30 capsules of a single strength per bottle.  
On Day 1 of each  treatment  cycle,  talazoparib will be dispensed by the clinical team.  The 
patient  and/or  caregiver  should be instructed on how to maintain the product  in the bottle 
during treatment cycle, keep investigational products away from children, and will be 
instructed to return the bottle  to the site  on Day 1 visit of the subsequent  treatment  cycle.  
Talazoparib is a cytotoxic agent, and therefore precautions regarding the appropriate 
secure storage and handling must be used. To minimize undue exposure to study personnel,  dispensing, handling and safe disposal  of talazoparib should only be done by 
qualified personnel  at MSKCC.  Patients  should be advised that talazoparib is an oral anti- 
cancer  therapy  and therefore handling of the  agent should be  done always be used  with 
gloves.  
9.2 Avelumab  Administration  
Avelumab /  MSB0010718C  will be  provided to the pharmacy  as a sterile,  clear,  colorless 
solution that  can be prepared for intravenous administration.  Each  participant  will receive 
a dose of 800 mg intravenously  every 14 days.  Therefore,  4 vials of avelumab drug product 
will then be diluted with 0.9% saline solution. Detailed information regarding instructions  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
29  
 for avelumab preparation with dilution and subsequent administration is available in the 
Investigational  Brochure and above. Any  spills  that occur  during  administration should be 
cleaned by facility’s standard cleanup procedures for biological products.  
9.3 Talazoparib and Avelumab  Combination Administration  
For each 28- day cycle, combination talazoparib and avelumab will be administered on 
Days 1 and15. For Cycle 1, Day 1, medications will be administered per the following 
order:  
1. All required tests  and assessments  will be performed  prior to medication dosing.  
2. Avelumab premedication and talazoparib will be administered to the patient  in any 
order chosen by the study team.  
3. Avelumab infusion will start within 30 -60 minutes after the avelumab premedication 
was administered.  
For subsequent  cycles where patients are administered  both study agents, patients may 
take talazoparib prior to being seen by the clinical team and are encouraged to continue 
the same dosing order as above.  
9.4 Medication  Compliance  
All doses of avelumab will be administered at MSKCC by trained medical  staff. All start 
and stop times of  the avelumab infusion, as well as dosing information including infusion 
time, volume administered, interruption to infusion and/or changes in rate will be 
documented in patient  medical  records.  Vials  of avelumab that are assigned and prepared 
for patients will be recorded in the pharmacy records,  and these records will be made 
available to the Sponsor representatives to verify medication compliance.  
All doses of talazoparib will be given to the patient  at the start of each cycle, and all 
patients will be required to return all unused talazoparib a t the start of the subsequent 
cycle.  The number  of capsules  returned by  the patient  will be counted, documented,  and 
recorded by investigational personnel and reconciled with the patient’s dosing diary to support talazoparib accountability. Study personnel  should make reasonable efforts to 
obtain study drug packaging and unused capsules from those patients who do not 
routinely return them  at the  study  site visit, and unreturned capsules  will be considered to 
have been taken unless otherwise reported by the patient.  
A medication dosing diary will be given to the patient to aid in patient compliance and 
dosing instructions.  The diary  will be maintained by the patient and will include entry  items 
for the patients to include information regarding taken, missed,  or changed talazoparib 
doses.  Patients will be required to return  this completed patient dosing diary on Day  1 of 
every new cycle for timely review by the study personnel during clinical visit. During the 
medical visit, review of this diary as well as discussion regarding missed doses or 
compliance issues  will be done to ensure  medication compliance and accurate data entry. 
During  this clinic  visits in  which  patients present  for avelumab  (day 1 and day 15), patients  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
30  
 are instructed to delay talazoparib dose administration so that it is performed in clinic, 
witnessed by study personnel.  
Treatment  compliance will ultimately be reported as a percentage and will be defined by 
the number of capsules taken during study treatment / number of expected capsules 
taken, multiplied by 100.  
9.5 Talazoparib  Dose  Modifications  
Talazoparib dose modifications can be implemented to help manage toxicities 
encountered during treatment.  Dose  reduction will be done per  dosing level scheme listed 
below  (Table 6). All patients will start on 1 mg daily (RP2D,  Pfizer  internal communication ) 
and be allowed 1 dose level reduction at  a time depending on the starting dose,  type and 
severity of the toxicity. For patients with known moderate renal impairment 
(Creatinine Clearance=30- 59 mL/min  by Cockcroft -Gault Equation) at treatment 
start or if renal impairment  unrelated to study drug develops during the study, 
talazoparib should be  reduced by one dose level (e.g. starting dose 0.75 mg daily). 
If the renal function improves, per investigator judgement this dose can then be increased.  
Patients experiencing dose- limiting toxicities from talazoparib will be dose- reduced to the 
next lower level. In the event of planned dose reduction, patients should hold study treatment for at least 48 hours prior to re- initiation of dose reduced therapy. Such dose 
reductions  may be performed prior to scheduled initiation  of subsequent  study  cycles, i.e. 
in the course  of a treatment  cycle. In such cases  lower -strength capsules  will be dispensed 
mid-cycle, rather  than delaying re- initiation  of therapy  at lower  dose.  Left-over capsules  at 
the prior strength  will be returned  to the study  team  at the next scheduled Day 1 clinic  visit. 
Once the talazoparib dose has been reduced to a dose level because of toxicity for a patient, all subsequent cycles should be administered at that dose level unless further 
reduction is required. Subsequent  re-escalation to prior dose  levels will not  be permitted. 
Patients who are unable to tolerate 0.25 mg (dose level -3) daily will be permanently 
discontinued from  the talazoparib but may  be considered for continuation of  single -agent 
avelumab.  
If talazoparib is held for >28 consecutive days, it should be permanently discontinued. 
Should the treating investigator determine that  exceptional circumstances  apply  and that 
it would  be clinically  beneficial for  the patient to  re-initiate  therapy  after a longer  treatment 
break, then re- initiation must be discussed with and approved by the study PI. If 
talazoparib is discontinued, patients may  continue avelumab.  
 
Dose  Level  Talazoparib  Dose  
Dose  Level  0 1 mg  daily 
Dose  Level  -1 0.75 mg daily 
Dose  Level  -2 0.5 mg 
Dose  Level  -3 0.25 mg daily 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
31  
 Table 6: Talazoparib  Dose  Levels for Cohorts  1 and 2. 
9.6 Avelumab  Dose  Modifications  
There will be no dose modification for avelumab during the duration of this study. If the 
treatment cannot be delivered due to an immune  related adverse event, then avelumab 
will be placed on hold. It is  acceptable for the patient  to continue  avelumab with resolution 
of ≤1 grade I immune related adverse event, and if patient is ≤10 mg prednisone (or equivalent)  as deemed by investigator.  
If avelumab is held for > 42 consecutive days, it should be permanently discontinued. 
Should the treating investigator determine that  exceptional circumstances  apply  and that 
it would  be clinically  beneficial for  the patient to re-initiate  therapy  after a longer  treatment 
break,  then re-initiation  must  be discussed  with and approved by  the study  PI. If avelumab 
is discontinued, patient may continue talazoparib.  
9.7 Concomitant  Medications  
Concomitant  treatments are considered necessary  for patients’ well- being (anti-emetics, 
analgesics etc.) and may be given at the discretion of the investigator. All concomitant medications  including herbal  supplements,  and supportive  medications  will be recorded  in 
medical record from screening visit to 90 days after last dose of therapy. If after study 
treatment has concluded and patient had started new anti -cancer therapy, then further 
details regarding medications will be recorded until start  of new anti -cancer  therapy.  
Allowed  Therapy  
1. Anti-emetics and antidiarrheal medications are allowed prophylactically according to 
standard  clinical practice  as indicated. All patients who experience diarrhea should be 
advised to drink  liberal quantities of liquids and if sufficient  oral intake is  not feasible, 
intravenous infusion of fluid and/or electrolytes should be performed.  
2. Bisphosphonates  or RANK -L inhibitors  may be used  to control  bone  loss if started prior 
to trial initiation or for hypercalcemia treatment if the benefit outweighs risk per investigator’s discretion. As osteonecrosis of the jaw has been reported in those 
patients  treated  with bisphosphonate therapy,  oral examination and serial  examination 
during study is advised in those patients on bisphosphonate therapy.  
3. Anticoagulation is allowed if the patient can  be provided safely  and effectively. This 
includes:  
(1) Use of low molecular  weight  heparin (LMWH)  or direct  oral anti coagulants  (DOAC)  
such  as rivaroxaban  or apixaban is  permitted provided the patient has  no evidence 
of untreated brain  metastases  and has had no complications  from thromboembolic 
event on the anticoagulation regimen within 14 days of starting study  therapy.  
(2) All anticoagulants must be managed with accepted clinical guidelines. This 
includes standard patient education regarding medication compliance and 
administration, potential adverse drug reactions, monitoring of laboratory 
parameters  (i.e. PT/INR/PTT/anti -Xa level),  dose  adjustments  per standard  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
32  
 practice (i.e. dose adjustments  for renal  insufficiency),  with consideration of referral 
to benign hematology for continued follow up and monitoring.  
(3) Immunosuppressive  drugs  are permitted  if initiated f or management  of treatment - 
related adverse events and in accordance with adverse event management 
recommendations in this protocol (See Section 11). Systemic corticosteroids, if 
indicated for management of cancer -related complications (e.g. with palliativ e 
radiation)  are permitted. Depending on dosage (≤ vs.  > 10mg prednisone daily or 
equivalent), administration of immunosuppressants may require avelumab 
treatment delays  (See Section 11).  
4. Caution and monitoring for potential  increased  adverse  reactions  should be used upon 
concomitant  use of the following transporter inhibitors with talazoparib: atorvastatin, 
azithromycin, conivaptan, curcumin, cyclosporine, diltiazem, diosmin, eliglustat, 
elacridar [GF120918], eltrombopag, felodipine, flibanser in, fluvoxamine, piperine, 
quercetin, and schisandra chinensis extract.  
 
 
Prohibited Therapy  
 
1. Any other  anti-cancer  therapy  (chemotherapy,  biological  therapy, immunotherapy, 
vitamins used as cancer  therapies) other than talazoparib and avelumab.  
2. Any other  investigational  agents  other  than talazoparib or avelumab  for anti-cancer 
or non -cancer related therapy.  
3. Immunosuppressive  drugs  while  on avelumab treatment  other  than indicated as 
above. Patients  who have permanently  discontinued avelumab  for any reason and 
remain on study for talazoparib monotherapy are permitted to receive 
immunosuppressive drugs.  
4. Potent P -gp inhibitors: amiodarone, carvedilol, clarithromycin, cobicistat, 
dronedar one, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, 
ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, 
saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, 
and verapamil) whil e on talazoparib treatment (see Appendix 5).  
5. EPO  stimulating agents:  i.e. erythropoietin alpha,  darbepoetin  alfa, 
6. TPO stimulating agents:  i.e. romiplostim,  eltrombopag,  thrombopoietin  
9.8 Concomitant  Surgery  
As the appropriate timing  between surgery  and administration of investigational  agents  is 
unknown, appropriate intervals must be taken to minimize the risk of impaired wound 
healing and bleeding. Therefore,  investigational  products  should be temporarily  on hold in 
the case  of surgi cal procedure and be reinitiated on clinical assessment  of satisfactory 
surgery recovery. The timing of such treatment interruption will be per treating investigator’s discretion. Surgical removal of target lesions should prompt permanent discontinuation of study treatment.  
9.9 Concomitant  Radiation  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
33  
 Palliative  radiation to  non-target  lesions may  be administered  in the setting  of painful  bony 
lesions  and other sites  as considered medically necessary  per investigator. Sites that  are 
to be irradiated  must  be present  at the time of prior screening tumor  assessment,  and the 
investigator  must  be clear  that the requirement  for palliative radiation is not  truly indicative 
of disease progression.  Prior to radiati on therapy, attempts should be made to truly rule 
out disease  progression  in the event there is localized  pain.  Investigational  agents should 
be held during the duration of palliative radiotherapy and can be restarted upon 
satisfactory  recovery for any radiotherapy related toxicities, but no sooner than 48 hours 
post-radiotherapy. Radiation of  target  lesions or  radiotherapy prompted by local growth  of 
metastatic disease are not permitted.  
9.10 Hypercalcemia Management  
Bisphosphonate or denosumab therapy  can be administered as per loc al clinical practice. 
The need to start or escalate bisphosphonate  or denosumab therapy for  the management 
of malignant hypercalcemia during investigational drug treatment for those patients >2 weeks on investigat ional drug products may be considered a symptom of disease 
progression.  As such,  radiographic  reassessment  of disease  extent  should be considered 
if there is suspicion of disease progression.  
10.0 EVALUATION DURING  TREATMENT/INTERVENTION 
10.1 Screening  
All screening activities must  be completed  ≤28 days prior to study enrollment. 
Procedures  during screening are detailed under the Schedule of Activities (See  Section 
10.7).  
10.2 Treatment  Period  
All activities during treatment period have been detailed under the Schedule of  Activities 
(See  Section 10.7).  During  times  where  multiple  tests  or procedures  are scheduled during 
the same  time point,  the following priority  should be assigned and adhered to in this order:  
1. Vital Signs should be obtained prior to clinical safety laboratory testing but may be 
performed before or after ECG.  
2. Clinical Laboratory  Testing 
3. All other study related procedures should be performed as close to scheduled times 
but may be obtained before o r after blood specimen collection unless sampling is 
determined to impact results.  
Every  effort  should be made to ensure that the protocol  required tests  and procedures  are 
completed as described. If it is not feasible for the patient to perform the test, the 
investigator  should make all necessary  efforts to ensure the safety and well -being of the 
patient. When the protocol -related test cannot be performed, the investigator should 
document  the reason for this and any corrective or  preventative action  to ensure that 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
34  
 normal  processes  are adhered to in the  future for that patient. The study  team should be 
informed of these incidents in a timely manner.  
10.3 Safety  Assessments 
Safety  assessments  will include,  but are not limited  to, collection  of adverse events (AEs), 
serious adverse events (SAEs), vital signs, physical examination, 12- lead 
electrocardiogram (ECG), laboratory assessments,  pregnancy tests, and verification of 
concomitant  medication and treatments. Adverse events will include the type, incidence, 
severity (as graded by NCI CTCAE v5.0), timing, seriousness and relatedness.  
All patients  should  undergo height  and weight  (height will  be measured  at screening only), 
assessment  for ECOG performance status, vital signs, and physical examination (full 
physical  examination at  screening,  focused  physical  exam as indicated during follow- ups) 
prior to study treatment administration.  
All patients will require a  baseline ECG,  and on- treatment  ECGs should be performed  as 
clinically  indicated. Clinically  significant  findings on subsequent  ECGs  should be recorded 
as adverse events and best practice management should be followed including 
consideration of referral to cardiology for further ev aluation and/or management.  
Safety monitoring with hematologic and blood chemistry  labs will be drawn at the time 
points as described in the Schedule of Activities (see Section 10.7). The required safety 
testing should be reviewed prior to study drug administration on Days 1 and 15 of each 
treatment cycle. Blood chemistry and hematologic  assessment must be performed at 
baseline, prior  to each  avelumab dose,  end of treatment  visit, and 30  days post -treatment 
for safety  follow up. For  female patients  of childbearing potential, urine pregnancy  testing 
must  be performed  at baseline and at least  every  month  during  treatment.  Thyroid function 
testing (Free  T4, Free T3, TSH)  must  be performed  at baseline,  and at least  every  4 weeks 
during treatment, and at the end of treatment visit or 30 days post -treatment in safety 
follow up (if not perform ed within 8 weeks of study treatment end).  
 
Safety  Lab Monitoring  During 
Treatment  Lab Parameters  
Hematology  WBC  with differential,  hemoglobin,  hematocrit, 
Platelets, Absolute Neutrophils, Absolute 
Lymphocytes, Absolute Monocytes, Absolute 
Eosinophils, Absolute Basophils  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
35  
  
Chemistry  AST, ALT, Alkaline Phosphatase, Sodium, 
Potassium, Chloride, Total Calcium, Total 
Bilirubin, Urea/BUN, Creatinine, Glucose 
(non- fasted), Albumin, Total protein 
(screening), amylase (screening), Lipase 
(screening), LDH (screening)  
Thyroid  Function  Testing  TSH,  Free T4, Free T3 
Urinalysis  Urine dipstick for urine protein – if positive, 
collect microscopic reflex testing. Urine 
dipstick for blood –  if positive, collect 
microscopic reflex  testing.  
Pregnancy  Testing  For female patients of childbearing potential, 
serum testing with a sensitivity of at least 25 
mIU/mL.  
Table 7: Lab Monitoring During Therapy . Abbreviations:  WBC=white blood cell; ALT=alanine 
aminotransferase, AST=aspartate aminotransferase, BUN=blood urea nitrogen, LDH=lactate 
dehydrogenase,  TSH=thyroid stimulating hormone,  T4=thyroxine,  T3=triiodothyronine 
10.4 Pregnancy/Contraception Safety  Monitoring for  Female  Patients of 
Childbearing Potential  
All pregnancy tests in this study must  have a sensitivity of at least 25 mIU/mL human 
chorionic  gonadotropin  (hCG) and must  be performed  by a certified  laboratory. For  those 
female patients enrolled who are of childbearing potential, 2 negative pregnancy t ests 
are required before receiving study treatment. These two tests will include negative 
pregnancy  test during the screening period,  and an additional negative pregnancy  test at 
baseline on Cycle 1 Day 1 prior to receiving study treatment.  
Following the negative pregnancy tests obtained at screening for trial enrollment, 
appropriate contraception must be commenced if sexually active. Pregnancy tests will 
then be required at baseline and will be  repeated on Day 1 of every treatment  cycle  prior 
to dosing eit her study drug during active treatment period, and again at the End of 
Treatment visit to confirm that the patient has not become pregnant during the study 
period. Pregnancy  tests  will also  be done during the study  treatment  if there is suspicion 
for pregnancy and may be requested by institutional review board (IRB)/ethics 
committees. In the case of a confirmed positive pregnancy test, the patient will be 
immediately withdrawn from the study treatment but may remain the study for follow -up 
purposes only (short term follow -up and long -term follow- up). 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
36  
 For female patients who are of childbearing potential and male patients capable for 
fathering children, affirmation that they meet criteria for the correct  use of two selected 
methods  of contraception must  be obtained. The investigator or study  personnel s hould 
discuss with the patient the need for contraceptive use consistently.  In addition,  patients 
will be instructed by the study personnel to call immediately if one or both selected contraception methods are discontinued, or if pregnancy is known or suspected in the 
patient or patient’s partner.  
10.5 Disease Response  Evaluation  During Treatment  
Tumor assessments will include all previously known disease sites. At screening, all 
patients  will undergo cross- sectional  imaging with CT chest/abdomen/pelvis with contrast 
if able, or non- contrast CT chest with paired MRI of abdomen/pelvis with contrast if 
patients are unable to receive CT contrast. Patients who have contraindications to MRI 
imaging but are not deemed candidates  to receive iodine- based contrast  will proceed with 
CT chest/abdomen/pelvis without IV contrast.  
All patients will also undergo baseline brain MRI or contrast enhanced brain CT at 
screening. Again, patients unable to receive either will proceed with CT brain imaging 
without IV contrast. For those  patients who have stable brain metastases present at 
baseline, brain imaging will be performed at each tumor assessment.  For those patients 
without baseline brain metastases,  brain imaging with MRI or CT  will only be performed 
when clinically indicated and if new brain metastases are suspected.  
All CT scans  will be performed assuming ≤5 mm  thickness. FDG -PET/CT  or ultrasound 
measurements  will not be allowed  in lieu of MRI/CT  for tumor  assessments  in this protocol. 
If a new lesion is  identified by  ultrasound during study  duration, CT  and/or MRI should be 
used for confirmation and inclusion of information.  
If feasible,  the same  imaging  technique  should  be used to characterize  each identified  and 
reported lesi on at baseline screening and in follow -up tumor assessments. Tumor 
assessments will be performed at the end of every  8 weeks  for the  first 12 months  of study 
drug therapy. After 12 months,  radiographic assessments  are obtained every 12 weeks. 
Timing of disease assessments  should follow calendar days and should not be adjusted 
for delays in cycle  start times. The allowable time windows for tumor assessments  is ±7 
days. Best response to treatment will be determined by  iRECIST (further details are 
provided in section 12.0). Date of progression will be determined for progression- free 
survival analysis in secondary endpoint review by RECIST v1.1. Although a clear progression of non-target lesions  without progression of target lesions is  rare, the opinion 
of the treating physician should prevail in all circumstances. Tumor assessments will 
continue until disease progression or if a patient  discontinues  therapy  due to reasons  other 
than progression, including toxicity.  
10.6 Treatment  Beyond  Progression 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
37  
 Immune  checkpoint blockade agents including avelumab may  produce anti -tumor  effects 
by potentiating  immune  effector responses,  and responses  may be delayed compared  to 
typical response  patterns seen with targeted or cytotoxic agents. Clinical  responses may 
include an initial increase in tumor burden and/or appearance of new lesions with then 
eventual regression of disease, termed “pseudoprogression”. Therefore, if radiographic imaging shows  disease progression,  tumor assessment  should be repeated  4 weeks  later 
to confirm true progressive disease (PD) per iRECIST criteria ( 68). Patients may also 
continue to receive investigational agents at the investigator’s discretion if the patient is determined to be clinically benefiting,  as defined by:  
1. No declines  in ECOG  performance  status  
2. Absence of rapid progressive  disease by radiographic  imaging  
3. Absence of clinical signs  or symptoms  of disease  progression  (including worsening 
laboratory values)  
4. Absence of progressive tumor at critical anatomic sites (i.e. cord compression), 
which may  require urgent or emergent alternative  medical  interventions  
The investigator’s  judgement  should be  based on the overall benefit risk  assessment  and 
the patient’s clinical condition including performance status,  clinical symptoms,  adverse 
events, and laboratory data. Before therapy continues at confirmed progressive disease 
(PD) per iRECIST  criteria ( 63), investigators  must  discuss  allowance with the PI, and the 
patient must  be re- consented to this protocol with the understanding that they may be 
foregoing approved therapy options with possible clinical benefit.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
38  
 10.7 Schedule  of Activities  
 
Activity  Screening   Cycle  1-3+ Follow -Up 
  
≤28 days C1 
D1 C1 
D15 C2 
D1 C2 D15 C3+ D1 C3+ D15 End of 
Treatment (EOT)*  
Short  
Term Follow - 
Up  
Long Term  
Visit Window*   ± 3 
days ± 3 
days ± 3 
days ± 3 days ± 3 days ± 3 days ± 30 days ± 7 days ± 28 
days 
Informed 
Consent1 X          
Medical  History2 X          
Pathology  
Review3 X          
Optional Tissue 
Biopsy4  
X   X (± 
7 
days)        
Height5 X          
Physical  
Examination5 X X X X X X  X X  
Vital Signs  5 X X X X X X X X X  
ECOG  
Performance Status
6  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Hematology7 X X X X X X X X X  
Chemistry7 X X X X X X X X X  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
39  
  
Amylase,  Lipase, 
Total Protein7 X Perform as clinically indicated     
Urinalysis  8 X Perform  as clinically  indicated     
Serum  
Pregnancy  Test9 X X  X  X  X   
Hepatitis  B and 
Hepatitis  C 
Serology  
Testing10  
X          
Serum LDH X          
Thyroid  Function 
Testing11 X   X  X     
Optional  Bone  
Scan16 X Perform as clinicallyindicated     
Brain  Scan16 X Perform  as clinicallyindicated     
12-lead ECG12 X Perform  as clinically  indicated     
Talazoparib14  Continuous     
Premedication  for 
Avelumab15  X X X X Optional  administration  per prior 
presence/severity  of infusion reactions     
Avelumab   X X X X X X    
Tumor  
Assessments  (CT 
CAP w/ contrast 
OR CT chest  + 
MRI A/P)16  
 
X  
Perform every 8 weeks for  56 weeks,  then every 12 weeks thereafter  until disease 
progression (±7 days)     
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
40  
  
Research  Blood 
Testing17  X  X  X  X   
Toxicity  
Assessments18 X X X X X X  X X  
Concomitant 
Treatment  Use 
Assessment19  
X  
Monitored and Recorded Continuously   
X   
Survival20          X 
* End of Treatment  (EOT) visit window  may occur  within  30 days  of last dose. 
 
1. Informed Consent  must  be obtained prior to undergoing any protocol -related procedures and must  be obtained ≤28 days prior to 
enrollment onto study protocol.  
2. Medical History  Review:  Review of the patient’s medical  history  should  be performed  to allow for accurate  screening and enrollment 
into protocol. This should include patient’s  prior cancer  and non- cancer  medical history, and concomitant  medication use.  
3. Pathology  Review: Confirmation of  existing documentation of  renal cell carcinoma  histology through a specialized genitourinary 
pathology review at Memorial Sloan Kettering Cancer Center.  
4. Optional  Tumor  Biopsy:  Patients  may undergo screening tumor  biopsy  of primary  or metastatic  site, and on-treatment  biopsy  at 
Cycle  2 D1  (± 7 days).  
5. Vital Signs will include blood pressure, pulse rate, temperature and weight. Height will be recorded on screening visit only.  Full 
physical  examination will be  performed at screening,  and subsequent  visits should include focused  physical  exams of  major  body 
systems.  
6. ECOG  Performance Status  must  be documented  in associated toxicity  assessment  sheet  during visits  per Appendix  1. 
7. Laboratory  Testing:  Required safety  laboratory tests  will include: complete  blood count  (hemoglobin, platelets,  white  blood cell with 
differential), blood chemistry (AST, ALT, Alkaline Phosphatase, Sodium, Potassium, Chloride, Total Calcium, Total Bilirubin, 
Urea/BUN,  Creatinine,  Glucose (non- fasted),  Albumin.  Amylase,  lipase  and total protei n are checked  at baseline.  These labs should 
be reviewed prior to study  drug administration on Days 1 and days 15 of each treatment cycle.  
8. Urinalysis:  Urine dipstick  for urine protein – if positive,  collect  microscopic  reflex  testing.  Urine dipstick  for blood – if positive,  collect 
microscopic reflex  testing.  
9. Serum  Pregnancy  Testing:  for women  of childbearing potential,  pregnancy  test results  must  be reviewed prior to study  drug 
administration on Day  1 of each  treatment cycle.  See section on  childbearing potential  (Section 6.1, Section 6.3), and monitoring 
(Section 10.4)  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
41  
 10. Hepatitis  B and C Screening: HBV  surface  antigen, HBV core antibody, with HBV PCR performed reflexively  if abnormal results . 
Screening for hepatitis C: anti -HCV antibody and HCV RNA PCR performed reflexively if abnormal results  
11. Thyroid Function Testing:  TSH,  Free T4, Free T3 
12. 12-lead ECG: ECG is to be obtained at screening and as clinically indicated at follow up visits. If mean  QTc is prolonged > 500 
msec,  ECGs must  be obtained to monitor serially during each day 1 of cycle visits.  
13. Enrollment:  patients  meeting all entry  criteria  will be enrolled  initiate  investigational  product  administration preferable on  the same  
day as enrollment.  Product  administration  must  begin within  5 days  of enrollment.  
14. Talazoparib Administration: On  Day 1  and Day  15 of each  treatment  cycle,  the daily dose of talazoparib should not be  taken  prior 
to the study  visit and will be  taken  in the  clinic  after all assessments  have  been completed,  and before the  avelumab  infusion.  Drug 
supply will be considered when scheduling visit.  
15. Premedication  with Avelumab will be administered  in the outpatient  infusion  suites  on Days  1 and 15 of treatment  cycle  per Section  
5.3. Premedication may be discontinued per presence/severity of infusion reactions seen during Cycle 1 and 2 at Cycle 3 per 
investigator.  
16. Tumor  Assessments:  Assessments  will be performed using  iRECIST  and RECIST  v1.1.  Baseline scans  are to be performed  within  
28 days  prior to the first dose  of the study  treatment.  Baseline bone  scans  are to be performed if clinically  indicated. Imaging should 
be performed  with contrast  agents  unless  strictly  contraindicated  for medical  reasons.  Timing  of disease assessment  should follow 
calendar  days  and should not be adjusted  for delays  in cycle  starts.  Tumor  assessment  should also be performed whenever  disease 
progression is suspected per individual investigator. For patients who discontinue treatment for reasons other than PD, 
assessments should continue after end of treatment until PD. Repeat imaging obtained 4 weeks after initial documentation of response  should be performed for response confirmation. End of Treatment (EOT)  scan  is not required.  
17. Research Blood Testing:  Peripheral  blood will be collected for exploratory  analyses  prior to treatment  initiation  on C1D1,  and serially 
during study. Details r egarding collection methods are  listed  in the  lab manual (Appendix 6).  
18. Toxicity  Assessments will be performed  by CTCAE  v5.0 grading (See  Section 11.1)  
19. Medication reconciliation will be performed  at follow- up visits  to ensure safe and appropriate concomitant  medication  use with study 
treatments.  
20. Survival follow up will be logged at long- term follow- up appointments as described (Section 12.2) until start of new anti -cancer 
therapy, death, withdrawal of study consent  or study discontinuation, whichev er comes first.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
42  
 11.0 TOXICITIES/SIDE  EFFECTS 
11.1 Severity Assessments 
All patients will be assessed for toxicity assessments  per Common  Terminology Criteria 
for Adverse  Events  (CTCAE)  v.5.0., to  describe  the maximum  intensity  of adverse events. 
If the event  is serious,  the CTCAE  grade must  be documented  and be consistent  with the 
description of the CTCAE grade included in the narrative section of the serious adverse 
event report.  
CTCAE grading is displayed by 1 -5, with unique clinical des criptors for each severity of 
AE. The general guideline for this grading scheme relates to the severity of the AE, and 
follows:  
 
Grade  I Mild,  asymptomatic  or mild symptoms.  Clinical  and diagnostic  
observations  only, intervention  may not be indicated.  
Grade  II Moderate:  minimal,  local,  or non-invasive intervention may  be 
indicated. Limiting age -appropriate instrumental ADLs  
Grade  III Severe  or medically  significant,  but not  immediately  life-threatening: 
hospitalization or prolongation of hospitalization may be required.  
Limiting  self-care ADLs, disabling.  
Grade  IV Life-threatening  consequences,  urgent  intervention  is required  
Grade  V Death  related  to adverse  event  
Table 8:  CTCAE  v5.0 General  Grading Guidelines.  
11.2 Adverse Events  
An AE is any untoward medical  occurrence  in a patient  or clinical trial subject  administered 
a medicinal product and which does not necessarily have a causal relationship with this 
treatment.  An adverse event can therefore be any unfavorable and unintended sign (e.g. 
an abnormal  laboratory  finding),  symptom,  or disease temporarily associated with the use 
of a medicinal product , whether considered related to the medicinal  product. An adverse 
event can arise from any use of the drug (e.g. off -label use, use in combination with 
another drug) and with any route of administration, formulation, or dose, including an 
overdose.  This definition also  includes  AEs associated with medication errors  and uses  of 
the investigational product outside what is in the protocol, including misuse and abuse. 
Pre-existing medical  conditions  that worsen during the  study should be recorded as AEs. 
Abnorm al laboratory  values,  ECG  findings, or  vital signs  are to be recorded  as AEs  if they 
meet  the criteria described  in this protocol. All untoward events that occur  after informed 
consent  through 30  days after  the decision to discontinue study  treatment  (or the date  the 
subject is deemed to be a screen  failure) are to be recorded by the investigational site. 
This requirement  includes AEs  from unscheduled  as well as scheduled visits  and includes 
the new onset of or increase in pain during this pe riod. 
Adverse event terms  recorded on the CRFs  will be  mapped to preferred terms  using the 
Medical Dictionary  for Regulatory Activities (MedDRA). Seriousness,  severity grade, and  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
43  
 relationship to study  treatment  will be assessed by the investigator. Severity grade will  be 
defined by the current  version  of the National  Cancer  Institute  (NCI) -Com mon Terminology 
Criteria for Adverse Events (CTCAE).  
11.3 Relationship to Study Treatment  
Assessment  of the relationship of the AE to the study treatment by the investigator is 
based on the following two definitions:  
Not-Related:  A not-related AE is defined as an AE that is not associated with the study 
treatment  and is  attributable to another cause or there is no  evidence to support  a causal 
relationship;  
Related:  A related AE is  defined as  an AE  where a causal  relationship between the event 
and the study treatment is a reasonable possibility. A reasonable causal relationship is 
meant to convey that there are facts (e.g., evidence such as de -challenge/re -challenge) 
or other clinical arguments to suggest a causal  relationship between the AE and study 
treatment. Possibly and probably  related AEs should be documented as related.  
11.4 Follow  up of Adverse Events 
Any related SAEs or any AEs assessed as related that led to treatment discontinuation, 
including clinically  significant  abnormal  laboratory  values that meet  these  criteria,  ongoing 
30 days after the decision to discontinue study treatment must be followed until either 
resolution of the event or determination by the investigator that the event has become stable or irreversible.  This follow- up guidance  also applies  to related  SAEs  that occur  more 
than 30 days after the decision to discontinue study treatment. The status of all other 
continuing AEs will be documented  as of  30 days after the decision to discontinue study 
treatment.  
11.5 Pregnancy and Fertility  Assessments  
Pregnancy  testing is required at  screening and recommended monthly  until the end of the 
trial. Serum  testing should be performed at screening and at  the end of  the study. Serum 
pregnancy testing should be performed at each new cycle  visit every 4 weeks.  There are 
no adequate data from the use of this combination in pregnant women. If a subject 
becomes pregnant during the study, she will be taken off study treatment and will be 
followed up until the outcome of pregnancy is known. Women  on trial should not breast 
feed.  
11.6 Medication  Errors/Overdose  
Any overdose,  or study  drug administration  error that  results in an AE, even if it does not 
meet the definition of serious, requires reporting to Pfizer within 2 business days.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
44  
 11.7 Talazoparib  Toxicity  
11.7.1  Hematologic  Toxicity  Related  to Talazoparib  
Myelosuppression related to talazoparib has been reported and usually requires dose 
adjustment as described below. The rate of grade ≥3 anemia, neutropenia, 
thrombocytopenia in solid tumor patients treated with talazoparib was 39%, 21%, and 15%,  respectively,  and this led  to ultimate  discontinuation of  treatment  in 0.7%, 0.3%,  and 
0.3%  respectively.  Myelodysplastic syndrome  (MDS)  / acute myeloid  leukemia (AML) has 
been reported in 2/584 patients (0.3%) solid tumor patients treated with talazoparib in 
clinical trials. The duration of talazoparib treatment in these patients prior to developing 
MDS/AML  was 4  months  and 24 months,  respectively, and both patients had a history  of 
prior chemotherapy.  
For grade ≥3 anemia,  neutropenia,  thrombocytopenia deemed  related to study  treatment, 
treatment with  talazoparib must  be interrupted with weekly blood counts  until recovery is 
grade ≤1. At that time point, talazoparib  can then be resumed with dose level reduction  as 
outlined in Section 9.5.  
Granulocyte colony stimulating factor (GCSF) may be administered to manage febrile neutropenic episodes per standard of care  guidelines  but should not be used routinely. 
Patients who require transfusion of packed red blood cells (PRBC)  or platelet  transfus ion 
or growth  factor  support  with GCSF  must  therefore  undergo dose reduction upon recovery 
if study  treatment  is to be resumed.  Growth  factor  support  for anemia or thrombocytopenia 
is not permitted on the trial.  
If hematologic  toxicity has not recovered after 4 weeks  in the absence of talazoparib,  it will 
be strongly recommended that the patient undergo evaluation by benign hematology for 
further evaluation for etiology. If the patient does  not have recovery  to baseline within 4 
weeks of dose interruption and/or the patient has undergone 2 dose  reductions, then the 
patient should be discontinued from talazoparib.  
If AML/MDS  is diagnosed during this study,  the patient  must  be withdrawn  from the study.  
 
Hematologic  
Toxicity  Talazoparib  Avelumab  
Platelet 
Count  75- 
99, 
1st 
occurrence Study  medication  must  be 
interrupted until platelet 
count is ≥100/uL with 
weekly CBC counts until 
recovery.  
If recovery  within  4weeks, 
the study medication may 
be resumed at the same 
dose or reduced dose 
based on clinical  
judgement.  Continue  as per schedule  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
45  
  
   
Platelet 
Count  75- 
99/uL,  
 
2nd 
occurrence Study  medication  must  be 
interrupted until platelet 
count is ≥100/uL with 
weekly CBC counts until 
recovery.  
If recovery  within  4 weeks, 
the study medication may be resumed at the same dose or reduced dose 
based on clinical 
judgement.  
If 2nd treatment  interruption 
occurs in <3 weeks after 
resuming from first occurrence, then dose 
reduction should be 
performed.  Continue  as per schedule  
Platelet 
Count  < 75 
/uL Study  medication  must  be 
interrupted until platelet 
count is ≥100/uL with 
weekly CBC counts unt il 
recovery.  
If recovery within  4 weeks, 
the study medication may 
be resumed  at the reduced 
dose level.  1. Consider  workup  for immune  related 
thrombocytopenia to evaluate 
causative role for avelumab.  
2. Consider hold of avelumab and 
reinitiate  avelumab once  toxicity 
Grade ≤1 or baseline.  
Absolute 
Neutrophil  
<1,000 / uL Study  medication  must  be 
interrupted until absolute 
neutrophil  ≥1000 / uL with 
weekly CBC counts until 
recovery.  
If recovery within  4 weeks, 
the study medication may be resumed  at the reduced 
dose level.  1. Consider hold avelumab and 
reinitiate  avelumab  once  toxicity 
Grade ≤1 or b aseline.  
2. Permanently  discontinue avelumab if 
the same  Grade 3 toxicity recurs if 
talazoparib had already been 
discontinued and recurrent event occurs on avelumab only.  
Hemoglobin  
<8 g/dL Study medication must be 
interrupted until hemoglobin 
is ≥9  g/dL with  weekly CBC 
counts until recovery.  
If recovery  within  4 weeks, 
the study medication may  1. Consider workup for hemolytic 
anemia to evaluate causative role for 
avelumab.  
2. Consider hold avelumab and 
reinitiate  avelumab  once  toxicity 
Grade ≤1 or baseline.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
46  
  
 be resumed  at the reduced 
dose level.  3. Permanently  discontinue avelumab  if 
the same  Grade 3 toxicity recurs (if 
talazoparib had already been 
discontinued and recurrent event 
occurs on avelumab only).  
Table 9: Dose  Modification Guide for Hematologic  Toxicity for Talazoparib and Avelumab  
11.7.2  Talazoparib Related  Non-Hematologic  Toxicity  
In EMBRACA,  the most  common  non-hematologic  toxicities  observed  with single agent 
talazoparib (≥20%, all grade) was  decreased  appetite (21%), headache  (33%), nausea 
(49%), vomiting (25%), diarrhea (22%), alopecia (25%), and  fatigue (62%). The  rate of 
these events at toxicity grade 3 was as  follows:  decreased  appetite <1%,  headache 2%, 
nausea <1%, vomiting 2%, diarrhea 1%, alopecia  0%, and  fatigue 3%, and none of 
these adverse events  were  grade 4.  
General management regarding talazoparib management in the setting of non-  
hematologic toxicity is outlined in Table 10.  General guidelines regarding management 
of immune -related  adverse events suspected  to be from  avelumab only is  outline in later 
sections (starting Section 11.4).  
For toxicities  that are  unequivocally related  to talazoparib,  not to  avelumab, infusions  of 
avelumab may  continue per schedule even if talazoparib is held.  
 
Talazoparib -related  
toxicity  Talazoparib  
Grade  1 No changes  indicated  
Grade  2 
Laboratory 
toxicities,  non-heme  • Repeat  laboratory  assessment  within  7 days;  
• continuation of talazoparib per investigator’s 
discretion.  
Grade  2 
Non-Laboratory 
toxicities,  non-heme  • Repeat  investigator  assessment  in 7-14 days 
• continuation of talazoparib per investigator’s 
discretion.  
Grade  3 • hold talazoparib, unless  toxicity deemed  not 
clinically significant (e.g. increase  amylase  / 
lipase  without imaging  or clinical correlate  of 
pancreatitis)  
 
• Resume talazoparib if toxicity resolves to 
Grade≤1 or  baseline within 4 weeks  of dose 
interruption.  
• If the same Grade 3 toxicity  recurs,  reduce  by 1 
dose level.  
• Permanently discontinue if toxicity does not 
improve  to Grade  1 or baseline within  4 weeks.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
47  
  
 • Exceptions  are laboratory  values that  do not 
have any clinical correlate.  
Grade  4 Permanently discontinue talazoparib unless 
laboratory  values do  not have  a clinical  correlate  
Table 10: Dose  Modification  Guide for Non-Hematologic  Toxicity for Talazoparib and Avelumab  
11.7.3  Talazoparib  Related  Gastrointestinal  Toxicity 
Gastrointestinal adverse  reactions  have been reported  with talazoparib. In  ≥20%  of solid 
tumor  patients treated on  EMBRACA,  all grade  events included nausea (49%),  vomiting 
(25%), and diarrhea (22%). Rates  of grade  3 events for nausea, vomiting and diarrhea 
were <1%, 2%, and 1%, respectively, with no grade 4 events reported.  
Rates  of gastrointestinal  lab parameter  changes  have  been  reported with talazoparib.  In 
>20% of patients  at all grade, the rate of increase  in glucose (54%), increase in 
aspartate  aminotransferase (AST)  (37%),  increase  in alkaline  phosphatase (36%), and 
increase in alanine aminotransferase (ALT) (33%). Grade 3 -4 events for each lab 
parameter  occurred with an increase  in AST  2%, increase  in alkalin e phosphatase  2%, 
ALT 1%.  
Guidelines regarding talazoparib management  in the setting of gastrointestinal  toxicity 
can be followed per non- hematologic toxicity guide in Table 10.  
11.8 Avelumab  Toxicity  
11.8.1  Avelumab  Related  Pulmonary  Toxicity  
Pulmonary adverse events have been observed following treatment with avelumab, 
including a fatal case with monotherapy avelumab. In the combined safety data of solid 
tumors (67 ), pneumonitis occurred in 1.2% of patients, and among the 21 patients the 
median time of onset was 2.5 months and duration were 7 weeks (range 4 days -4+ 
months).  All patients were treated with systemic  corticosteroids,  and resolution occurred 
in 12/21 (57%)  patients at time of data cut -off. The majority  of patient reported cases  are 
grade 1 or 2, with study participants presenting with either asymptomatic radiographic 
changes (i.e. focal ground glass opacities, patchy infiltrates etc.) or with symptoms of 
dyspnea, cough or fever. Subjects with  reported grade 3 or 4 pulmonary  AEs were  noted 
to have severe symptoms  with more extensive radiographic findings and hypoxia.  
Asymptomatic patients may be initially managed with consideration of dose delay, per 
investigator’s judgement. Subjects with grade 2 pneumonitis will be managed with dose 
delay and treatment with corticosteroids. In subjects who do not initially respond to 
corticosteroids, anti -tumor necrosis alpha (anti -TNFa) therapies like infliximab and/or 
other immunosuppressants like cyclophosphamide may be considered. Please see Appendix 4 for toxicity related algorithm.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
48  
 11.8.2  Avelumab  Related  Gastrointestinal  Toxicity  
Gastrointestinal AEs have been observed following treatment with avelumab. Most of 
cases  of diarrhea were  low grade (grade 1 -2), with colitis occurring  less frequently than 
diarrhea. High grade  cases  of diarrhea and colitis were  managed are to be managed with 
corticosteroid use and/or  non-steroidal  immunosuppressants  as detailed in toxicity  related 
algorithm (please see appendix 4).  
Immune mediated colitis  occurred in 1.5%  (26/1738 patients),  and all patients  were  treated 
with corticosteroids with 15/26 patients (58%) receiving high dose corticosteroids. Resolution occurred in 18/26 patients (70%) at the time of data cut off, with median duration of colitis 6 weeks.  
Hepatic adverse events including elevated liver function tests, and infrequently, dr ug 
induced liver injury, have been observed in patients following treatment with avelumab. 
Most cases are low or moderate grade, with higher -degree of hepatic adverse events 
management with corticosteroids (with or without mycophenolate mofetil). Early recognition and treatment  of elevated LFTs  and DILI are critical for medical  management. 
If patients notice jaundice, or if they develop bruising, bleeding or right sided abdominal pain, they should be advised to seek medical management immediately. As LFT abnormalities are also common  in patients with malignancy, it is important to distinguish 
whether LFT changes are due to infection, progression of disease, concomitant medications,  alcohol etc. Please see Appendix  4 for toxicity related algorithm.  
Immune mediated hepatitis occurred  in 0.9% of patients receiving avelumab and led to 
the discontinuation in 0.5% of patients (9/1738 patients). Among the 16 patients who 
demonstrated immune mediated hepatitis, median time to onset was 3.2 months, and 
median duration of hepatitis was 2.5 months, and all patients were treated with corticosteroids  for a median  of 14 days. Resolution of hepatitis occurred  in 9/16 patients 
(56%) at time of data cut off.  
11.8.3  Avelumab  Related  Endocrine  Toxicity  
Endocrinopathies may oc cur during or after treatment with avelumab, and therefore 
continued monitoring during and after treatment is needed. Immune mediated thyroid disorders occurred in 6% of patients (98/1738 patients), with the majority of hypothyroidism (5%) of patients. Mos t cases of thyroid related disorders 
(hypothyroidism/hyperthyroidism) are found with changes in thyroid function testing. The 
median time  to onset was 2.8 months,  and immune mediated thyroid disorders resolved 
in 7% (7/98) patients. More than 1 organ invol vement can  be seen (i.e. thyroid disorder 
and adrenal disorder). Moderate and high -grade cases are treated with hormone 
replacement therapy, with or without the addition of corticosteroids. Guidelines  for the 
recommended  management of endocrine related tox icity is provided in Appendix  4. 
Avelumab has been found to cause type I diabetes mellitus (diabetic ketoacidosis) and 
occurred  in 0.1%  (2/1738)  of patients including two cases  of grade  3 hyperglycemia which  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
49  
 led to permanent discontinuation. Avelumab has also been found to cause adrenal 
insufficiency, occurring in 0.5% (8/1738) of patients. All patients were treated with 
subsequent corticosteroids.  
11.8.4  Avelumab  Related  Skin  Toxicity  
Dermatologic conditions including rash, pruritis has been seen following treatment with 
avelumab. Rashes  that occur  are most  typically maculopapular  in appearance, occurring 
in the trunk, back or extremities. In some cases,  the rash and pruritis resolves w ithout 
intervention, and in others, topical corticosteroids and anti -histamines are used for the 
rash and pruritis, respectively. Severe cases respond to systemic corticosteroids. Guidelines regarding the recommended management of skin AEs are provided in 
Appendix 4.  
11.8.5  Avelumab  Related  Renal  Toxicity  
Elevated creatinine, as well as biopsy proven tubulointerstitial nephritis and allergic 
nephritis  are infrequently observed  during treatment  with avelumab.  Subjects  with RCC or 
prior nephrectomy  do not appear  to be at higher  risk. Immune mediated nephritis occurred 
in 0.1% (1/1738) patients and was permanently discontinued in this patient. Please see Appendix 4 for toxicity related algorithm.  
11.8.6  Avelumab  Related  Neurologic  Toxicity  
Neurologic adverse events  have been uncommonly described following treatment with 
avelumab. Neurologic adverse events  may manifest  as central abnormalities  (i.e. aseptic 
meningitis, encephalopathy, or encephalitis), or peripheral sensory/motor neuropathies 
(i.e. myasthenia gravis, Guillan- Barre syndrome). Recommended management of 
neurologic AEs is provided in Appendix  4. 
11.9 Combination Talazoparib / Avelumab  – Dose Modifications  for Treatment - 
Emergent, Unrelated Adverse Events  
Per FDA label,  unrelated Grade 2 renal  impairment  will require talazoparib dose reduction 
to at most  dose  level -1 since  the drug is renally cleared.  
For grade 3 toxicities related to study treatment both agents should be placed on hold during diagnostic workup & AE management; once either drug deemed to have no 
causative role in the development of the adverse event, that agent may  be resumed  per 
treating investigator’s discretion,  while t he other drug (the one  deemed causative)  is held  
/ dose -modified / discontinued as per drug-specific  guidelines  in the protocol  (see Section 
11, above).  
12.0 CRITERIA FOR  THERAPEUTIC  RESPONSE/OUTCOME  ASSESSMENT  
Measurable disease is defined by disease that is accurately measured in at least one 
dimension (further details  below).  All tumor  assessments  will then be recorded in mm. All 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
50  
 patients will be evaluated by iRECIST and RECIST v1.1, Appendix 2 ( 68). Patients are 
evaluable for the primary  endpoint if  they have received at least  50% of the planned doses 
for each agent during Cycle 1. Patients who have taken less than 50% of the planned 
doses  during Cycle  1 will be replaced  for the primary  endpoint, but will  be evaluated in all 
safety  and correlative  analyses.  Patients  who have taken at least  50% of the planned dose 
but do not have a second tumor scan  due to toxicity will be counted as a failure for the 
primary analyses on efficacy. Note, gi ven unpublished data on this drug, we anticipate 
inevaluability  and patients not receiving a second scan to be a rare if not unobserved 
event.  
The following  criteria  will apply to target  and non-target  lesions:  
1. Previously irradiated lesions: Lesions that are previously irradiated will not be 
considered measurable  unless  progression is documented  radiographically previously 
or if a biopsy confirms persistence of disease ≥ 90 days following completion of 
therapy.  
2. Malignant Lymph Nodes: Lymph nodes are considered pathologically enlarged and 
measurable if >15 mm in short axis when assessed by CT scan.  At baseline and in 
follow- up, only the short -axis will be used in measurement.  
3. Measurable  disease,  other: Visceral  lesions are considered measurable if the longest 
diameter measures >10mm.  
4. Non-measurable disease:  Lesions  that include small  lesions  (longest  diameter  <10 
mm) or pathological lymph nodes with <15 mm in short axis will be considered non - 
measurable.  Bone  lesions  without extraosseous  component,  leptomeningeal disease, 
malignant ascites, pleural/pericardial effusion, lymphangitic disease, inflammatory breast disease is not considered measurable.  
5. Target Lesions: Up to five selected measurable lesions (maximum of 2 lesions per 
organ),  will be identified as target  lesions  by the study  radiologist to represent  relevant 
distribution of disease burden and will be measured and recorded at baseline. Target 
lesions should be reproducibly measured in follow up. It may be the case that the 
largest lesions do not lend themselves to reproducibility, at which point next largest lesions should then be selected.  A sum of the diameters of the longest  for non- nodal 
lesions and short -axis for nodal lesions should then be used for the target lesion 
calculation and the sum  of diameters should be used for  baseline. The  baseline sum 
will be used as a reference to further characterize  any objective tumor response.  
6. Non-Target  Lesions:  All other  lesions  or sites of disease including measurable lesions 
over the 5 target  lesions chosen should  be identified as non-target lesions and should 
be recorded at baseline. Measurement of these lesions is not required, but the 
presence, absence, or unequivocal progression of these should be noted during follow- up imaging.  
7. Cystic Lesions: Cystic lesions that meet requirements for radiographic si mple cysts 
should not be considered malignant. Cystic lesions that are thought to represent 
metastases can be considered measurable if they meet the above criteria.  
8. Clinical lesions: clinical lesions will only be considered measurable when they are 
superficial (i.e. skin nodules,  palpable lymph nodes), and >10 mm in diameter when 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
51  
 assessed  using calipers.  In the case  of skin lesions,  documentation  by color 
photography  including ruler to estimate size of lesion  is required  if used  for follow- up. 
 
 
Target  Lesions  
Complete 
Response (iCR)  Disappearance  of all target  lesions.  Any pathological  lymph  nodes 
must  have a reduction in short axis to <10 mm.  
Partial  Response 
(iPR)  At least  30% decline in the sum of diameters of  target lesions  as 
compared  to the reference baseline sum of diameters.  
 
 
Unconfirmed 
Progressive 
Disease  (iUPD)*  At least 20% increase in the sum of diameters of target lesions 
compared  to the reference of the smallest sum of the study (this 
includes the baseline sum if that is the smallest  on the study). In 
addition to the  relative  increase  of 20%,  sum must  demonstr ate an 
absolute increase of at least 5  mm. This will need to  be confirmed 
with imaging for iCPD assessment to  be performed 4 weeks (± 7 
days) later.  
Stable Disease 
(iSD)  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for  PD, compared to reference of the smallest  
sum of diameters  while  on study  
Non-Target  Lesions  
Complete 
Response  Disappearance  of all non -target lesions.  All lymph  nodes must  be 
non-pathological  in size <10 mm  
Non-CR / Non- 
PD Persistence  of one or more  non-target  lesions  
Unconfirmed 
Progressive 
Disease  (iUPD)*  Appearance of one of more new lesions and/or unequivocal 
progression of existing non- target lesions. Unequivocal  
progression should be representative of overall disease status 
changes and not single lesions increases.  
Treatment  beyond  iUPD  / Confirmation  of disease  progression  
 
 
 
Confirmed 
Progressive 
Disease  (iCPD)  If further increase  in tumor  burden, compared  to the last 
assessment,  is seen  as evidenced by  one or  more  of the 
following:  
- if new lesions  were  previously  identified and they  have increased 
in size (≥5 mm in sum of measures for new lesion target or any 
increase for new lesion non- target) or number; if no change is 
seen in new lesions (size  or number) from last timepoint, 
assignment remains iUPD  
OR 
- Further  increase in the size  of non-target disease (does not  need 
to meet RECIST 1.1 criteria for unequivocal progression)  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
52  
  
 OR 
- further increase in the sum  of measures ≥5 mm; otherwise 
assignment remains iUPD  
OR 
- further  increase  in previously identified target lesion iUPD in  sum 
of measures >5 mm or  non-target lesion iUPD (previous 
assessment need  not have shown unequivocal progression)  
OR 
- further increase  in previously  identified target  lesion iUPD sum 
of measures  ≥5 mm, previously identified non-target lesion iUPD 
(does not need to be unequivocal), or an increase  in the size  or 
number of new lesions previously identified  
OR 
- increase in the size  or number  of new lesions previously 
identified  
Table 11: iRECIST  Criteria  for Response Guidelines.  Adapted from (68). 
 
*If iUPD remains  unconfirmed  at the next assessment,  then the appropriate response will 
be assigned (iSD,  iPR or iCR).  Prior  iUPD does  not preclude subsequent  iCR, iPR, or iSD 
on further  assessments  or as best overall  response provided that iCPD is not documented 
at the next assessment after iUPD.  
In the case of dose interruptions, the next cycle should follow the patient’s original 
calendar schedule.  Treatment  cycle  timing will not be delayed for treatment interruptions 
and therefore tumor assessments should continue to occur according to the original 
schedule regardless  of whether  study  treatment  is interrupted. If the patient  discontinues 
treatment prior to confirmed disease progression, tumor imaging should c ontinue at the 
specific  time intervals  until progression or until the start of subsequent  anti-cancer  therapy. 
Disease progression assessments outside of the scheduled windows will not be disregarded.  
Patients may  be treated by investigator pending radiology read on Day  1 of treatment 
cycle  after clinical assessment.  If assessment  subsequently  determines  iCPD the  study 
team will contact the patient to discontinue talazoparib unless the study team determines that the patient is to continue treatment beyond  confirmed progression per 
section 10.6.  
12.1 Calculated  Study  Endpoints  
1. Objective Response Rate (ORR): proportion of  patients with confirmed complete 
response (iCR) or partial response (iPR) assessed by iRECIST, relative to the total 
population of patients evaluable after 4 months.  Confirmed  responses  are those that 
persist  on repeat imaging 4 weeks after initial documentation of response. The final 
best response rate will be calculated 4 months after last patient  accrued.  
2. Progression- free Survival  (PFS):  duration of  time from start of treatment  until death or 
progression of disease by RECIST  v1.1. Patients  who are progression- free at time  of 
analysis will be censored at the time of last valid tumor  assessment.  Patients  with 2 or 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
53  
 more consecutive tumor assessments missing will be censored at last valid tumor 
assessment.  
3. Overall  Survival (OS): duration o f time  from start of treatment  until death of any  cause 
of study  participants.  Patients who are still alive at the time  of analysis and those  lost 
to follow -up will be censored at the time of last follow up.  
12.2 Short -Term and Long- Term Follow  Up 
All patients would continue to be  followed for safety  every 30  days (±  7 days)  through 90 
days in short -term follow up, and then every 12 weeks (±14 days)  in long- term follow up 
until the start of new anti- cancer therapy, death, withdrawal of study consent, or study 
discontinuation, whichever comes first.  
Patients with  ongoing treatment related toxicity following study treatment  discontinuation 
will be followed at  least  every 4  weeks  until the toxicity resolution  or by clinical judgement 
by study  investigat or for  expectation of  further improvement.  If a patient has  discontinued 
study treatment for reasons other than disease progression, patient should continue to 
undergo assessments  during the short -term follow period (+ 90 days) as if they were still 
on therapy,  until new anti-cancer  therapy starts.  For long-term follow up procedures,  visits 
may be conducted in the outpatient clinic or by remote contact  by telephone.  
12.3 Study  Research  Plan 
Tumor  Tissue 
Archival  tumor  tissue will be requested  from patients  who have  undergone biopsy  or tumor 
resection as part of routine clinical care prior to study participation. Patients may  undergo 
pre-treatment biopsy during the screening period if archival tissue is insufficient for 
baseline analysis.  
Optional tumor  biopsies of the primary  renal mass  or metastatic  sites will be offered to all 
patients, to be performed during  screening (within 28d of Cycle  1 D1) and at Cycle  2 D1 
(± 7 days).  While  not a requirement,  every  effort  should be made to perform  a tumor  biopsy 
at confirmed disease progression or if a patient discontinues study treatment due to 
disease progression,  except  in instances  where  the procedure poses  an unacceptable risk 
to the patient in clinical research  setting. Tumor specimen may include nephrectomy or 
metastatic site specimen  and should include 4 core biopsy specimens. 
 
Sample Preparation and Transport  
Fresh tissue: On  the date of biopsy, part  of the specimen will be  transported to the Chan 
Lab. Two core biopsies will be utilized for  RNA/DNA  extraction, 1 core biopsy  will be snap 
frozen,  and 1 core biopsy  will be formalin  fixed and  paraffin embedded.  Portions of  tumors 
and normal tissue can then be prepared for further storage and analysis per laboratory 
guidelines. This will include placement  of portions of tissue  in aliquoted conical tubes in 
RPMI solution in TPS. The snap frozen specimens may be then stored for  future 
investigation,  including micro - and microdissection as well as for DNA/RNA  extraction,  and 
ultimately stored at -80ºC.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
54  
 Archival  Tissue:  If available,  1-2 paraffin embedded tissue blocks  containing formalin -fixed 
tumor slides will be r equested. Paraffin blocks may then be processed according to 
standard institutional protocol, with final preparation of 20 unstained slides for available 
analysis. Specifications regarding tumor  acquisition, sample processing,  and exploratory 
analyses planned are detailed in the  protocol’s laboratory manual  (Appendix  6). 
 
All specimens  will be delivered with the attached specimen submission form.  All tissue will 
then be stored at the Chan  Lab at IPOP,  MSKCC Zuckerman Research Center  (417 East 
68th Street, New York, NY). Samples will be processed for in- depth biomarker 
investigation, including nucleic acid extraction for next generation sequencing analysis 
and mass spectrometry -based approaches as detailed in protocol’s laboratory manual 
(Appendix 6).  
 
Peripheral  Blood  Samples 
Peripheral blood samples  will be collected serially, processed and stored  for all patients 
registered on the trial. This will include Vacutainer CPT whole blood tubes, EDTA  whole 
blood tubes for plasma processing, and Streck BCT tubes for circulating tumor DNA 
assessments. Additional details  on the collection  plan,  sample processing and storage are 
provided in the protocol’s laboratory manual (Appendix 6).  
Time  Points : C1D1,  C2D1,  C3D1,  C5D1+  (every  8 weeks),  End of Treatment  
 
Materials  and Collection : 
 Study  Time  Points**  
Materials§ C1D1*  C2D1  & 
C3D1  C5D1+  (every  8 
weeks)  End of Treatment*  
Vacutainer 
CPT Tubes 
(8mL/each 
tube)  X (3 tubes)  X (2 tube)  X (2 tube)  X (3 tubes)  
Streck BCT 
Tube 
(10mL/each 
tube)  X (1 tube)  X (1 tube)  X (1 tube)  X (1 tube)  
EDTA  Tube  
(6cc/each 
tube)  X (1 tube)  X (1 tube)  X (1 tube)  X (1 tubes)  
 
Table 12: Peripheral  Blood Sample  Schedule  
*All blood  draws  should  occur prior  to avelumab administration.  Collections  may occur  ±7 days  of 
specified time point.  
**An additional  two blood draws  at different  time points  beyond those listed is permitted when  
feasible based upon clinical  / immunological  findings  
§Changes  to these methods may be adapted depending upon the most recent, generally  accepted 
protocols.  
 
Peripheral  Blood  Sample  Preparation 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
55  
 Vacutainer  CPT Tubes:  The BD Vacutainer CPT Tube (Catalog:  362761), or  equivalent, 
will be used. For collection, standard phlebotomy will fill tubes with 8 mL of blood, with 
attempt  to obtain  full 8 mL during collection  attempt.  The tube will then be inverted several 
times after collection to ensure adequate mixing. The patient’s name, MRN, adhesive 
stickers will be attached to the tube. The date/time will be noted on the collection requisition form.  The RSA  will then deliver all specimens  to Chan Lab at IPOP, MSKCC 
Zuckerman Research Center (417 East  68
th Street, New York,  NY). 
Streck Tubes: The Streck Cell -Free DNA BCT tube (Streck Catalog No 218961), or 
equivalent,  will be used.  For collection,  standard  phlebotomy will fill each  tube with  10 mL 
of blood, with attempt to obtain full 10 mL during collection attempt. The tube should be inverted several times after collection. The patient’s name,  MRN should be documented 
on adhesive stickers to each  tube.  The date/time  will be noted on the requisition form,  and 
the tubes  will be placed in a biohazard  bag at room  temperature.  The RSA will then deliver 
all specimens  to Chan Lab at  IPOP,  MSKCC Zuckerman Research Center  (417 East  68
th 
Street, New York, NY).  
EDTA  Tubes:  The BD lavender  tube (BD Catalog: 367863) will be used. For collection, 
standard phlebotomy will  fill each  tube with 6 mL  of blood, with  attempt  to obtain full 6  mL 
during collection attempt.  The tube should be inverted several times  after collection. The 
patient’s name, MRN should be documented on adhesive stickers to each tube. The 
date/time will be noted on the requisition form,  and the tubes  will be  placed in a biohazard 
bag at room temperature.  The RSA  will then deliver all specim ens to Chan  Lab at IPOP, 
MSKCC Zuckerman  Research  Center  (417 East 68th Street,  New York,  NY). Samples  may 
then be stored at -80ºC per standard practice procedure for future analysis.  
 
Data  Entry  for Specimen  Collection  
MSKCC RSA and/or Chan laboratory personnel will collect information into a secured 
database once samples are collected and transported. If a sample  is not fully collected, 
the reasoning  for incomplete or partial collection should be documented into the  database 
as well for accurate records.  
Select  Corelative  Planned Studies 
 
Select  studies  include:  
1. Tissue whole  exome  sequencing,  specifically  identifying  
a. DDR Mutations / Homologous Recombination Deficiency (HRD) Mutations: 3 
DNA based HRD- scoring algorithms will be generated, including HRD loss of 
heterozygosity score (LOH), HRD telomeric allelic  imbalance score (TAI), and 
HRD large scale transition  score ( LST).  Select  genes  to be included in evaluation 
include BRCA1,  BRCA2, PARP1,  ATM,  ATR, RAD51C,  BAP1,  PALB2, MRE11, 
BARD1/BRIP1, RAD50/51/51B/51D,  ERCC2, ERCC3, ERCC4, ERCC5, MMR 
genes , POLE, FANCC,  FANCA, BLM, CHEK1,  CHEK2, RB1,  ATRX  as well as  
others.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
56  
 b. Tumor Mutational Burden: Tumor mutational burden is defined as the total 
number  of mutations  in the genome,  or number  of mutations  per DNA  mega  base 
if derived from targeted sequencing. This analysis will include evaluation of 
INDELs, breakpoint locations and structural  rearrangements.  
2. Tumor  RNA  Sequencing: This will focus  on immune  deconvolution via computational 
methods including CIBERSORT and s ingle sample gene expression analysis 
(ssGSEA) for Immune Subset Profiling: Characterization of immune cell subsets based on PCR based T- cell receptor sequencing, IHC  analysis (PD -L1 expression), 
and T- cell enrichment scores, as well as immune deconvolution as above in 
combination with flow  cytometry data.  
3. Metabolomics: Characterization of tissue  specimens  for oncometabolite expressions 
through mass  spectrometry, with specific attention to fumarate and succinate levels 
as predicted changes in cohort 2 FH/SD H patients only.  
4. FH/ SDH patients: FH and SDH Functional Assessment: With available tissue 
specimens,  all patients  in cohort  2 will undergo MSK -IMPACT  testing for germline  and 
somatic  mutational testing. Further,  all FH/SDH patient  specimens  may also undergo 
investigational  immunohistochemical  staining with research  antibody  testing  (i.e. 2SC) 
to compare  functional loss with genomic and state -approved FH/SDH assay testing.  
5. RMC patients:  while  loss of SMARCB1  (INI1)  is not part of eligibility  it will be assessed 
in all patients  who can provide archival tumor tissue.  
Further specification regarding tumor acquisition, sample processing, and techniques 
used for exploratory analyses planned are detailed in the protocol’s laboratory manual 
(Appendix 6).  
In the course  of this research it is possible that some  patients whose tumors  are analyzed 
through investigational “next -generation” profiling in a research (non-CLIA) environment 
will be found to have somatic or germline mutations in genes that are known to be 
associated with an increased risk of cancer or other diseases. I t will be stated in the 
consent  that the participants will not  receive any  specific results  from research tests. The 
consent will tell participants that if they wish to have genetic testing done for personal 
reasons than they should make an appointment  with the MSK Clinical Genetics Service. 
If in the course of this research a research  finding is obtained that, in the opinion of the 
investigator, may be critical to the preventive care of the participant or their family, the investigator  can communicate  that finding  to the IRB Genomic Advisory  Panel (GAP).  The 
finding will be  reviewed by  the GAP to determine whether  the incidental finding should be 
discussed  with the participant. For MSK, in the event that the GAP determines that the 
finding should be discussed with the participant, and the participant has consented  to be 
re-contacted,  then the treating/consenting physician shall  be contacted by the panel and 
asked to refer  the participant to  the Clinical Genetics Service  for further discussion of the 
research  finding.  
The following  information must  be provided to GAP  for review:  
• Participant  Name/MRN  # 
• Type of Biospecimen  (tissue,  blood,  saliva)  
• Incidental  Finding  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
57  
 • Collection  Protocol  # 
• Contact:  rtmgapirb@mskcc.org  
 
13.0 CRITERIA  FOR  REMOVAL  FROM  STUDY  
13.1 Study  Treatment  Discontinuation  
Reasons  for study  treatment  withdrawal  include,  but are not limited  to: 
1. Voluntary withdrawal by the patient  who is at any time free to discontinue clinical trial 
participation without prejudice for further treatment 
2. Unacceptable toxicity: if attribute to only one of the two investigational study 
treatments, the investigator may continue treatment with the other investigational 
study treatment. If both medications have been interrupted for ≥8 weeks, the patient should be discontinued from the study treatment. 
3. Progressive  Disease: Patients  with confirmed  disease progression by iRECIST  (iCPD) 
or patients who are no longer experiencing clinical benefit as determined by 
investigator should be discontinued from study treatment. Patients with confirmed 
disease progression who are continuing to derive clinical benefit as assessed by 
treating physician may be eligible to continue study treatment, provided that the treating physician has determined that the risks  and benefits remain favorable. Study 
drug discontinuation will be applied to all other cases of disease progression.  
4. Global  deterioration  of health status  
5. Risk to patient  as determined by study  team  and treating physician  
6. Severe non-compliance  as determined by investigator  team  
7. Incorrect  enrollment  of patient  (i.e. patient  does  not satisfy  inclusion  or exclusion 
criteria on review)  
8. Patient  becomes  pregnant  or starts  breast  feeding during clinical trial 
9. Patient  is lost to follow up 
10. Significant  protocol  deviation 
11. Study termination by trial  sponsor  
12. Necessity for other  anti-cancer  therapy  
13. Sexually active patients who refuse to use medically accepted methods for 
contraception during this study and post -study completion (5 months for women, 7 
months for men).  
14. Study  termination or hold by  regulatory agencies  
15. Death 
 
Any patient who  discontinues  study  drugs  should be seen at 30 days post -discontinuation 
treatment  for clinical assessment.  At that time,  patient’s tumor  status  should be assessed 
clinically, and if appropriate, disease status or progression should be confirmed by 
radiographic assessment.  The investigator will provide best available observation, tests, 
and evaluation, and complete safety assessments for the patient given cl inical trial 
participation.  After  the discontinuation of all medications,  all ongoing AEs must  be followed 
for resolution,  unless deemed unlikely  to resolve  due to underlying disease by treating  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
58  
 physician. Any new AEs that develop in the 30 days period post study treatment 
discontinuation should also be assessed in the setting of late onset immune related 
adverse events. Given the potential risk for delayed immune- related toxicities, safety 
follow- up must  be performed up to 90 days after  the last dose  of avelumab  administration. 
Patients should also be continually followed as per iRECIST and RECIST v1.1.  
Patients  should be followed  for survival  follow- up, unless  otherwise  specified  including:  
1. Patie nt refuses  follow- up 
2. Patient  is lost to follow- up 
3. Study  is terminated  by sponsor  
4. Death 
 
13.2 Voluntary  Withdrawal of  Consent  
Patients may withdraw consent from clinical trial participation at any time at their own 
request, or they may be withdrawn at the discretion of the investigator team for safety, 
behavioral reasons,  or inability to comply  with protocol related procedure. The patient is 
free from prejudice regarding future care or treatment.  
 
If a study participant does withdraw from clinical trial participation, the patient should 
continue to be followed for survival unless the patient additionally withdraws consent  for 
disclosure of future information or for further contact from study team. I n that case, no 
study specific evaluation should be performed, and no additional data will be collected. 
Patients  should then notify the  investigator  in writing of  the decision to withdrawal consent 
from future  follow up.  Upon withdrawal,  all unused talazoparib should be returned and the 
patient should be requested to return for final return visit for drug return and to follow up 
with the patient  on any unresolved AEs. The withdrawal of consent  should be explained 
in detail in the medical records by t he investigator as to whether the withdrawal is from 
only further receipt of investigational drug or also from study procedure and/or post - 
treatment follow up. For vital status follow up (i.e. whether the patient is alive or dead), 
publicly available information should also be used  as directed  in accordance to local law. 
 
13.3 Lost  to Follow -Up 
If a study participant does not return for a protocol related scheduled visit, every effort 
should be made by the study team to contact the patient and report upon the ongoing 
status.  All attempts  to contact  the patient  and information received  during contact  must  be 
documented in the patient’s medical record.  In any circumstance,  every effort should be 
made to document  patient  outcome if possible.  Patient  will be deemed lost to follow- up by 
the inability to reach  the patient after a minimum  of 2 documented  phone calls,  emails or 
faxes,  and lack  of response by the  patient to an additional  1 registered mail letter. If, after 
all attempts, the patient remains lost to follow- up, then the last known alive data as 
determined by the study  team  should  be reported  and documented  in the patient’s  medical 
record.  
14.0 BIOSTATISTICS  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
59  
 For both cohorts,  the primary  endpoint  will be best  ORR  as measured after 4  months,  with 
independent  secondary endpoints including PFS and OS  as calculated below:  
1. Objective Response Rate (ORR): proportion of patients with confirmed complete 
response (CR)  or partial  response (PR) assessed by iRECIST  after 4 months  from the 
start of  therapy, relative to the total population of patients evaluable. Confirmed 
responses  are those  that persist  on repeat  imaging  4 weeks  after initial documentation 
of response, and if not, they will otherwise be counted as a non -responder during 
assessment  of ORR.  Additionally,  patients  with inadequate data for tumor  assessment 
will be  considered as non- responders.  The two- sided exact 90%  confidence int ervals 
for ORR will be calculated. The final best response rate will be calculated 4 months 
after last patient accrued.  
2. Progression- free Survival  (PFS):  duration of  time from start of treatment  until death  or 
progression of disease. Patients who do not hav e an event (PD or death) will be 
censored on the date of last adequate tumor  assessment.  Additionally,  patients who 
start new anti -cancer therapy prior to event or who have 2 or more missing tum  or 
assessments will also be censored.  
3. Overall  Survival  (OS):  duration of time from start of treatment  until death  of any  cause 
of study  participants. Patients without  an event (death)  will be  censored  at the data of 
last contact.  
14.1 Cohort  1 Enrollment  and Statistical  Plan 
The primary endpoint is best overall response rate after 4 months of therapy.  The first 
cohort is designed using optimal Simon two- stage design, allowing us to terminate the 
study at an interim timepoint if the data do not s how preliminary efficacy. In stage 1, we 
will accrue 10 patients.  If 1 or more  have  a response in the first 10 patients,  we will continue 
for a total of  29 patients.  If no responses  are observed  in the  first 10 patients, then  cohort 
1 will be  terminated early.  If 4 or more  of the 29  patients have a response,  the study can 
be deemed a success.  If the study  stops early, or if 3 or less have a response,  the study 
will not  be deemed  a success.  If needed (i.e. patients in stage  1 are still on study  and we 
have not observed 4 patients with a response), we will hold accrual prior to enrolling patients on stage 2.  
This design discriminates  between response rates of 5% versus  20% and assumes  80% 
power and a one- sided type I error of 5%. The probability of early termination under the 
null is 60%. A case  report of RCC patients pre- treated with PD -1/PD -L1 inhibitors who 
then went  on to  receive a different PD -1 inhibitor has shown  progressive  disease as best  
response to therapy to subsequent PD -1 agent ( 69). There remains insufficient 
prospective data regarding the efficacy of  immune  checkpoint  inhibitors (monotherapy or 
combination strategy) after progression through a prior immune checkpoint inhibitor 
therapy.  Thus,  since  patients  in Cohort  1 are refractory  to PD-1/PD -L1 inhibitors,  a 5% null 
rate was selected  for this study.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
60  
 As of October 2021,  the cohort is  now closed. The PI, Co- PI, and study  team met 
to review and discuss study compliance, adverse events, toxicities, and overall 
response experienced by  the first  10 patients  enrolled in Cohort 1 on 10/11/2021. 
Patients  were  treated  with talazoparib 1 mg PO daily and Avelumab 800mg IV Q2 
weeks. All patients met the minimum dose exposure criterion as specified in the 
protocol (at  least 50%  of drug in the first cycle) and therefore all  were considered 
evaluable for primary endpoint. All patients had follow -up evaluation by imaging, 
and if the imaging was  performed prior  to scheduled scan per  protocol it  was due 
to concern for early progressive disease. Upon summary review, no patients 
achieved an objective response per iRECIST criteria, and therefore the efficacy threshold was notmet to adv ance to stage 2 per protocol. Therefore, we have 
decided to close Cohort 1 as per study design.  
 
14.2 Cohort  2 Enrollment  and Statistical  Plan 
Cohort  2 includes  rare sub-types  of RCC  including FH- and SDH- deficient  RCCs  and renal 
medullary carcinoma  (RMC). Give n the rarity of these cancers and considering limited 
historical  data,  the sample size for this cohort  is not based  on a formal  delineation of a null 
and alternative hypothesis. All analyses of ORR, PFS and OS will be descriptive. It is 
feasible that we will accrue 15 patients in Cohort 2 in a reasonable timeframe. The 
maximum 90% exact  confidence interval  half-width  for ORR  in a sample size of 15 is 0.23. 
If we observe 1 response, the response rate and 90% exact confidence interval is as 
follows: 6.7% with 90% CI of (.34%, 27.93%).  
For both cohorts,  ORR will be estimated with a 90% confidence interval.  PFS and OS will 
be estimated using Kaplan- Meie r methods. Safety and tolerability will be summarized 
descriptively as frequencies.  Compliance will be summarized by the calculating the 
amount of dose received over the study period.  
14.3 Sample  Size/Accrual  Rate  
The total planned size of cohorts 1 (29 patient s total) and cohort 2 (15 patients). The 
anticipated accrual  time for both cohorts  at MSKCC  is 3 years.  This is based  on the historic 
accrual  patterns that are seen in early and large scale clear cell RCC clinical trials, that 
would  account  for the  majority of  cohort  1 enrollment. Cohort  2 consists  of a rare subtype 
of RCC,  and therefore estimation is more  challenging regarding accrual  patterns.  In prior 
study of non- clear cell RCC, by which FH - and SDH - loss would be accounted for, 34 
patients were accrued within 3 years at the MSK Manhattan site. Therefore, we expect 
accrual  to this cohort  to also be reasonably completed in this timeframe as well.  
Patients are evaluable for the primary  endpoint if they have received at least  50% of the 
planned doses for  each  agent during  Cycle  1. Patients who  have taken less  than 50%  of 
the planned doses during Cycle 1 will be replaced for the primary endpoint, but will be 
evaluated in all safety  and correlative analyses.  Patients who  have taken at least  50% of 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
61  
 the planned dose  but do not  have a second  tumor  scan  due to toxicity will be  counted as 
a failure for  the primary  analyses on efficacy.  Note, given unpublished data on  this drug, 
we anticipate inevaluability  and the  number  of patients not receiving a second scan  to be 
a rare if not unobserved event.  
14.4 Exploratory  Analyses  
Exploratory analyses of biomarkers for response to therapy will be performed in 
accordance  to studies  set forth in the protocol’s  laboratory manual  (Appendix 6).  Analyses 
will be separated by cohort given distinct genomic differences, and all analyses will be 
descriptive and graphical as noted below. Biomarker data will include baseline and on - 
treatment/end of treatment  assessments  of changes to biomarker  data including, but not 
limited to, centrally assessed  defects. Measures are detailed in section  12.3.  
For all continuous measurements  used in biomarker analysis,  summary  statistics  (i.e. the 
mean, standard deviation, median, percent of coefficient of variation, and 
minimum/maximum levels) will be calculated at baseline and on treatment/end of 
treatment  time points,  as appropriate based on patient’s available samples.  Change  from 
baseline measurements will be calculated.  
For discrete measurement biomarkers (e.g., tumor marker status), frequencies and 
percentages of categorical biomarker measures  will be determined at baseline and on 
treatment/post treatment time points, as appropriate; shift tables may also be provided.  
Data from biomarker assays  will be analyzed using graphical methods. Specifically, we 
will graphically examine the relationship between the biomarkers and measures of 
efficacy,  such  as ORR and progression  free survival.  If the data allow,  these relationships 
will be tested using a Fisher’s  exact  test, a Wilcoxon  test, or a log-rank test as appropriate.  
15.0 RESEARCH PARTICIPANT  REGISTRATION  AND RANDOMIZATION 
PROCEDURES  
15.1 Research Participant  Registration  
 
Confirm eligibility as defined in the section entitled Inclusion/Exclusion Criteria. 
Obtain informed consent, by following procedures defined in section entitled 
Informed Consent Procedures. During the registration process registering individuals  will be  required to complete  a protocol  specific  Eligibility  Checklist.  The 
individual signing the Eligibility Checklist is confirming whether or not the 
participant is  eligible  to enroll  in the study.  Study  staff are responsible for ensuring 
that all institutional  requirements  necessar y to enroll  a participant  to the study  have 
been completed. See related Clinical Research Policy and Procedure #401 
(Protocol Participant Registration).  
15.2 Randomization 
 
N/A. No randomization in this study.  
16. 0 DATA MANAGEMENT  ISSUES  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
62  
 A Clinical Research  Coordinator (CRC) will be assigned to this research protocol. The 
responsibilities of the CRC include data collection, abstraction and entry, aid in adverse 
reporting, sponsor communication, audit preparation, and generation of registration 
reports.  The data collected for this study will be entered into a secure database 
(Medidata).  The principal investigator will maintain ultimate responsibility for the clinical 
trial. 
16.1 Quality  Assurance 
Weekly registration reports will be generated to monitor for patient accrual and 
completeness in registration data. Routine data quality reports will also be generated to assess missing data and inconsistencies. Accrual rates and the extent and accuracy  of 
evaluations and follow -up will be monitored periodically throughout the study duration. 
Potential  issues  will be brought  to the attention  of the study  team  for discussion and action 
at protocol  related  meetings.  Random  sample data quality and protocol  compliance audits 
will the conducted by the study team.  
16.2 Data  and Safety  Monitoring 
The Data  and Safety  Monitoring (DSM)  Plans  at Memorial  Sloan- Kettering Cancer  Center 
were approved by the National Cancer  Institute in September 2001. The plans address 
the new policies set forth by the NCI in the document entitled “Policy of the National Cancer  Institute for Data  and Safety Monitoring  of Clinical Trials”  which can be found at: 
http://cancertrials.nci.nih.gov/researchers/dsm/index.html.  The DMS Plans at MSKCC 
were  established and are monitored  by the Clinical  Research Administration.  The MSKCC 
Data  and Safety  Monitoring Plans can  be found on the MSKCC Intranet at:  
http://mskweb2.mskcc.org/irb/index.htm
 There are several  different  mechanisms  by which 
clinical trials are monitored for data, safety and quality. There are institutional processes 
in place for quality assurance (e.g. Protocol  monitoring, compliance and data verification 
audits, therapeutic response, and staff education on clinical research QA) and 
departmental procedures for quality control, plus there are two institutional committees that are responsible for monitoring the activities of our clinical trials programs. The committees:  Data and Safety Monitoring Committee (DSMC) for Phase I and II clinical 
trials,  and the Data  and Safety  Monitoring Board (DSMB)  for Phase III clinical trials, report 
to the Center’s Research  Council  and Institutional  Review Board.  
During  the protocol  development  and review process,  each  protocol will be assessed for 
its level of risk and degree of monitoring required. Every type of protocol (e.g. NIH 
sponsored,  in-house  sponsored,  industrial  sponsored,  NCI cooperative  group,  etc.) will be 
addressed and the monitoring procedures will be established at the time of protocol activation.  
16.3 Study Treatment  Accountability  
The primary investigator and study team will maintain accurate  records of receipt of all 
study  treatment  including dates  of receipt.  In addition,  accurate records  will be kept 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
63  
 regarding the date, lot  number,  and how much study  treatment  is dispensed and used  by 
each subject  in the study. Reasons for deviation from the expected dispensing regimen 
must also be recorded. At completion of the study, to satisfy regulatory requirements 
regarding drug accountability,  all unused study  treatment  will be reconciled and destroyed 
according to applicable state, federal, and local regulations.  
16.4 Conditions  for Protocol Modification  
Protocol modifications including amendments may be made and will be prepared, 
reviewed and approved by representatives of the investigator. Protocol modifications or 
amendments must  be reviewed by Pfizer  prior to implementation.  
All protocol modification must be submitted to the IRB for information and approval in 
accordance with local requirements  and to regulatory agencies if  required. Approval must 
be obtained before any changes can be implemented, except for changes necessary  to 
eliminate an immediate hazard to study subjects or those that involve only logistical or administrative aspects of the trial (i.e. change in telephone number).  
16.5 Conditions  for Termination  of Study  
At any time,  the study  may be terminated by  MSKCC  or Pfizer.  Should this be necessary, 
Pfizer  and MSKCC will arrange the procedures on an individual  study basis after review 
and consultation. Adequate consideration is given for the protection of the subject’s interest. Upon study termination, MSKCC shall cease enrolling subjects into the study, and shall discontinue study conduct as soon as medically practicable.  
17. 0 PROTECTION  OF HUMAN  SUBJECTS  
 
Prior  to the enrollment  of each patient, the risks,  benefits and objectives  of the study  will 
be reviewed with the participant,  including a discussion of the possible toxicities and side 
effects.  Alternative, non -protocol, treatment options will be discussed with the patient. It 
will be reviewed  that participation in this clinical trial is  voluntary and  that the  patient may 
withdraw consent at any time. The study is designed with careful safety monitoring for 
toxicity including physician visits. Specific guidelines for symptom management are in place to protect the study participant.  
Human Subjects  Involvement  and Characteristics : All patients  at MSKCC who meet  the 
inclusion criteria will be eligible. Up to 44 patients will be enrolled on study.  Patients 
eligible will be  18 years of age or older  with an ECOG 0- 2. Both  men and women and 
members  of all ethnic groups are eligible for this trial. Pregnant and breast -feeding 
women are excluded from this study.  This protocol  does not include children because 
this disease does not occur  or occurs rarely in participants under 18 years. This 
statement  is based  on exclusion 4b of the NIH Policy  and Guidelines  on the Inclusion  of 
Children as Participants in Research  Involving Human Subjects.  
Consent  pr ocess : All patients  at MSKCC who meet  the inclusion criteria  will be eligible. 
Participation in the trial is voluntary.  All patients  will be required to sign a statement  of 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
64  
 informed  consent,  which  must  conform  to IRB guidelines.  The informed consent 
procedure is described in Section 18.0.  
Possible  Toxicities/Side -Effects : There  are risks associated with treatment  as described in 
Section 11.0; however, patients screened for enrollment will be deemed appropriate for 
treatment independent of  this study.  
Benefits : The re is a potential  benefit to society,  in that a successful  study  could lead to a 
larger  phase II or III trial which  would  improve our understanding of the treatment  of these 
diseases  and potentially  extend survival for  patients with RCC.  Participation in this study 
may not provide any benefit to the individual participant, and may or may not provide 
information which will ultimately benefit others.  
Costs : The  patient  will be responsible for all costs  related to  treatment and  complications 
of treatment. Costs to the patient (third party insurer) will include administration of 
avelumab, hospitalizations, routine blood tests and diagnostic studies, office visits, 
baseline EKG  and doctor’s fees.  However, Pfizer  will provide a  supply of talazoparib and 
avelumab at no cost  to the patient.  Patients will not be charged for correlative research 
work that is included in this trial. Patients will be responsible for the costs of standard 
medical care, including complications of treatment. Non- billable  tests include the tests 
performed for researc h purposes.  
Incentives:  No i ncentives  will be offered to patients/subjects  for study  participation.  
 
Alternatives : The alternative to this trial would be treatment with standard cytotoxic 
chemotherapy, immunotherapy or participation  in alternative clinical trial. 
 
Confidentiality : Every effort will be made to maintain patient confidentiality. Research 
and hospital records are confidential. Patients’ names and any other identifying 
information will not be used in reports or publications resulting from this s tudy. Other 
authorized agencies and appropriate internal personnel (e.g. qualified monitors from 
MSKCC) and external personnel, the FDA, and/or other governmental agencies) may review patient records as required.  
Patient safety:
  Patients  are monitored by physicians  and oncology nurses  who are very 
familiar with clinical trials. In the case of an adverse reaction, immediate medical 
attention is available. In the evenings and  weekends, we have a 24 -hour urgent care 
facility  for outpatients. The PI  or co -PI will also  be available at  all times to  organize any 
necessary  intervention.  
Monitoring of  data to ensure safety: This study  is to be monitored by the institutional IRB. 
This incorporates an  independent data and safety  monitoring committee established by 
arrangement with the National Cancer  Institute. The analysis of safety will include all 
patients. Adverse events, including all toxic effects of treatment, will be tabulated 
individually,  and summarized by severity and causality.  
 
17.1 Privacy 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
65  
 MSK’s Privacy Office may allow the use and disclosure of protected health information 
pursuant  to a completed and signed Research Authorization form.  The use and disclosure 
of protected health information will be limited  to the individuals described in the Research 
Authorization form. A Research Authorization form must be completed by the Principal 
Investigator  and approved by the IRB and Privacy  Board (IRB/PB).  
All parties will ensure protection of patient personal data and will not include patient 
names,  or other identifiable data in any reports,  publications or  other disclosures,  except 
if required by law. The investigator will maintain a confidential list of patients who participated in this study,  linking each patient’s  numerical  code  to his or her actual  identity.  
The consent indicates that individualized de identified information collected for the 
purposes of this study  may be  shared with  other qualified researchers.  Only researchers 
who have received approval from MSK will be allowed to access  this information which 
will not include protected health information, such as the participant’s name, except for 
dates. It is also stated in the Research Authorization that their research data may be shared with others at the time of study publication.  
 
The consent  indicates  that samples  and genetic information  collected  may be shared with 
other qualified researchers and placed in online databases. An example of an online databas e is the NIH dbGAP database, which is monitored by the National Institutes of 
Health, and may  be made accessible to investigators approved by the U.S. government. 
Such  information will not include identifying information such as name.  It is also stated in 
the Research  Authorization that research data (e.g. genomic sequence)  may be shared 
with regulators.  The requirements  for submission  of genotype/phenotype data into the NIH 
dbGAP or any other public database will be followed as per the IRB SOP  for Genomic 
Data Sharing.  
 
17.2 Serious Adverse Event  (SAE)  Reporting  
An adverse event  is considered serious  if it results  in ANY of the following  outcomes:  
• Death 
• A life-threatening adve rse event  
• An adverse  event  that results  in inpatient hospitalization or prolongation of 
existing  hospitalization  
• A persistent  or significant  incapacity  or substantialdisruption of the ability to 
conduct  normal life functions  
• A congenital  anomaly/birth defect  
• Important Medical Events  (IME) that may  not result in death, be  life 
threatening, or  require hospitalization may  be considered serious when, 
based upon  medical  judgment, they  may jeopardize the  patient or  participant 
and may require medical  or surgical intervention to prevent one of the 
outcomes listed in this definition 
Note : Hospital  admission  for a planned procedure/disease treatment  is not considered 
an SAE.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
66  
  
SAE reporting is required as  soon as  the participant  starts investigational 
treatment/intervention.  SAE reporting is required for 30 -days after the participant’s  last 
investigational  treatment/intervention.  Any event  that occur  after the 30 -day period that is 
unexpected and at least possibly  related to protocol  treatment  must  be reported . 
 
Please note: Any  SAE that occurs  prior to the start of investigational 
treatment/intervention  and is  related to a screening test or procedure (i.e., a screening 
biopsy) m ust be reported.  
All SAEs  must  be submitted  in PIMS.  If an SAE requires  submission  to the HRPP  office 
per IRB SOP  RR-408 ‘Reporting of Serious Adverse Events’,  the SAE report must  be 
submitted within  5 calendar  days of  the event.  All other SAEs  must  be submitted  within 
30 calendar days of the event.  
The report  should contain the following  information:  
 
• The date the adverse event  occurred 
• The adverse event  
• The grade of the event  
• Relationship of the adverse event  to the treatment(s)  
• If the AE was expected  
• Detailed  text that includes  the following  
o An explanation of  how the AE was handled  
o A description of the participant’s  condition  
o Indication if  the participant  remains  on the study  
• If an amendment  will need to be made  to the protocol  and/or  consent  form 
• If the SAE is an Unanticipated Problem  
For IND/IDE  protocols:  
The SAE report should be completed  as per above instructions.  If appropriate,  the 
report will be forwarded to the FDA  by the IND  Office  
 
Any overdose or  study  drug administration error  that results  in SAE even if  it does  not 
meet the criteria for definition of SAE.  
 
17.2.1  SAE Reporting to Pfizer  
All serious adverse events that occur  after the patients’ written consent to participate in 
the study  through  28 days  of discontinuation of dosing must  be reported to Pfizer,  whether 
related or  not related to the study  drug.  If applicable,  SAEs must  be collected that relate 
to any later protocol specific procedures.  
 
Following the subject’s written consent in the study, all SAEs, whether related or not 
related to study  drug, are collected including those thought to be associated with protocol 
specific procedures. The  investigator  should report  any SAE occurring after  these  time 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
67  
 periods,  which  is believed to be related to study  drug or protocol -specified procedure.  An 
SAE report  must  be completed for any event  where doubt  exists regarding its seriousness. 
SAEs  that occur  after completion of the reporting time as defined above  are reportable to 
Pfizer if the Investigator  suspects  a causal  relationship between the Pfizer  product  and the 
SAE.  
The time frame  for reporting an SAE to Pfizer  is immediately upon awareness  if the SAE 
is fatal or life -threatening (i.e. causes an immediate risk of death), regardless of the 
available information extent, or  within  24 hours  of first awareness  of the SAE if the SAE is 
not fatal or life -threatening.  
The following reportable events must be submitted to Pfizer within 24 hours (or 
immediately  for death or life -threatening  events)  using the provided Investigator- Initiated 
Research Serious Adverse Event Form (IIR SAE) with the Pfizer  Reportable Events Fax 
Cover Sheet with each SAE submis sion.  
• Serious  Adverse  Events  
• Exposure during Pregnancy  or Breastfeeding (even if  not associated  with adverse 
event)  
• Occupational  Exposure (even if not associated  with an adverse  event)  
• Potential  drug-induced liver  injury (Hy’s  Law cases): These  events are  considered 
important medical events and should be reported as SAEs.  
When new,  updated,  or corrected  information about  a previously  reported  SAE is obtained, 
a follow -up report should be submitted to Pfizer on a new SAE Report Form (or other 
agreed reporting method)  that includes the data that are new or revised from the  previous 
report.  Follow -up information should never  be added to a previously  submitted report  form. 
Ensure that any new  events included on a follow -up report are marked as serious and a 
causality assessment is provided for each of them.  
An occupational exposure is an exposure to a Pfizer product  for human use because of 
one's occupation. An occupational exposure is reportable regardless of whether  there is 
an associated SAE. An exposure during breastfeeding occurs if an infant or child may 
have been exposed through breast milk to the Pfizer  product during breastfeeding by a 
female taking the Pfizer product. Exposure during breastfeeding is reportable to Pfizer 
regardless of whether  there is an associated SAE in the infant or child. Exposure During 
Pregnancy  occurs  when a fetus  (from  pre-embryo  to birth)  may have  been  exposed at any 
time during pregnancy to a Pfizer  product (or blinded therapy).  
Contact information for submission of r eportable events  to Pfizer: 
Fax: Pfizer  U.S. Clinical Trial Department,  Fax 1-866-997-8322 or 
E-mail: USA.AEReporting@pfizer.com , specifying: 
• PROTOCOL:  
• SUBJECT:  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
68  
 • SITE/PI  
• SAE/ONSET  
 
MSK will provide Pfizer  a redact  internal  serious  adverse event  (SAE)  form.  
18.0 INFORMED  CONSENT  PROCEDURES  
Before protocol -specified  procedures  are carried out, consenting  professionals  will explain 
full details  of the protocol  and study  procedures  as well as the risks involved to participants 
prior to their inclusion in the study. Participants will  also be informed t hat they are free to 
withdraw from the study at any time. All participants must sign an IRB/PB -approved 
consent form indicating their consent to participate. This consent form meets the 
requirements of the Code of Federal Regulations and the Institutional Review 
Board/Privacy Board of this Center. The consent form will include the following:  
1. The nature  and objectives,  potential  risks and benefits  of the intended  study.  
2. The length of study  and the likely  follow- up required.  
3. Alternatives to the proposed study. (This will include available standard and 
investigational therapies. In addition, patients will be offered an option of 
supportive care  for therapeutic studies.)  
4. The name  of the investigator(s)  responsible for the protocol.  
5. The right of  the participant to accept  or refuse study  interventions/interactions  and 
to withdraw from participation at any time.  
Before any protocol -specific procedures can be carried out, the consenting professional 
will fully explain  the aspects of patient privacy concerning research  specific information. 
In addition to signing the IRB Informed Consent,  all patients must  agree to the Research 
Authorization  component  of the informed consent form.  
Each  participant and consenting professional will sign the consent form.  The participant 
must  receive a copy of the signed informed consent  form.  
19.0 REFERENCES  
1. R. L. Siegel, K.  D. Miller,  A. Jemal,  Cancer  statistics, 2018. CA Cancer  J Clin 68, 7 -30 
(2018).  
2. J. Gelfond  et al., Modifiable  risk factors  to reduce renal cell  carcinoma  incidence:  Insight 
from the PLCO trial. Urol Oncol  36, 340.e341 -340.e346 (2018).  
3. H. Moch, A. L.  Cubilla, P.  A. Humphrey, V. E.  Reuter,  T. M. Ulbright, The 2016 WHO 
Classification  of Tumours  of the Urinary System  and Male Genital  Organs  -Part A: Renal, 
Penile, and Testicular  Tumours. Eur Urol 70, 93 -105 (2016).  
4. C. J. Ricketts et al. , The Cancer  Genome Atlas Comprehensive Molecular 
Characterization of Renal Cell Carcinoma.  Cell Rep 23, 313- 326 e315 (2018).  
5. T. J. Mitchell et al. , Timing  the Landmark  Events in the Evolution  of Clear  Cell Renal Cell 
Cancer:  TRACERx Renal. Cell 173, 611 -623 e617 (2018).  
6. Y. B.  Chen et al., Molecular  analysis of  aggressive renal cell  carcinoma  with unclassified 
histology reveals distinct subsets. Nat Commun 7, 13131 (2016).  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
69  
 7. T. J. Mitchell et al. , Timing  the Landmark  Events in the Evolution  of Clear  Cell Renal Cell 
Cancer:  TRACERx Renal. Cell 173, 611 -623.e617 (2018).  
8. Y. Sato et al., Integrated  molecular  analysis  of clear -cell renal  cell carcinoma.  Nat Genet  
45, 860-867 (2013).  
9. A. A. Hakimi,  C. G. Pham,  J. J. Hsieh,  A clear  picture of renal  cell carcinoma.  Nat Genet  
45, 849-850 (2013).  
10. A. A. Hakimi et  al., TCEB1 -mutated  renal cell  carcinoma:  a distinct  genomic  and 
morphological subtype. Mod Pathol 28, 845- 853 (2015).  
11. J. R. Toro et al. , Mutations  in the fumarate hydratase gene cause hereditary 
leiomyomatosis  and renal  cell cancer  in families in  North America. American  journal  of 
human genetics 73 , 95-106 (2003).  
12. W. M. Linehan,  T. A. Rouault, Molecular pathways:  Fumarate hydratase- deficient kidney 
cancer --targeting the Warburg effect in cancer. Clinical cancer  research : an official 
journal of the American Association for Cancer Research 19 , 3345- 3352 (2013).  
13. C. Kadoch,  G. R. Crabtree,  Mammalian SWI/SNF  chromatin remodeling complexes  and 
cancer:  Mechanistic  insights gained from human genomics. Science advances 1, 
e1500447 (2015).  
14. P. Msaouel et al. , Comprehensive Molecular  Characterization Identifies  Distinct 
Genomic and Immune  Hallmarks  of Renal  Medullary  Carcinoma.  Cancer  Cell 37, 720- 
734.e713 (2020).  
15. S. P. Jackson,  J. Bartek,  The DNA -damage  response in human  biology  and disease.  
Nature 461, 1071- 1078  (2009).  
16. A. Torgovnick, B.  Schumacher,  DNA  repair mechanisms  in cancer  development and 
therapy. Frontiers in genetics 6 , 157 -157 (2015).  
17. C. J. Lord, A. Ashworth,  PARP inhibitors: Synthetic lethality in the  clinic. Science 355, 
1152- 1158 (2017).  
18. M. Robson  et al., Olaparib for  Metastatic Breast  Cancer  in Patients with  a Germline 
BRCA  Mutation.  New England Journal of Medicine 377, 523- 533 (2017).  
19. E. Pujade -Lauraine et al. , Olaparib tablets as  maintenance  therapy in patients with 
platinum -sensitive, relapsed ovarian cancer and a <em>BRCA1/2</em> mutation 
(SOLO2/ENGOT -Ov21):  a double- blind,  randomised,  placebo- controlled, phase 3 trial. 
The Lancet Oncology 18, 1274 -1284 (2017).  
20. J. K. Litton et al. , Talazoparib in Patients with Advanced Breast  Cancer  and a Germline 
BRCA Mutation.  379, 753 -763 (2018).  
21. M. R. Mirza et al., Niraparib Maintenance Therapy  in Platinum -Sensitive, Recurrent 
Ovarian Cancer. New England Journal of Medicine 375, 2154- 2164 (2016).  
22. R. L. Coleman  et al., Rucaparib maintenance treatment  for recurrent  ovarian carcinoma 
after response to platinum therapy (ARIEL3): a randomised, double- blind,  placebo-  
controlled, phase 3 trial. The Lancet 390, 1949- 1961 (2017).  
23. D. T. Le et al. , Mismatch  repair deficiency  predicts  response  of solid tumors  to PD -1 
blockade. Science (New York, N.Y.) 357, 409 -413 (2017).  
24. L. Gossage,  T. Eisen,  E. R. Maher,  VHL, the story  of a tumour  suppressor  gene.  Nature 
Reviews Cancer 15 , 55 (2014).  
25. J. L. Metcalf et  al., K63 -ubiquitylation of VHL by SOCS1  mediates  DNA  double- strand 
break repair. Oncogene 33, 1055 -1065 (2014).  
26. J. Espana- Agusti, A. Warren,  S. K. Chew,  D. J. Adams,  A. Matakidou,  Loss  of PBRM1 
rescues VHL dependent  replication stress to promote renal carcinogenesis. Nat 
Commun 8, 2026 (2017).  
27. M. A. Schults,  Y. Oligschlaeger,  R. W. Godschalk, F. -J. Van Schooten,  R. K. Chiu,  Loss 
of VHL  in RCC Reduces  Repair and Alters  Cellular Response to Benzo[a]pyrene. 
Frontiers in oncology 3, 270- 270 (2013).  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
70  
 28. N. Turner,  A. Tutt, A. Ashworth, Hallmarks  of &#39;BRCAness&#39;  in sporadic 
cancers. Nature Reviews Cancer 4 , 814 (2004).  
29. G. Warsow  et al., Genomic  features  of renal  cell carcinoma  with venous  tumor  thrombus.  
Scientific  Reports  8, 7477 (2018).  
30. S. E. Scanlon,  D. C. Hegan, P.  L. Sulkowski, P.  M. Glazer,  Suppression of homology - 
dependent  DNA  double- strand break  repair induces  PARP inhibitor  sensitivity in VHL- 
deficient human renal cell carcinoma. Oncotarget 9, 4647 -4660  (2018).  
31. S. E. Scanlon,  D. C. Hegan, P.  L. Sulkowski, P.  M. Glazer,  Suppression of homology - 
dependent  DNA  double- strand break  repair induces  PARP inhibitor  sensitivity in VHL- 
deficient human renal cell carcinoma. Oncotarget 9, 4647 -4660  (2017).  
32. J. Morales  et al., Review of poly (ADP -ribose)  polymerase  (PARP)  mechanisms  of action 
and rationale for targeting in cancer  and other diseases. Critical reviews in eukaryotic 
gene expression 24, 15 -28 (2014).  
33. K. B. Leszczynska,  N. Temper,  R. G. Bristow,  E. M. Hammond,  in PARP Inhibitors for 
Cancer  Therapy, N. J. Curtin, R. A. Sharma, Eds. (Springer International  Publishing, 
Cham, 2015), pp. 345 -361. 
34. N. Chan  et al., Contextual synthetic lethality of  cancer  cell kill based on the tumor 
microenvironment. Cancer research 70, 8045 -8054 (2010).  
35. S. Pena -Llopis  et al., BAP1  loss defines  a new class of renal  cell carcinoma.  Nat Genet  
44, 751-759 (2012).  
36. P. L. Sulkowski et al., Krebs -cycle -deficient  hereditary cancer  syndromes  are defined  by 
defects in homologous -recombination DNA repair. Nat Genet , (2018).  
37. D. Y. Heng et  al., Prognostic  factors  for overall survival in  patients with metastatic  renal 
cell carcinoma  treated with vascular endothelial  growth factor -targeted agents: results 
from a large, multicenter study. J Clin Oncol 27 , 5794- 5799 (2009).  
38. R. J. Motzer et al., Survival and prognostic  stratification of 670 patients  with ad vanced 
renal cell carcinoma. J Clin Oncol 17, 2530- 2540 (1999).  
39. R. J. Motzer et al., Nivolumab plus  Ipilimumab versus  Sunitinib in Advanced Renal -Cell 
Carcinoma.  N Engl J Med 378, 1277 -1290 (2018).  
40. R. J. Motzer et al., Nivolumab  versus  Everolimus  in Advanced Renal -Cell Carcinoma.  N 
Engl J Med 373, 1803- 1813 (2015).  
41. N. M. Tannir et  al., Everolimus  Versus Sunitinib Prospective  Evaluation in Metastatic 
Non-Clear Cell Renal Cell Carcinoma  (ESPN):  A Randomized Multicenter  Phase 2 Trial. 
Eur Urol 69 , 866 -874 (2016).  
42. A. J. Armstrong  et al. , Everolimus versus  sunitinib for  patients with  metastatic  non-clear 
cell renal cell  carcinoma (ASPEN): a multicentre,  open- label,  randomised  phase 2 trial. 
The Lancet Oncology 17, 378 -388 (2016).  
43. R. Srinivasan et al. , 5 Mechanism based  targeted therapy for  hereditary leiomyomatosis 
and renal cell cancer  (HLRCC) and sporadic papillary  renal cell carcinoma:  interim 
results  from a  phase  2 study  of bevacizumab  and erlotinib. European Journal  of Cancer 
50, 8 (2014).  
44. M. H. Voss et  al., Phase  II Trial and Correlative Genomic Analysis of Everolimus  Plus 
Bevacizumab in Advanced Non- Clear Cell Renal Cell Carcinoma.  J Clin  Oncol  34, 3846 - 
3853 (2016).  
45. V. S.  Koshkin et al., Clinical activity  of nivolumab in patients with  non-clear  cell renal cell 
carcinoma. Journal for ImmunoTherapy of Cancer 6 , 9 (2018).  
46. R. R. McKay  et al. , The Clinical Activity  of PD-1/PD -L1 Inhibitors  in Metastatic Non- Clear 
Cell Renal Cell Carcinoma. Cancer Immunol  Res 6, 758- 765 (2018).  
47. K. E. Beckermann et al. , Renal Medullary  Carcinoma:  Establishing Standards in 
Practice. J Oncol  Pract 13, 414 -421 (2017).  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
71  
 48. P. Msaouel et al. , Updated Recommendations  on the Diagnosis,  Management,  and 
Clinical Trial Eligibility Criteria for Patients With  Renal Medullary Carcinoma. Clin 
Genitourin Cancer 17, 1 -6 (2019).  
49. A. Y. Shah  et al. , Management  and outcomes  of patients with  renal medullary 
carcinoma:  a multicentre collaborative study.  BJU Int 120, 782- 792 (2017).  
50. R. A. Stewart,  P. G. Pilié, T.  A. Yap, Development of  PARP and Immune -Checkpoint 
Inhibitor  Combinations. Cancer Research,  (2018).  
51. A. Zehir et al. , Mutational  landscape of metastatic  cancer  revealed from prospective 
clinical sequencing of 10,000 patients. Nat Med 23 , 703 -713 (2017).  
52. M. D.  Hellmann et al. , Nivolumab plus Ipilimumab in Lung Cancer  with a High Tumor 
Mutational  Burden. New England Journal of Medicine 378, 2093- 2104 (2018).  
53. N. A. Rizvi et al., Cancer  immunology.  Mutational  landscape determines sensitivity  to 
PD-1 blockade in non- small  cell lung cancer. Science (New York,  N.Y.)  348, 124- 128 
(2015).  
54. L. Ding et al., PARP Inhibition Elicits  STING -Dependent Antitumor Immunity  in Brca1 - 
Deficient Ovarian Cancer.  Cell Reports 25 , 2972 -2980.e2975  (2018).  
55. S. Jiao et al., PARP Inhibitor  Upregulates PD -L1 Expression and Enhances Cancer - 
Associated Immunosuppression. Clinical Cancer Research 23, 3711 -3720 (2017).  
56. M. Friedlander  et al., A phase 1b study  of the anti -PD-1 monoclonal  antibody BGB -A317 
(A317) in combination with the PARP inhibitor BGB -290 (290) in advanced solid tumors. 
Journal of Clinical Oncology 36, 48 -48 (2018).  
57. Y. Shen  et al. , BMN 673, a Novel  and Highly Potent  PARP1/2  Inhibitor  for the Treatment 
of Human Cancers with DNA Repair Deficiency. Clinical Cancer Research 19, 5003 
(2013).  
58. G. Hamilton, B.  Rath,  Avelumab: combining immune  checkpoint inhibition and antibody - 
dependent cytotoxicity. Expert Opin Biol Ther 17 , 515- 523 (2017).  
59. C. R. Heery et al., Avelumab for  metastatic  or locally advanced previously treated solid 
tumours (JAVELIN  Solid Tumor): a phase 1a, multicohort, dose -escalation trial. The 
Lancet O ncology 18, 587 -598 (2017).  
60. H. L.  Kaufman et al., Avelumab in patients with chemotherapy -refractory  metastatic 
Merkel cell  carcinoma:  a multicentre,  single -group, open -label,  phase 2 trial. Lancet 
Oncol 17, 1374 -1385 (2016).  
61. S. P. D’Angelo,  J. Russell,  C. Lebbé, et  al., Efficacy  and safety  of first -line avelumab 
treatment in patients with stage iv metastatic merkel cell carcinoma:  A preplanned 
interim analysis of a clinical trial. JAMA  Oncology 4, e180077 (2018).  
62. T. A. Yap et al. , 1241TiPJAVELIN  PARP medley : A phase  Ib/II study  of avelumab (anti– 
PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. Annals of 
Oncology 29, (2018).  
63. M. R.  Patel et al., Avelumab in metastatic  urothelial  carcinoma after platinum failure 
(JAVELIN  Solid Tumor):  pooled results  from two expansion cohorts  of an open- label, 
phase 1 trial. The Lancet Oncology 19, 51 -64 (2018).  
64. U. N. Vaishampayan et al. , 877PFirst -line (1L) or second- line (2L) avelumab 
monotherapy in  patients  (pts) with advanced renal cell  carcinoma  (aRCC)  enrolled in the 
phase Ib JAVELIN  solid tumor trial. Annals of Oncology  29, mdy283.086 -mdy283.086 
(2018).  
65. R. J. Motzer et al., LBA6_PRJAVELIN  renal 101: A  randomized,  phase III study  of 
avelumab +  axitinib  vs sunitinib as  first-line treatment  of advanced renal cell  carcinoma 
(aRCC).  Annals of Oncology 29, mdy424.036 -mdy424.036 (2018).  
66. T. K. Choueiri et al., Preliminary  results for  avelumab plus axitinib  as first -line therapy in 
patient s with advanced clear -cell renal -cell carcinoma  (JAVELIN  Renal 100): an open - 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
72  
 label,  dose- finding and dose- expansion,  phase 1b  trial. Lancet  Oncol  19, 451 -460 
(2018).  
67. K. Kelly et al. , Safety  profile  of avelumab in patients with advanced solid tumors:  A 
pooled analysis  of data from the phase  1 JAVELIN  solid tumor  and phase  2 JAVELIN 
Merkel 200 clinical trials. Cancer  124, 2010- 2017 (2018).  
68. L. Seymour  et al., iRECIST:  guidelines for response criteria  for use in trials testing 
immunotherapeutics. The Lancet Oncology 18, e143- e152 (2017).  
69. D. J. Martini  et al. , Response to single  agent PD -1 inhibitor after  progression on previous 
PD-1/PD -L1 inhibitors:  a case  series. Journal for ImmunoTherapy of Cancer  5, 66 
(2017).  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
73  
 20.0 APPENDICES  
 
Appendix  1: Eastern  Cooperative Oncology  Group (ECOG)  Performance  Status Chart 
Appendix 2: iRECIST and RECIST v1.1. Guidelines  
Appendix 3: Avelumab Infusion Related Events and Management 
Appendix  4: Avelumab Immune  Related Adverse  Events  and Management 
Appendix 5: Talazoparib Medication Interactions  
Appendix  6: Correlative  Lab Manual  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
74  
 Appendix  1: Eastern  Cooperative  Oncology  Group (ECOG)  Performance Status  Chart  
 
Description  Grade  
Fully  active,  able to carry  on all pre-disease  performance without  restriction  0 
Restricted  in physically  strenuous activity, but  ambulatory and able  carry  out light or 
sedentary nature (i.e. light house work, office work)  1 
Ambulatory and capable  of all  self-care,  but unable to carry  out work  activities.  Up 
and about more than 50% of waking hours  2 
Capable  of only limited  self-care,  confined  to bed or chair  more  than 50% of waking  
hours  3 
Completely  disabled,  cannot  carry  on self-care.  Totally  confined to bed or chair  4 
Death  5 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
75  
 Appendix 2: iRECIST  and RECIST  v1.1 Guidelines.  
iRECIST and RECIST:  The following criteria  will apply to  target and non -target lesions,  adapted 
from Seymour et al. ( 68): 
1. Previously irradiated lesions:  Lesions that  are previously irradiated will not  be considered 
measurable unless progression is documented radiographically previously or  if a biopsy 
confirms persistence  of disease ≥ 90 days following completion of therapy.  
2. Malignant Lymph Nodes: Lymph nodes are considered pathologically enlarged and 
measurable if >15 mm in short  axis when assessed  by CT scan. At  baseline and in follow - 
up, only the short -axis will be used in measurement.  
3. Measurable disease, other: Visceral lesions are considered measurable if the longest 
diameter measures >10mm.  
4. Non-measur able disease: Lesions that include small  lesions (longest diameter <10 mm) 
or pathological  lymph  nodes  with <15 mm in short  axis will be considered non-measurable. 
Bone lesions without extraosseous component, leptomeningeal disease, malignant 
ascites,  pleural/pericardial  effusion,  lymphangitic disease,  inflammatory  breast  disease is 
not considered measurable.  
5. Target  Lesions:  Up to five selected measur able lesions  (maximum  of 2 lesions  per organ), 
will be identified as  target  lesions  by the study  radiologist  to represent relevant  distribution 
of disease  burden and  will be measured and recorded at  baseline. Target lesions should 
be reproducibly measured in follow up. It may  be the case that the largest  lesions do not 
lend themselves to reproducibility, at which point next largest lesions should then be 
selected. A  sum of the diameters of the longest  for non- nodal lesions and short -axis for 
nodal lesions should then be used for the target lesion calculation and the sum of 
diameters should be used for  baseline. The baseline sum will be used as a reference to 
further characterize  any objective tumor res ponse.  
6. Non-Target Lesions: All other lesions or sites of disease including measurable lesions 
over the 5 target  lesions chosen should be identified as non- target lesions and should be 
recorded at baseline. Measurement of these lesions is not required, but the presence, 
absence,  or unequivocal progression of these  should be noted during follow -up imaging.  
7. Cystic  Lesions:  Cystic  lesions  that meet  requirements  for radiographic  simple  cysts  should 
not be considered malignant. Cystic  lesions  that are thought to  represent  metastases  can 
be considered measurable if they meet the above criteria.  
8. Clinical lesions: clinical lesions will only be considered measurable when they are 
superficial (i.e. skin nodules, palpable lymph nodes), and >10 mm in diameter when 
assessed  using calipers.  In the case  of skin lesions,  documentation by color photography 
including ruler to estimate size of lesion is required if used for follow -up. 
 
In contrast  to RECIST  v1.1 guidelines,  iRECIST  guidelines:  
1. Require confirmation of  both progression  and response by imaging at  least  4 weeks from 
the date first documented 
2. Does  not necessarily  score  the appearance  of new lesions  as progressive  disease if the 
sum of the lesion  diameters  of target  lesions  (minimum  of 10 mm/lesion,  maximum  of 5 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
76  
 target lesions,  maximum of 2 per  organ), and measurable new lesions does not increase 
by ≥ 20%.  
 
The same method of assessment and technique should then be used to characterize each 
identified and reported target lesion(s) at baseline and throughout the study. Response 
assessment is defined then by the following:  
 
Target  Lesions:  
1. Complete Response (iCR):  Disappearance of all target lesions. Any pathological lymph 
nodes must  have a reduction in short axis to <10 mm.  
2. Partial  Response  (iPR):  At least  30% decline in the sum of diameters  of target  lesions  as 
compared  to the reference baseline  sum of diameters.  
3. Unconfirmed  Progressive Disease  (iUPD):  At least  20% increase in the sum  of diameters 
of target  lesions compared to the reference of the smallest  sum of the study  (this includes 
the baseline sum if that is  the smallest  on the study).  In addition to the relative increase of 
20%, sum  must  demonstrate  an absolute increase of at least 5 mm.  This will need to be 
confirmed with imaging for iCPD assessment  to be performed 4 weeks (± 7 days) later.  
4. Stable Disease  (iSD):  Neither  sufficient  shrinkage to qualify for  PR nor sufficient  increase 
to qualify  for PD, compared to reference of the smallest  sum of diameters  while on study.  
5. Confirmed  Progressive  Disease  (iCPD): If further increase  in tumor burden, compared  to 
the last assessment,  is seen as evidenced by one or more of the following:  
• if new lesions were previously identified and they have increased  in size  (≥5 mm in 
sum of measures  for new lesion target or  any increase  for new lesion no n-target) or 
number; if no change is seen in new lesions (size or number) from last timepoint, 
assignment remains iUPD  
• Further increase in the size of non -target disease (does not need to meet  RECIST 
1.1 criteria for unequivocal progression)  
• Further  increase in the sum of measures  ≥5 mm; otherwise assignment  remains  iUPD  
• Further increase in previously identified target lesion iUPD in sum of measures >5 
mm or non -target lesion iUPD (previous assessment need not have shown 
unequivocal progression) OR  
• Further  increase in previously identified target lesion iUPD sum of measures ≥5 mm, 
previously  identified non- target  lesion  iUPD (does  not need  to be unequivocal), or  an 
increase in the size  or number of new lesions previously identified 
• Further  increase in the size or number  of new lesions  previously  identified 
 
Non-Target  Lesions:  
1. Complete Response:  Disappearance of all non -target lesions. All lymph nodes must  be non-  
pathological in size <10 mm  
2. Non-CR / Non- PD: Persistence  of one or more  non-target  lesions  
3. Unconfirmed Progressive Disease (iUPD)*: Appearance of one of more new lesions and/or 
unequivocal progression of existing non- target lesions. Unequivocal progression should be 
representative of overall  disease status changes and not single lesions increases.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
77  
 For RECIST guidelines, see below: 
https://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf  
 
RECIST  v1.1 Response  Criteria  
Target  Lesions  
Complete 
Response 
(CR) Disappearance of all target  lesions. Any pathological  lymph nodes  must have a 
reduction in short axis to <10 mm.  
Partial 
Response (PR) At least  30% decline in the sum of  diameters  of target  lesions  as compared to the 
reference baseline sum of diameters.  
Stable Disease 
(SD) Neither  sufficient  shrinkage  to qualify  for PR nor sufficient  increase  to qualify  for PD, 
compared to reference of the smallest  sum of diameters  while  on study  
 
 
Progressive Disease (PD)  At least a 20%  increase  in the sum of diameters  of target  lesions, taking as  reference 
the smallest  sum on study  (this includes  the baseline sum if that is the smallest  on 
study). In addition to the relative increase of 20%,  the sum must  also demonstrate an 
absolute increase of at least 5 mm.  
Note:  the appearance of one or more  new lesions  is also  considered progression.  
Non-Target  Lesions  
Complete 
Response  Disappearance  of all non -target  lesions. All  lymph  nodes  must be  non-pathological  in 
size <10 mm in short axis.  
Non-CR / Non- 
PD Persistence of one  or more  non-target  lesions  and/or  maintenance  of tumor  marker 
levels  above  the normal  limits.  
Progressive 
Disease (PD)  Unequivocal  progression  of existing  non-target  lesions.  
 
Note:  the appearance of one or more  new lesions  is also  considered progression.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
78  
 Appendix  3: Avelumab Infusion Related  Events and Management  
 
NCI CTCAE  Severity  Grade  Treatment  Modification  
Grade  1 – mild 
• Mild transient  reaction; infusion 
interruption not indicated; intervention 
not indicated.  • Decrease the avelumab infusion rate by  
50% and monitor  closely for any  worsening.  
• Next scheduled  infusion can be re- 
attempted at original  rate, per treating 
investig ator’s  discretion.  
Grade  2 – moderate  
• Therapy  or infusion interruption indicated 
but responds  promptly  to symptomatic 
treatment (for  example, antihistamines, 
NSAIDs, narcotics, IV fluids; prophylactic 
medications indicated for ≤24 hours.  • Temporarily  discontinue avelumab 
infusion. 
• Resume avelumab infusion  at 50%  of 
previous  rate once infusion- related 
reaction has resolved or decreased to 
at least Grade 1 in severity  and monitor 
closely for  any worsening  
• Next scheduled  infusion should be 
initiated at 50% of original rate. Added 
premedication should be considered. 
Grade 3 or Grade 4 – severe or 
life-threatening  
• Grade 3: Prolonged (for example, not 
rapidly  responsive  to symptomatic 
medication and/or  brief interruption of 
infusion);  recurrence of symptoms 
following initial improvement; 
hospitalization indicated for  clinical 
sequelae.  
• Grade 4: Life- threatening consequences; 
urgent  intervention indicated.  • Stop the avelumab infusion immediately 
and disconnect infusion tubing from the patient.  
 
• Patients must be withdrawn immediately 
from avelumab treatment and should not 
receive  any further  avelumab treatment.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
79  
 Appendix 4:  Avelumab Immune Related Adverse Events and Management  
 
Gastrointestinal  irAEs  
Severity  of Diarrhea/Colitis 
(NCI-CTCAE  v5) Initial  Management  Follow -up Management  
Grade  1 
 
• Diarrhea:  <4 
stools/day  over 
Baseline 
• Colitis:  asymptomatic  • Continue avelumab therapy  
• Symptomatic treatment (eg, 
loperamide).  • Close monitoring for 
worsening symptoms  
• Educate patient to report worsening immediately  
• If worsens, treat as 
Grade 2, 3 or 4  
Grade  2 
 
• Diarrhea: 4 to 6 stools 
per day over  Baseline; 
IV fluids indicated <24 
hours; not interfering with ADL  
• Colitis:  abdominal 
pain; blood in stool  • Withhold avelumab  therapy  
• Symptomatic  treatment.  • If improves  to Grade ≤1, 
resume avelumab therapy  
• If persists >5- 7 days or 
recurs, treat as Grade 3 or 
4. 
Grade  3 to 4 
 
• Diarrhea (Grade  3): 
≥7 stools per day over 
Baseline; 
incontinence;  IV fluids  
≥24 h; interfering with 
ADL 
• Colitis (Grade 3): 
severe abdominal 
pain, medical 
intervention indicated, 
peritoneal  signs  
• Grade  4: 
life-threatening, 
perforation  • Withhold avelumab  for Grade  3 
• Permanently  discontinue avelumab 
for Grade 4 or recurrent Grade  3 
• 1.0 - 2.0 mg/kg/day prednisone IV 
or equivalent  
• Add prophylactic  antibiotics for 
opportunistic infections  
• Consider  lower  endoscopy  • If improves,  continue 
steroids until Grade ≤1, 
then taper over  at least 1 
month; resume avelumab 
therapy following steroids 
taper (for  initial Grade 3) 
• If worsens, persists >3 to 
5 days, or recurs  after 
improvement,  add 
infliximab 5 mg/kg (if no 
contraindication).  Note: 
infliximab should not be used in cases of 
perforation or sepsis  
Dermatological  irAEs  
Grade of Rash 
PFS(NCI -CTCAE  v5) Initial  Management  Follow -up Management  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
80  
  
Grade  1 to 2 
 
Covering ≤30% body 
surface area • Continue avelumab therapy  
• Symptomatic therapy (for  example, 
antihistamines, topical steroids)  • If persists >1 to 2 weeks or 
recurs, withhold avelumab 
therapy  
• Consider  skin biopsy  
• Consider  
0.5-1.0 mg/kg/day 
prednisone or equivalent. 
Once improving, taper 
steroids over  at least  
1 month, consider 
prophylactic antibiotics for 
opportunistic infections, 
and resume avelumab therapy following steroids 
taper  
• If worsens, treat as 
Grade 3 to 4  
Grade  3 to 4 
 
• Grade  3: Covering  
>30% body surface 
area 
• Grade 4: Life 
threatening 
consequences  • Withhold avelumab  for Grade  3 
• Permanently  discontinue for Grade 
4 or recurrent  Grade 3 
• Consider  skin biopsy  
• Consider  dermatology  consult 
• Consider  1.0 - 2.0 mg/kg/day 
prednisone or equivalent  
• Consider  addition of prophylactic 
antibiotics for opportunistic infections. • If improves  to Grade ≤1, 
taper steroids over  at least 
1 month; resume 
avelumab therapy  
following steroids taper (for 
initial Grade 3) 
Pulmonary  irAEs  
Grade of Pneumonitis 
(NCI-CTCAE  v5) Initial  Management  Follow -up Management  
Grade  1 
 
Radiographic  changes 
only • Consider  withholding avelumab 
therapy  
• Monitor for symptoms every  2 - 3 
days 
• consider pulmonary  and infectious 
disease consults  • Re-assess at least every 
3 weeks  
• If worsens, treat as 
Grade 2 or Grade 3 to 4 
Grade  2 
 
Mild to moderate new 
symptoms  • Withhold avelumab  therapy  
• Consider  pulmonary  and infectious 
disease consults  
• Monitor symptoms daily; consider hospitalization 
• 1.0 - 2.0 mg/kg/day prednisone or 
equivalent  
• Consider Add prophylactic 
antibiotics for opportunistic infections  
• Consider bronchoscopy, lung 
biopsy. • Re-assess every  1 to 3 
days 
• When symptoms return to 
Grade ≤1, taper steroids 
over at least 1 month, and 
then resume avelumab 
therapy  following  steroids 
taper  
• If not improving after 
2 weeks  or worsening, 
treat as Grade 3 to 4.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
81  
  
Grade  3 to 4 
 
• Grade  3: Severe new 
symptoms; 
New/worsening 
hypoxia; 
• Grade  4: 
Life-threatening  • Permanently  discontinue avelumab 
therapy  
• Hospitalize 
• Consider  pulmonary  and infectious 
Disease consults.  
• 1.0 - 2.0 mg/kg/day prednisone or 
equivalent  
• Consider  addition of prophylactic 
antibiotics for opportunistic 
infections  
• Consider  bronchoscopy,  lung 
biopsy  • If improves  to Grade ≤1, 
taper steroids over  at least 
1 month 
• If not improving after 
48 hours  or worsening, 
add additional  
immunosuppression (for 
example, infliximab, 
cyclophosphamide,  IV 
immunoglobulin,  or 
mycophenolate mofetil)  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
82  
  
Hepatic  irAEs  
Grade of Liver  Test 
Elevation 
(NCI-CTCAE  v5) Initial  Management  Follow -up Management  
Grade  1 
 
• AST or ALT >ULN  - 
3.0 x ULN if baseline 
was normal;  1.5 - 3.0 x 
baseline if baseline 
was abnormal  
• And/or  total bilirubin  
>ULN  - 1.5 x ULN if 
baseline was normal; 
> 1.0 - 1.5 x baseline if 
baseline was  
abnormal  • Continue avelumab therapy. • Continue liver function 
monitoring  
• If worsens, treat as 
Grade 2 or 3 to 4.  
Grade  2 
 
• >3.0 - 5.0 x ULN if 
baseline was 
normal;  >3.0 - 5.0 x 
baseline if baseline 
was abnormal  
• and/or  total bilirubin  
>1.5 - 3.0 x ULN if 
baseline was normal; >1.5 - 3.0 x 
baseline if baseline was abnormal  • Withhold avelumab  therapy  
• Increase frequency  of monitoring 
to every  3 days.  • If returns  to Grade ≤1, 
resume routine monitoring; 
resume avelumab therapy  
• If elevation persists >5 to 
7 days or worsens, treat as 
Grade 3 to 4.  
Grade  3 to 4 
 
>5.0 x ULN  if baseline was 
normal; >5.0 - 20.0 x 
baseline if baseline was 
abnormal  and/or  total 
bilirubin  >3.0 x ULN if 
baseline was normal;  >3.0 
x baseline if baseline  was 
abnormal  • Permanently  discontinue 
avelumab therapy  
• Increase frequency  of monitoring 
to every  1 to 2 days  
• 1.0 - 2.0 mg/kg/day prednisone 
or equivalent  
• Add prophylactic  antibiotics for 
opportunistic infections  
• Consult gastroenterologist/ 
hepatologist  
• Consider  obtaining MRI/CT  scan 
of liver  and liver biopsy if 
clinically warranted.  • If returns  to Grade ≤1, 
taper steroids over  at least 
1 month 
• If does  not improve in >3 
to 5 days, worsens  or 
rebounds,  add 
mycophenolate mofetil  
1 gram  (g) twice  daily 
• If no response within an 
additional  3 to 5 days, 
consider other immunosuppressants  per 
local guidelines.  
Renal  irAEs  
Grade of Creatinine 
Increased (NCI-CTCAE 
v5) Initial  Management  Follow -up Management  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
83  
  
Grade  1 
 
Creatinine increased  
>ULN  to 1.5 x ULN • Continue avelumab therapy. • Continue renal function 
monitoring  
• If worsens, treat as 
Grade 2 to 3 or 4.  
Grade  2 to 3 
 
Creatinine increased >1.5 
and ≤ 6 x ULN  • Withhold avelumab  therapy  
• Increase frequency  of monitoring 
to every  3 days  
• Add prophylactic  antibiotics for 
opportunistic infections  
• Consider  renal  biopsy  
• 1.0-2.0 mg/kg/day prednisone or 
equivalent.  • If returns  to Grade ≤1, 
taper steroids over  at least 
1 month, and resume 
avelumab therapy  
following steroids taper.  
• If worsens,  treat as Grade 
4. 
Grade  4 
 
Creatinine increased >6 x 
ULN • Permanently  discontinue 
avelumab therapy  
• Monitor  creatinine daily 
• Add prophylactic  antibiotics for 
opportunistic infections  
• Consider  renal  biopsy  
• Nephrology  consultation.  • If returns  to Grade ≤1, 
taper steroids over  at least 
1 month.  
Cardiac  irAEs  
Myocarditis  Initial  Management  Follow -up Management  
• New onset of cardiac 
signs or symptoms  
• and / or new 
laboratory  cardiac 
biomarker  elevations 
(e.g., troponin,  
CK-MB, BNP)  
• or cardiac imaging 
abnormalities 
suggestive of 
myocarditis. • Withhold avelumab  therapy  
• Hospitalize 
• In the presence of life threatening 
cardiac decompensation,  consider 
transfer  to a facility experienced in 
advanced heart failure and 
arrhythmia management  
• Cardiology  consult to establish 
etiology and rule- out 
immune- mediated myocarditis  
• Guideline based supportive 
treatment as per cardiology consult*  
• Consider  myocardial biopsy if 
recommended per cardiology 
consult • If symptoms improve and 
immune- mediated etiology 
is ruled  out, re- start 
avelumab therapy  
• If symptoms do not improve/worsen,  viral 
myocarditis is excluded, 
and immune- mediated 
etiology  is suspected or 
confirmed following 
cardiology  consult, 
manage as 
immune- mediated 
myocarditis  
Immune -mediated 
myocarditis  • Permanently  discontinue avelumab  
• Guideline based supportive 
treatment as appropriate as per 
cardiology  consult*  
• 1.0-2.0 mg/kg/day prednisone or 
equivalent  
• Add prophylactic  antibiotics for 
opportunistic infections  • Once improving, taper 
steroids over  at least 1 
month  
• If no improvement  or 
worsening,  consider 
additional 
immunosuppressants (e.g., azathioprine, 
cyclosporine A).  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
84  
  
*Local  guidelines,  or e.g., ESC or AHA guidelines  ESC guidelines  website: 
https://www.escardio.org/Guidelines/Clinical -Practice- Guidelines  
AHA guidelines  website: 
http://professional.heart.org/professional/GuidelinesStatements/searchresults.jsp?q=&y=&t=1001  
Endocrine irAEs  
Endocrine Disorder  Initial  Management  Follow -up Management  
Grade 1 or Grade 2 
endocrinopathies 
(hypothyroidism, hyperthyroidism,  adrenal 
insufficiency,  type I 
diabetes mellitus)  • Continue  avelumab  therapy  
• Consider  Endocrinology  consult 
• Start thyroid hormone replacement 
therapy (for  hypothyroidism),  
anti-thyroid treatment (for 
hyperthyroidism),  corticosteroids  
(for adrenal  insufficiency)  or insulin 
(for Type I diabetes  mellitus) as 
appropriate.  
• Rule-out secondary 
endocrinopathies  
(i.e., hypopituitarism  / hypophysitis)  • Continue  hormone 
replacement/suppression 
and monitoring of 
endocrine function  as 
appropriate.  
Grade 3 or Grade 4 
endocrinopathies 
(hypothyroidism, 
hyperthyroidism,  adrenal 
insufficiency,  type I 
diabetes mellitus)  • Withhold  avelumab  therapy  
• Consider  hospitalization 
• Consider  endocrinology  consult 
• Start thyroid hormone replacement 
therapy (for  hypothyroidism),  
anti-thyroid treatment (for 
hyperthyroidism),  corticosteroids  
(for adrenal  insufficiency)  or insulin 
(for type I diabetes  mellitus) as 
appropriate  
• Rule-out secondary 
endocrinopathies  
(i.e., hypopituitarism /  
hypophysitis).  • Resume avelumab  once 
symptoms and/or  
laboratory  tests  improve to 
Grade ≤1 (with or without 
hormone 
replacement/suppression)  
• Continue hormone 
replacement/suppression and monitoring of 
endocrine function  as 
appropriate  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
85  
  
• Hypopituitarism  
• Hypophysitis 
(secondary 
endocrinopathies)  If secondary thyroid and/or  adrenal 
insufficiency is confirmed (i.e., 
subnormal  serum FT4 with 
inappropriately  low TSH and/or  low 
serum cortisol with inappropriately  low 
ACTH):  
• Consider  referral  to endocrinologist 
for dynamic  testing as indicated 
and measurement  of other 
hormones  (FSH, LH, GH/IGF -1, 
PRL, testosterone in men,  
estrogens  in women)  
• Hormone replacement/suppressive 
therapy as appropriate 
• Consider  pituitary MRI and visual 
field examination as indicated 
 
 
If hypophysitis  confirmed:  
 
• Continue avelumab if mild 
symptoms with normal MRI. 
Repeat  the MRI in 1 month 
• Withhold avelumab if moderate, 
severe or life- threatening 
symptoms of hypophysitis and/or 
abnormal  MRI 
• Consider  hospitalization. Initiate 
corticosteroids  (1 to 2 mg/kg/day 
prednisone or equivalent)  followed 
by corticosteroids taper during at 
least 1 month  
• Consider  addition of prophylactic  
antibiotics for opportunistic 
infections. • Resume avelumab  once 
symptoms and hormone 
tests  improve to Grade ≤1 
(with or without  hormone 
replacement)  
• In addition, for 
hypophysitis with abnormal  MRI, resume 
avelumab only once 
shrinkage of the pituitary 
gland on MRI/CT  scan  is 
documented  
• Continue hormone 
replacement/suppression 
therapy  as appropriate 
Other  irAEs  (not described  above)  
Grade of other irAEs 
(NCI-CTCAE  v5) Initial  Management  Follow -up Management  
Grade 2 or Grade 3 
clinical signs or 
symptoms  suggestive 
of a potential irAE  • Withhold avelumab  therapy 
pending clinical investigation.  • If irAE is ruled  out, 
manage as appropriate 
according to the diagnosis 
and consider re- starting 
avelumab therapy  
• If irAE is confirmed, treat 
as Grade  2 or 3 irAE.  
Grade 2 irAE  or first 
occurrence of Grade 3 
irAE • Withhold  avelumab  therapy  
• 1.0 - 2.0 mg/kg/day  prednisone or 
equivalent  
• Add prophylactic  antibiotics for 
opportunistic infections  
• Specialty  consult  as appropriate.  • If improves  to Grade  ≤1, 
taper steroids over  at least 
1 month and resume 
avelumab therapy  
following steroids taper.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
86  
  
Recurrence of same 
Grade 3 irAEs  • Permanently  discontinue avelumab 
therapy  
• 1.0 - 2.0 mg/kg/day prednisone or 
equivalent  
• Add prophylactic  antibiotics for 
opportunistic infections  
• Specialty  consult  as appropriate.  • If improves  to Grade  ≤1, 
taper steroids over  at least 
1 month.  
Grade  4 • Permanently  discontinue avelumab 
therapy  
• 1.0 - 2.0 mg/kg/day prednisone or 
equivalent  and/or other 
immunosuppressant  as needed 
• Add prophylactic  antibiotics for 
opportunistic infections  
• Specialty  consult.  • If improves  to Grade  ≤1, 
taper steroids over  at least 
1 month.  
Requirement for  10 mg 
per day or greater 
prednisone  or 
equivalent for  more  
than 12 weeks for 
reasons other than 
hormonal replacement 
for adrenal insufficiency  
 
 
 
Persistent  Grade 2 or 3 
irAE lasting  12 weeks or 
longer  • Permanently  discontinue avelumab 
therapy  
• Specialty  consult.   
Abbreviations:  ACTH=aadrenocorticotropic  hormone;  ADL=activities of daily  living; ALT=alanine 
aminotransferase;  AST=aspartate aminotransferase;  BNP=B- type natriuretic  peptide;  
CK-MB=creatinine kinase MB; CT= computed tomography;  FSH=follicle -stimulating  hormone; 
GH=growth  hormone;  IGF-1=insulin -like growth factor 1; irAE=immune- related adverse event; 
IV=intravenous;  LH=luteinizing hormone;  MRI=magnetic  resonance imaging; NCI -CTCAE=National 
Cancer  Institute- Common Terminology  Crite ria for  Adverse  Events;  PRL=prolactin;T4=thyroxine; 
TSH=thyroid- stimulating hormone;  ULN=upper  limit of normal.  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
87  
  
 
Appendix  5: Prohibited  Potent  P-gp Inhibitors  
 
Amiodarone  
Carvedilol  
Clarithromycin  
Cobicistat  
Dronedarone  
Erythromycin  
Glecaprevir/pibrentasvir  
Indinavir  
Itraconazole  
Ketoconazole  
Lapatinib  
Lopinavir  
Propafenone  
Quinidine  
Ranolazine  
Ritonavir  
Saquinavir  
Sofosbuvir/velpatasvir/voxilaprevir  
Telaprevir  
Tipranavir  
Valspodar  
Verapamil  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
88  
 Appendix  6: Correlative  Laboratory Manual  
Tissue  Specimen  Collection and Storage 
Time  Points:  Pre-treatment  (optionally  at screening),  and during  study  period 
 
Tumor  Specimens:  
• Fresh Tumor  Biopsy:  Tumor  biopsies may  be obtained for  patients  upon  entry into  clinical 
study during screening period, as well as while on- treatment. Tumor specimen may 
include nephrectomy or metastatic site specimen and should include 4 core biopsy 
specimens.  On the date of biopsy, part of the specimen will be transported to the Chan 
Lab. Two core biopsies will be utilized for  RNA/DNA  extraction, 1 core biopsy  will be snap 
frozen,  and 1 core biopsy  will be formalin  fixed and  paraffin embedded.  Portions of  tumors 
and normal tissue can then be prepared for further storage and analysis per laboratory guidelines. This will include placement  of portions of tissue  in aliquoted conical tubes in 
RPMI solution in TPS. The snap frozen specimens may be then stored for  future 
investigation,  including micro - and microdissection as well as for DNA/RNA  extraction,  and 
ultimately stored at -80ºC.  
• Archival  Tissue:  If available,  1-2 paraffin embedded tissue blocks  containing formalin -fixed 
tumor slides will be requested. Paraffin blocks may then be processed according to 
standard institutional protocol, with final preparation of 20 unstained slides for available analysis.  
• All specimens  will be delivered with the attached specimen submission form.  All tissue will 
then be stored at the Hakimi Lab at IPOP, MSKCC Zuckerman Research Center (417 
East 68th Street, New York,  NY). 
 
Peripheral  Blood  Sample Collection  and Storage 
Time  Points : C1D1,  C2D1, C3D1, , End  of Treatment  
 
Materials  and Collection : 
  
Materials§ C1D1*  C2D1  & 
C3D1  End of Treatment*  
Vacutainer 
CPT Tubes 
(8mL/each 
tube)  X (3 tubes)  X (2 tube)  X (3 tubes)  
Streck BCT 
Tube 
(10mL/each 
tube)  X (1 tube)  X (1 tube)  X (1 tube)  
EDTA  Tube  
(6cc/each 
tube)  X (1 tube)  X (1 tube)  X (1 tubes)  
Table  1: Peripheral  Blood  Sample Schedule 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
89  
 *All blood  draws  should occur prior to avelumab administration. Collections  may occur ±7 days of 
specified time point.  
**An additional  two blood draws at different  time points  beyond those listed is  permitted when 
feasible based upon clinical / immunological findings  
§Changes  to these  methods  may be adapted  depending upon the most  recent,  generally accepted 
protocols.  
 
 
Preparation:  
Vacutainer  CPT Tubes:  The BD  Vacutainer  CPT Tube (Catalog: 362761), or  equivalent,  will be 
used.  For collection,  standard  phlebotomy will  fill tubes with  8 mL of blood, with  attempt  to obtain 
full 8  mL during collection attempt.  The tube will then be inverted  several  times  after collection  to 
ensure adequate  mixing.  The patient’s  name,  MRN,  adhesive stickers will be  attached to the tube. 
The date/time will be noted on the collection requisition form. The RSA will then deliver all 
specimens  to Hakimi Lab at IPOP, MSKCC Zuckerman Research  Cent er (417 East  68th Street, 
New York, NY). 
Streck Tubes:  The Streck  Cell-Free DNA BCT  tube (Streck  Catalog No  218961), or equivalent, 
will be used. For collection, standard phlebotomy will fill each tube with 10 mL of blood, with 
attempt  to obtain full 10 mL during collection attempt.  The tube should be inverted several times 
after collection. The patient’s name, MRN should be documented on adhesive stickers to each tube. The date/time will be noted on the requisition form, and the tubes will be placed in a biohazard bag at room temperature. The RSA will then deliver all specimens to Hakimi Lab at 
IPOP, MSKCC Zuckerman Research  Center (417 East 68
th Street, New York, NY).  
EDTA  Tubes:  The BD lavender  tube (BD Catalog: 367863) will  be used.  For collection,  standard 
phlebotomy  will fill each  tube with 6 mL of blood,  with attempt  to obtain full 6 mL during collection 
attempt. The tube should be inverted several times after collection. The patient’s name, MRN should be documented on adhesive stickers to each tube. The date/time will be noted on the requisition form,  and the tubes will be placed  in a biohazard bag at room temperature.  The RSA 
will then deliver  all specimens  to Hakimi Lab at IPOP, MSKCC Zuckerman  Research Center  (417 
East 68
th Street, New York, NY). Samples may then be stored at -80ºC per standard practice 
procedure for future analysis.  
 
 
 
 
Data  Entry  for Specimen  Collection  
MSKCC RSA  and/or Chan laboratory personnel will collect information into a secured  database 
once samples  are collected and transported. If a sample is not fully collected, the reasoning for 
incomplete or partial collection should be documented into the database as well for accurate 
records.  
RNA/DNA  Preparation Methodology  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
90  
 Tumor  samples will be p repared with the AllPrep DNA/RNA/Protein Mini Kit from Qiagen (CAT: 
80004).  Samples  then will be  used include fresh  snap frozen  core biopsies,  biopsies preserved in 
RNA later, or alternatively paraffin embedded core biopsies. When samples are in paraffin 
embedded, the RNeasy FFPE  Kit and QIAamp DNA FFPE Tissue Kit will be used.  Changes to 
the RNA/DNA preparation methodology may be adapted depending upon the most recent, 
generally  accepted protocols.  
Tumor  Exome  Sequencing and matched normal  DNA  from blood 
Whole exome sequencing will be  carried  out using the Illumina Hiseq 2100 according to Nextera 
Rapid Capture kit (Cat # FC -140-1000) protocol with using 50 ng of genomic DNA as input. 
Nextera Rapid Capture kit targets 214,405 coding exons offering comprehensive coverage of 
human exomes with target size of 37 Mb. Changes to the methods for exome sequencing may 
be adapted  depending upon the most  recent, generally  accepted  protocols.  
DNA  Damage  Responses  will then be characterized using homologous recombination deficiency 
(HRD) assays which encompass multiple parameters. This may include loss of heterozygosity 
scoring (LOH),  large scale transition scoring (LST),  and telomeric allelic imbalance  scoring (TAI).  
Transcriptome  Sequencing of Tumor  RNA 
Messenger RNA is isolated from Total RNA  using  the Life Technology Dynabeads mRNA  Direct 
Microkit (Cat#  61021). The isolation relies on base pairing between the poly  (A) residue  at the 3’ 
end of most mRNA, and the oligo (dt) 25 residues covalently coupled to the surface of the 
Dynabeads.  Other  RNA  species  lacking  a poly (A)  tail do not hybridize  to the bead and are readily 
washed away. Briefly, 1 ug of RNA is heat denatured at 70°C and 50 ul of lysis/binding buffer and beads are added to bind the mRNA to the beads. Two rounds of mRNA isolation are performed and finally mRNA is eluted in 10 ul of nuclease free water. The resulting isolated mRNA contains  low ribosomal RNA content, which allows for most  accurate measurement  of 
coding transcripts.  
The mRNA  is subsequently converted to representative cDNA libraries for strand -specific  RNA 
sequencing on the Ion Torrent Personal Genome Machine (PGM) system using the Life Technology Ion Total RNA –Seq kit (Cat #4475936). Briefly, 1-500 ng of mRNA  is fragmented 
with RNAse III enzyme and purified using beads.  The size of the fragmented RNA is assessed 
on the Agilent  2100  Bioanalyzer.  The fragmented  RNA  is hybridized and  ligated with Ion adapters 
and subsequently reverse transcribed using SuperScript III  to generate single stranded cDNA 
copies  of the  fragmented RNA molecule.  Library generation uses a magnetic bead -based, size 
selection process,  to enrich  library  fragments  with 200 -bp length.  Complementary DNA library 
is subsequently  amplified  using Ion PCR primers,  and Platinum PCR High  Fidelity enzyme as 
per the protocol.  The size and yield of the resultant amplified cDNA  library size  is determined on 
the Agilent High sensitivity DNA Bioanalyzer chip.  
The library dilution factor is determined for the template preparation. Template preparation is 
carried out on OneTouch Emulsion PCR system using the Life Technology Ion  PGM Template 
OT2 200  kit (Cat #4480285).  OneTouch uses membrane passages and microfluidics to  create 
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
91  
 bulk emulsion of DNA  library  in oil and performs  an in situ thermocycling PCR  to produce template 
beads. The template beads are enriched on OneTouch ES using streptavidin beads to bind to 
biotinylated, properly adapted library fragments. This emulsion PCR and enrichment yields a sequencing template bead population where 95% of beads carry the template. The template 
beads are deposited on to the sequencing chip and sequenced on PGM using the Ion PGM Sequencing 200 Kit (Cat # 4482006)  from Life Technologies.  Changes to  these  methods  may be 
adapted depending  upon the most  recent, generally accepted protocols. 
Specific Pathways of interest that will be included for analysis include DDR  pathways: BRCA1, 
BRCA2, PARP1, ATM, ATR, RAD51C, BAP1, PALB2, MRE11, BARD1/BRIP1, RAD50/51/51B/51D,  ERCC2,  ERCC3,  ERCC4, ERCC5,  MMR  genes , POLE,  FANCC,  FANCA,  
BLM,  CHEK1,  CHEK2, R B1, ATRX,  as well as others.  
Somatic  Mutation Identification and Verification  
Matched tumor and normal exome sequencing reads will be mapped to the human reference genomic using Bowtie2. Non- uniquely mapped reads are then discarded, and calculation of 
mismatch statistics  for each  position is performed for both samples.  The aligned reads are then 
trimmed  at the  5’ and 3’ end at the points  where  the mismatch rate goes  above  1% based 
on this analysis. To reduce bias introduced  through PCR  amplification during library preparation, 
multiple reads with alignments starting at the same genom ic location with their consensus  are 
replaced. MuTect, which is one of the methods used in the TCGA project to call somatic mutations, is then used to predict somatic variants single nucleotide  variants (SNVs) from 
matched tumor and normal aligned reads. Haplotype inference over called SNV genotypes is performed  using the RefHap Single Individual  Haplotyping algorithm  that uses  read evidence to 
phase blocks of proximal SNVs.  
RNA -Seq reads are mapped on a diploid human transcript  library derived from the NCBI CCDS 
(http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi
) annotations. Expressed genes are 
identified by inferring gene expression levels from the RNA -Seq aligned reads, using IsoEM. 
IsoEM is an accurate EM algorithm that makes use of information such as insert size,  quality 
scores,  and read pairing,  if available,  to handle read mapping ambiguities.  Epitope prediction 
is done  for somatic SNVs  that appear  in expressed genes,  according  to FPKM  (Fragment 
per Kilobase  Per Million reads) values predicted by IsoEM.  
After  the candidate neo- epitope peptides are selected, the SNVs  encoding these peptides will 
be verified by reverse -transcriptase  PCR followed by DNA sequencing. Two sets of primers  are 
synthesized  for each SNV with the second  set of primers  as nested primers.  RNA will be  extract 
from ea ch tumor sample using Qiagen RNAeasy Mini  Kit. The first primer set will be used to 
synthesize cDNA samples from RNA samples. The cDNA will be used as template for reverse 
transcriptase PCR reaction using the second set of primers. The PCR product will be purified using QIAquick  PCR Purification Kit. Purified  PCR product  and the second primer set will be used 
to Genewiz  to sequence verify  the SNVs  called  by high throughput  sequencing analysis.  Changes 
to these methods  may be adapted depending upon  the most  recent,  generally accepted protocols.  
Neo-Antigen Prediction  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
92  
 For each somatic SNV in the expressed gene, reference and mutated peptide sequences are 
then generated  based  on the two inferred  haplotypes  for each  CCDS  transcript.  Generated  amino 
acid sequences are then processed using the NetMHC  epitope prediction program  and scored 
using an Artificial Neural Network (ANN) algorithm, for the patients’ identified HLA alleles. The Differential Agretopic Index (DAI), which is the difference between the NetMHC score for the mutated peptide and its un- mutated wild type counterpart, is calculated for each peptide, by 
subtracting the wild type score from the mutant score.  Epitopes based on DAI will be ranked. 
Multiple mutational antigen prediction scores  (Net MHC, DAI, pathogen -associated sequences) 
may be compared in an exploratory fashion and each will be tested against response rates. Changes  to these methods  may be adapted depending upon the most  recent,  generally accepted 
protocols.  
MSK- IMPACT  Analysis  
MSK- IMPACT  will be performed according to the institutional protocol. This assay analyzes a 
pre-defined set of cancer  susceptibility  genes  which  are captured  and sequenced on an Illumina 
HiSeqTM. Tumor  mutational burden will be calculated using  the total number  of non -synonymous 
mutations divided by the total genomic target region for which mutations are reported. TMB will 
be reported as an estimate / mB of DNA. Copy number assessment  will be used to determine 
gene amplification or deletion (amplification defined as >2-fold change, deletion defined  as <2 - 
fold change).  Degree of copy  number  change  is influenced by tumor  purity  and content.  Changes 
to these methods  may be adapted depending upon  the most  recent,  generally accepted protocols.  
Immune Infiltrate Analysis  
The immune infiltrate analysis will be performed using several techniques, including IHC, 
immunofluorescence, flow cytometry and/or computational approaches (deconvolution) based 
upon RNA sequencing data analysis. Matrix type analysis will be performed including 
CIBERSORT and single -sampl e gene expression set analysis (ssGSEA). Populations of  cells 
analyzed may include, but will not be limited to CD4, CD8, Treg populations, B cells, MDSC, monocytes,  and dendritic  cells and expression  of biologically  relevant/phenotypic  markers  thereof. 
Standard established institutional protocols will be applied. Changes to these methods may be 
adapted depending  upon the most  recent, generally accepted protocols. 
Peripheral  blood analysis  
Peripheral blood analysis will be performed using flow cytometry, and/or computational 
approaches including immune deconvolution based upon RNA sequencing data analysis. Populations of cells that may be characterized include, but are not limited to, CD4, C D8, Treg 
populations, B cells, MDSC, monocytes, and dendritic cells and expression of biologically relevant/phenotypic  markers  thereof. Standard  established institutional protocols  will be  applied. 
Changes  to these  methods  may be adapted  depending upon  the most  recent,  generally accepted 
protocols.  
Peripheral blood analysis will also include analysis for circulating tumor DNA (ctDNA). Tumor 
DNA  will be extracted using  QIAamp  circulating  nucleic  acid kit, and libraries  will then be prepared  
Memorial  Sloan  Kettering  Cancer  Center 
IRB Number: 19- 195 A(8)  
Approval date: 01 -Dec-2021  
93  
 using previously  described and captured  gene specific DNA  probes.  This may  include gene  sets 
as described by MSK- ACCESS, as well as targeted amplification for select genes of interest in 
RCC.  Changes to these methods may be adapted depending upon the most  recent, generally 
accepted protocols.  
Metabolomic  Profiling  
Tissue samples will be identified for metabolite changes with metabolite identification and 
quantification. Snap frozen core biopsy samples will be incubated and prepared to precipitate polar metabolite  proteins for  mass  spectrometer  analysis per  standard procedures.  Non-targeted 
gas and liquid chromatography coupled with mass  spectrometer  (LC/MS) analyses will then be 
performed, with lower limit of quantitation of 100 ng/g of tumor. Metabolites  of interes  t may 
include, but is  not limited to,  specific TCA  cycle metabolites:  fumarate, succinate,  malate, alpha- 
ketoglutarate, citrate, isocitrate, malate, fumarate, glutamine, glutamate, ATP, 2 -HG, aspartic 
acid, asparagine, orotic acid. Changes to these methods may  be adapted depending upon the 
most recent, generally accepted protocols.  